"Document.ID","Topic","Score","document","gamma"
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418580158874e-07
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313887903e-06
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section I Validation Audits",7.8012054801943e-06
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section B.  Calculation of Fee for Service Cost",5.50936891098641e-06
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section G.  MA Employer Group Waiver Plans",8.42420574183048e-06
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section L.  Normalization Factors",1.14232413853408e-05
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045104891e-06
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section IV   Medicare Medicaid Plans",0.67131723688014
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329665e-05
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section III CY 2019 Formulary Submission Window",1.21641982342935e-05
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351391e-05
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section E.  Clinical Trials",2.21636701369672e-05
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775132e-05
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section II Part C Cost Sharing Standards",1.48376036820401e-05
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section II Total Beneficiary Cost (TBC)",1.32115891376859e-05
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032524031e-05
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section C.  Part D Risk Sharing",2.55140908046316e-05
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.4985316250553e-05
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703429e-05
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section O.  Quality Payment Program",2.52847571990406e-05
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section II Health Related Supplemental Benefits",3.44788570211497e-05
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741372e-05
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928527e-05
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section III Improving Access to Part D Vaccines",2.62277505669603e-05
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.2928234786855e-05
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650602e-05
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section I Innovations in Health Plan Design",3.17543788246033e-05
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081104e-05
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section III Tier Composition",4.59243068332443e-05
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496469e-05
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.5643882464923e-05
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section III Expanding the Part D OTC Program",5.52438803782596e-05
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section D.  ESRD Rates",3.65706624378636e-05
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section I Plan Corrections",4.1416609866315e-05
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section A.  Update of the RxHCC Model",2.28230186141294e-05
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275519949e-05
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048513962e-05
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098557e-05
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724262968e-05
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section II Plans with Low Enrollment",5.12202792258055e-05
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273153e-05
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268815e-05
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598819e-05
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328375e-05
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669243e-05
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319152
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section B.  FFS Growth Percentage",4.0424640461849e-05
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section C.  IME Phase Out",7.3536633701136e-05
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114307e-05
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410136e-05
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.6575108000057e-05
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543168e-05
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078871
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897673e-05
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section II Cost Plan Competition Requirements",0.000117601526802609
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655973
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966431e-05
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.7896929609176e-05
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474099
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270565e-05
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.00014610629255971
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734739e-05
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313586
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777681
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section II Outpatient Observation Services",0.000109941138994693
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156113
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777674
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section I Annual Calendar",5.38342337295105e-05
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section III Specialty Tiers",0.000124543815635094
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820145e-05
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section A.  MA Growth Percentage",0.000146106292559711
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.000202086368443959
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768406
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640234
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635086
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section III Benefit Review",0.000122732519844415
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474094
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356358
"CMS-2017-0163-1150-1-4",1,"3.7546923563129e-05","Section II Employer Group Waiver Plans",0.000207044385747012
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",0.091695075990418
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313878528e-06
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section I Validation Audits",7.80120548018655e-06
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section B.  Calculation of Fee for Service Cost",5.50936891097326e-06
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section G.  MA Employer Group Waiver Plans",8.42420574183417e-06
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section L.  Normalization Factors",1.14232413853389e-05
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045104539e-06
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section IV   Medicare Medicaid Plans",5.48787256305555e-06
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329637e-05
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section III CY 2019 Formulary Submission Window",1.21641982342953e-05
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351433e-05
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section E.  Clinical Trials",2.21636701369577e-05
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775117e-05
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section II Part C Cost Sharing Standards",1.48376036820375e-05
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section II Total Beneficiary Cost (TBC)",1.32115891376869e-05
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032523953e-05
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section C.  Part D Risk Sharing",2.55140908046365e-05
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505546e-05
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703414e-05
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section O.  Quality Payment Program",2.528475719904e-05
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section II Health Related Supplemental Benefits",3.44788570211406e-05
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741236e-05
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928487e-05
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section III Improving Access to Part D Vaccines",2.62277505669544e-05
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868448e-05
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650456e-05
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section I Innovations in Health Plan Design",3.17543788245974e-05
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506080905e-05
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section III Tier Composition",4.59243068332443e-05
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.7474411449644e-05
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649218e-05
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section III Expanding the Part D OTC Program",5.52438803782639e-05
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section D.  ESRD Rates",3.65706624378781e-05
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section I Plan Corrections",4.14166098663129e-05
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section A.  Update of the RxHCC Model",2.28230186141136e-05
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275519978e-05
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048514033e-05
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098611e-05
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724262943e-05
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section II Plans with Low Enrollment",5.12202792258094e-05
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273202e-05
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268769e-05
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598932e-05
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328336e-05
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669099e-05
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319153
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section B.  FFS Growth Percentage",4.04246404618533e-05
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section C.  IME Phase Out",7.3536633701136e-05
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114379e-05
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410068e-05
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.6575108000055e-05
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543085e-05
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section D.  Retiree Drug Subsidy Amounts",0.00015411072607887
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.5035911989774e-05
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section II Cost Plan Competition Requirements",0.00011760152680261
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655972
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966508e-05
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091842e-05
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474099
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270489e-05
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559709
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section III Coordination of Benefits (COB) User Fee",7.6886531673473e-05
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313585
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777682
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section II Outpatient Observation Services",0.000109941138994691
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156114
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777679
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section I Annual Calendar",5.38342337295128e-05
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section III Specialty Tiers",0.000124543815635089
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820143e-05
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section A.  MA Growth Percentage",0.000146106292559707
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.000202086368443957
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768405
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640231
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635086
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section III Benefit Review",0.000122732519844413
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.0001007530724741
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356354
"CMS-2017-0163-1150-1-4",2,"3.75469235631257e-05","Section II Employer Group Waiver Plans",0.000207044385747007
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579982941e-07
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313889018e-06
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section I Validation Audits",7.801205480195e-06
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section B.  Calculation of Fee for Service Cost",5.5093689109921e-06
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section G.  MA Employer Group Waiver Plans",8.42420574184215e-06
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section L.  Normalization Factors",1.14232413853619e-05
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045106661e-06
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section IV   Medicare Medicaid Plans",5.48787256296988e-06
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329769e-05
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section III CY 2019 Formulary Submission Window",1.21641982343156e-05
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351556e-05
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section E.  Clinical Trials",2.21636701369792e-05
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775281e-05
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section II Part C Cost Sharing Standards",1.48376036820635e-05
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section II Total Beneficiary Cost (TBC)",1.3211589137696e-05
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032524005e-05
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section C.  Part D Risk Sharing",2.55140908046388e-05
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505734e-05
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703493e-05
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section O.  Quality Payment Program",2.52847571990465e-05
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section II Health Related Supplemental Benefits",3.44788570211496e-05
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741403e-05
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928765e-05
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section III Improving Access to Part D Vaccines",2.62277505669674e-05
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868624e-05
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650677e-05
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section I Innovations in Health Plan Design",3.17543788246095e-05
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081131e-05
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section III Tier Composition",4.59243068332547e-05
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496538e-05
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649495e-05
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section III Expanding the Part D OTC Program",5.524388037827e-05
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section D.  ESRD Rates",3.65706624378777e-05
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section I Plan Corrections",4.14166098663191e-05
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section A.  Update of the RxHCC Model",2.28230186141278e-05
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section II Tiered Cost Sharing of Medical Benefits",5.75024275520093e-05
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048514006e-05
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098712e-05
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section II Cost Plan Transition to MA under MACRA",7.75934724263247e-05
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section II Plans with Low Enrollment",5.12202792258109e-05
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273249e-05
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.7215762826893e-05
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598878e-05
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328514e-05
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669198e-05
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319154
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section B.  FFS Growth Percentage",4.04246404618591e-05
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section C.  IME Phase Out",7.35366337011407e-05
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114447e-05
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410277e-05
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000568e-05
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543161e-05
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section D.  Retiree Drug Subsidy Amounts",0.192540152662861
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897785e-05
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section II Cost Plan Competition Requirements",0.00011760152680264
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655991
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966462e-05
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091924e-05
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section I Enforcement Actions for Provider Directories",0.000100753072474102
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270607e-05
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559706
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section III Coordination of Benefits (COB) User Fee",7.68865316734697e-05
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313613
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777684
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section II Outpatient Observation Services",0.000109941138994712
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section II Part C Optional Supplemental Benefits",0.00011441274415612
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777683
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section I Annual Calendar",5.3834233729529e-05
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section III Specialty Tiers",0.000124543815635106
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820206e-05
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section A.  MA Growth Percentage",0.000146106292559714
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.00020208636844396
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.00012097315376841
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640243
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635113
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section III Benefit Review",0.000122732519844423
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474121
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356355
"CMS-2017-0163-1150-1-4",3,"0.0194642807792559","Section II Employer Group Waiver Plans",0.0321369598470896
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418580167392e-07
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313883751e-06
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section I Validation Audits",7.80120548019306e-06
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section B.  Calculation of Fee for Service Cost",5.5093689109949e-06
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section G.  MA Employer Group Waiver Plans",8.4242057418333e-06
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section L.  Normalization Factors",1.1423241385348e-05
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045106495e-06
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section IV   Medicare Medicaid Plans",5.48787256308983e-06
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329739e-05
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section III CY 2019 Formulary Submission Window",1.2164198234312e-05
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351536e-05
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section E.  Clinical Trials",2.21636701369667e-05
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775356e-05
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section II Part C Cost Sharing Standards",1.48376036820569e-05
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section II Total Beneficiary Cost (TBC)",1.32115891376893e-05
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032523975e-05
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section C.  Part D Risk Sharing",2.55140908046383e-05
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505602e-05
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703497e-05
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section O.  Quality Payment Program",2.52847571990431e-05
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section II Health Related Supplemental Benefits",3.44788570211503e-05
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741324e-05
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928479e-05
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section III Improving Access to Part D Vaccines",2.6227750566959e-05
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868451e-05
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650475e-05
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section I Innovations in Health Plan Design",3.1754378824602e-05
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",0.997108581295878
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section III Tier Composition",4.59243068332432e-05
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496397e-05
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649248e-05
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section III Expanding the Part D OTC Program",5.52438803782656e-05
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section D.  ESRD Rates",3.65706624378798e-05
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section I Plan Corrections",4.14166098663228e-05
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section A.  Update of the RxHCC Model",2.28230186141261e-05
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section II Tiered Cost Sharing of Medical Benefits",5.7502427552004e-05
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048513968e-05
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.5947545409868e-05
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724262956e-05
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section II Plans with Low Enrollment",5.122027922581e-05
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273193e-05
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268818e-05
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598868e-05
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328306e-05
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669173e-05
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319162
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section B.  FFS Growth Percentage",4.04246404618547e-05
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section C.  IME Phase Out",7.35366337011397e-05
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114417e-05
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410105e-05
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000674e-05
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543152e-05
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078871
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897757e-05
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section II Cost Plan Competition Requirements",0.000117601526802607
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655976
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966442e-05
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091919e-05
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474111
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270699e-05
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559703
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734765e-05
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313591
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777682
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section II Outpatient Observation Services",0.000109941138994698
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156114
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777681
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section I Annual Calendar",5.38342337295179e-05
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section III Specialty Tiers",0.000124543815635093
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820394e-05
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section A.  MA Growth Percentage",0.000146106292559712
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.00020208636844396
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768411
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640232
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635091
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section III Benefit Review",0.000122732519844414
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474099
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356356
"CMS-2017-0163-1150-1-4",4,"3.75469235631425e-05","Section II Employer Group Waiver Plans",0.000207044385747009
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579876037e-07
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.9644331388877e-06
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section I Validation Audits",7.80120548019619e-06
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section B.  Calculation of Fee for Service Cost",5.50936891099193e-06
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section G.  MA Employer Group Waiver Plans",8.42420574183968e-06
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section L.  Normalization Factors",1.14232413853498e-05
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045106337e-06
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section IV   Medicare Medicaid Plans",5.48787256308425e-06
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329715e-05
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section III CY 2019 Formulary Submission Window",1.21641982343104e-05
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351495e-05
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section E.  Clinical Trials",2.21636701369677e-05
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775293e-05
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section II Part C Cost Sharing Standards",0.998679453272298
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section II Total Beneficiary Cost (TBC)",1.32115891376948e-05
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032524e-05
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section C.  Part D Risk Sharing",2.55140908046328e-05
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505728e-05
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703464e-05
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section O.  Quality Payment Program",2.52847571990393e-05
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section II Health Related Supplemental Benefits",3.44788570211494e-05
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741371e-05
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",0.996550903772836
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section III Improving Access to Part D Vaccines",2.6227750566969e-05
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868488e-05
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650552e-05
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section I Innovations in Health Plan Design",3.17543788245965e-05
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081022e-05
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section III Tier Composition",4.59243068332396e-05
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496427e-05
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649359e-05
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section III Expanding the Part D OTC Program",5.52438803782643e-05
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section D.  ESRD Rates",3.65706624378697e-05
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section I Plan Corrections",4.14166098663211e-05
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section A.  Update of the RxHCC Model",2.28230186141209e-05
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275519897e-05
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048513951e-05
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098643e-05
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724263032e-05
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section II Plans with Low Enrollment",5.12202792258044e-05
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273261e-05
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268888e-05
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598849e-05
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328399e-05
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669191e-05
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319154
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section B.  FFS Growth Percentage",4.04246404618549e-05
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section C.  IME Phase Out",7.35366337011352e-05
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114379e-05
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410166e-05
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000648e-05
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543176e-05
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section D.  Retiree Drug Subsidy Amounts",0.0306230472971137
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897717e-05
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section II Cost Plan Competition Requirements",0.000117601526802612
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655992
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.9794507696644e-05
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091845e-05
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474101
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270579e-05
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559713
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734653e-05
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313586
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.00010449577977768
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section II Outpatient Observation Services",0.000109941138994702
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156117
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777678
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section I Annual Calendar",5.38342337295202e-05
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section III Specialty Tiers",0.000124543815635089
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820199e-05
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section A.  MA Growth Percentage",0.000146106292559711
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.00020208636844396
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768406
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640238
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.00012454381563509
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section III Benefit Review",0.000122732519844412
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474118
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356358
"CMS-2017-0163-1150-1-4",5,"3.75469235631376e-05","Section II Employer Group Waiver Plans",0.000207044385747005
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418580160595e-07
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313886967e-06
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section I Validation Audits",7.80120548018718e-06
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section B.  Calculation of Fee for Service Cost",5.50936891076163e-06
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section G.  MA Employer Group Waiver Plans",8.42420574183586e-06
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section L.  Normalization Factors",1.14232413853446e-05
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",0.425546161191319
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section IV   Medicare Medicaid Plans",5.48787256309989e-06
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329653e-05
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section III CY 2019 Formulary Submission Window",1.21641982343021e-05
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351486e-05
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section E.  Clinical Trials",2.21636701369661e-05
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775223e-05
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section II Part C Cost Sharing Standards",1.48376036820534e-05
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section II Total Beneficiary Cost (TBC)",1.32115891376891e-05
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032524015e-05
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section C.  Part D Risk Sharing",2.55140908046348e-05
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505605e-05
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703444e-05
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section O.  Quality Payment Program",2.52847571990442e-05
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section II Health Related Supplemental Benefits",3.447885702114e-05
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741329e-05
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928486e-05
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section III Improving Access to Part D Vaccines",2.62277505669572e-05
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868514e-05
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650496e-05
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section I Innovations in Health Plan Design",3.17543788245968e-05
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081063e-05
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section III Tier Composition",4.59243068332396e-05
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496525e-05
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649284e-05
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section III Expanding the Part D OTC Program",5.5243880378259e-05
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section D.  ESRD Rates",3.65706624378713e-05
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section I Plan Corrections",4.1416609866316e-05
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section A.  Update of the RxHCC Model",2.2823018614114e-05
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275519948e-05
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048513943e-05
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098609e-05
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724263015e-05
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section II Plans with Low Enrollment",5.12202792258173e-05
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273194e-05
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.7215762826883e-05
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598871e-05
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328364e-05
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.0466454466916e-05
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319155
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section B.  FFS Growth Percentage",4.0424640461847e-05
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section C.  IME Phase Out",7.35366337011474e-05
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114336e-05
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.5186604541003e-05
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000626e-05
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.1533056654314e-05
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078877
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897744e-05
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section II Cost Plan Competition Requirements",0.000117601526802608
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655971
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966573e-05
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091815e-05
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474104
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270605e-05
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.00014610629255971
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734743e-05
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313586
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777683
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section II Outpatient Observation Services",0.000109941138994696
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156117
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777678
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section I Annual Calendar",5.38342337295109e-05
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section III Specialty Tiers",0.000124543815635093
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820174e-05
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section A.  MA Growth Percentage",0.000146106292559705
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.00020208636844396
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.0001209731537684
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.00011288233364023
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635092
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section III Benefit Review",0.000122732519844415
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474099
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356351
"CMS-2017-0163-1150-1-4",6,"3.75469235631405e-05","Section II Employer Group Waiver Plans",0.000207044385747011
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579873811e-07
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313881749e-06
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section I Validation Audits",7.80120548019477e-06
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section B.  Calculation of Fee for Service Cost",5.50936891099185e-06
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section G.  MA Employer Group Waiver Plans",8.42420574183994e-06
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section L.  Normalization Factors",1.14232413853484e-05
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045106768e-06
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section IV   Medicare Medicaid Plans",5.48787256309005e-06
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329694e-05
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section III CY 2019 Formulary Submission Window",1.21641982343128e-05
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351507e-05
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section E.  Clinical Trials",2.21636701369713e-05
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775345e-05
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section II Part C Cost Sharing Standards",1.48376036820601e-05
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section II Total Beneficiary Cost (TBC)",1.32115891376907e-05
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032523993e-05
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section C.  Part D Risk Sharing",2.551409080464e-05
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505657e-05
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703508e-05
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section O.  Quality Payment Program",2.52847571990454e-05
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section II Health Related Supplemental Benefits",3.44788570211593e-05
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.0492278874141e-05
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.8753890192857e-05
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section III Improving Access to Part D Vaccines",2.62277505669593e-05
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868571e-05
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650498e-05
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section I Innovations in Health Plan Design",3.17543788246068e-05
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081128e-05
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section III Tier Composition",4.59243068332467e-05
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496526e-05
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649289e-05
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section III Expanding the Part D OTC Program",5.52438803782712e-05
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section D.  ESRD Rates",3.65706624378763e-05
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section I Plan Corrections",4.14166098663224e-05
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section A.  Update of the RxHCC Model",2.28230186141222e-05
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275520057e-05
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048514098e-05
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098751e-05
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724263042e-05
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section II Plans with Low Enrollment",5.12202792258173e-05
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273311e-05
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268827e-05
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598955e-05
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328464e-05
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669231e-05
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319157
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section B.  FFS Growth Percentage",4.04246404618594e-05
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section C.  IME Phase Out",7.35366337011402e-05
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114385e-05
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410211e-05
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.657510800007e-05
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.1533056654314e-05
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078873
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897728e-05
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section II Cost Plan Competition Requirements",0.000117601526802614
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655974
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966536e-05
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091882e-05
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section I Enforcement Actions for Provider Directories",0.00010075307247411
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270635e-05
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559707
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734749e-05
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313596
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777686
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section II Outpatient Observation Services",0.0001099411389947
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156117
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777688
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section I Annual Calendar",5.38342337295204e-05
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section III Specialty Tiers",0.000124543815635092
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820213e-05
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section A.  MA Growth Percentage",0.000146106292559713
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.000202086368443961
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.00012097315376841
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640237
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.988915600408477
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section III Benefit Review",0.000122732519844414
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474102
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356358
"CMS-2017-0163-1150-1-4",7,"3.75469235631368e-05","Section II Employer Group Waiver Plans",0.000207044385747011
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579945826e-07
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313890001e-06
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section I Validation Audits",7.80120548019419e-06
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section B.  Calculation of Fee for Service Cost",5.50936891099024e-06
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section G.  MA Employer Group Waiver Plans",8.42420574184359e-06
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section L.  Normalization Factors",1.1423241385347e-05
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045106108e-06
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section IV   Medicare Medicaid Plans",5.48787256308912e-06
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329716e-05
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section III CY 2019 Formulary Submission Window",1.21641982343072e-05
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351576e-05
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section E.  Clinical Trials",2.21636701369732e-05
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775319e-05
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section II Part C Cost Sharing Standards",1.48376036820624e-05
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section II Total Beneficiary Cost (TBC)",1.32115891376922e-05
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032524039e-05
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section C.  Part D Risk Sharing",2.55140908046403e-05
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505651e-05
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.5493966770347e-05
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section O.  Quality Payment Program",2.52847571990455e-05
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section II Health Related Supplemental Benefits",3.44788570211643e-05
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741345e-05
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928556e-05
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section III Improving Access to Part D Vaccines",2.62277505669603e-05
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868535e-05
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650536e-05
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section I Innovations in Health Plan Design",3.17543788246084e-05
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081054e-05
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section III Tier Composition",4.59243068332426e-05
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496435e-05
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649283e-05
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section III Expanding the Part D OTC Program",5.52438803782699e-05
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section D.  ESRD Rates",3.65706624378715e-05
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section I Plan Corrections",4.14166098663188e-05
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section A.  Update of the RxHCC Model",2.28230186141231e-05
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275520061e-05
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048513993e-05
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098692e-05
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724262973e-05
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section II Plans with Low Enrollment",5.12202792258205e-05
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273247e-05
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268881e-05
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598861e-05
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.5197887032851e-05
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669278e-05
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319154
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section B.  FFS Growth Percentage",4.04246404618585e-05
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section C.  IME Phase Out",7.35366337011396e-05
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114497e-05
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410115e-05
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000717e-05
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.1533056654319e-05
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078873
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897754e-05
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section II Cost Plan Competition Requirements",0.00011760152680261
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655978
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966452e-05
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091909e-05
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474101
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270595e-05
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559707
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734783e-05
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313592
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777682
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section II Outpatient Observation Services",0.000109941138994704
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section II Part C Optional Supplemental Benefits",0.00011441274415612
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777685
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section I Annual Calendar",5.38342337295242e-05
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section III Specialty Tiers",0.000124543815635095
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820237e-05
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section A.  MA Growth Percentage",0.00014610629255971
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.00020208636844396
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768409
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.989953472306019
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.0001245438156351
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section III Benefit Review",0.000122732519844415
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474101
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356355
"CMS-2017-0163-1150-1-4",8,"3.75469235631334e-05","Section II Employer Group Waiver Plans",0.00020704438574701
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.9941857988601e-07
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313865939e-06
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section I Validation Audits",7.80120548018955e-06
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section B.  Calculation of Fee for Service Cost",5.50936891098079e-06
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section G.  MA Employer Group Waiver Plans",8.42420574183931e-06
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section L.  Normalization Factors",1.14232413853471e-05
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045106579e-06
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section IV   Medicare Medicaid Plans",5.48787256304994e-06
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.1532515932992e-05
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section III CY 2019 Formulary Submission Window",1.21641982343138e-05
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351494e-05
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section E.  Clinical Trials",2.2163670136964e-05
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.515740287754e-05
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section II Part C Cost Sharing Standards",1.48376036820513e-05
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section II Total Beneficiary Cost (TBC)",1.32115891376909e-05
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",0.998148968810536
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section C.  Part D Risk Sharing",2.5514090804638e-05
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505665e-05
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703513e-05
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section O.  Quality Payment Program",2.52847571990452e-05
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section II Health Related Supplemental Benefits",3.44788570211518e-05
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741438e-05
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928528e-05
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section III Improving Access to Part D Vaccines",2.62277505669584e-05
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868576e-05
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650596e-05
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section I Innovations in Health Plan Design",3.1754378824606e-05
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081102e-05
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section III Tier Composition",4.59243068332499e-05
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496445e-05
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649379e-05
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section III Expanding the Part D OTC Program",5.52438803782684e-05
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section D.  ESRD Rates",3.65706624378814e-05
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section I Plan Corrections",4.14166098663215e-05
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section A.  Update of the RxHCC Model",2.28230186141217e-05
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275519992e-05
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.4018204851399e-05
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098746e-05
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724262953e-05
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section II Plans with Low Enrollment",5.12202792258185e-05
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273207e-05
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268818e-05
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598888e-05
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.5197887032835e-05
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669224e-05
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319155
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section B.  FFS Growth Percentage",4.04246404618604e-05
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section C.  IME Phase Out",7.35366337011414e-05
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114419e-05
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410066e-05
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000709e-05
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543328e-05
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section D.  Retiree Drug Subsidy Amounts",0.00015411072607887
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897769e-05
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section II Cost Plan Competition Requirements",0.000117601526802607
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655978
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966498e-05
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091924e-05
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474102
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.4529948427059e-05
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559709
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734768e-05
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313594
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777682
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section II Outpatient Observation Services",0.0001099411389947
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156119
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777678
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section I Annual Calendar",5.38342337295156e-05
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section III Specialty Tiers",0.000124543815635097
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820195e-05
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section A.  MA Growth Percentage",0.00014610629255971
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.00020208636844396
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768427
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640238
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635091
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section III Benefit Review",0.000122732519844415
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474111
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356355
"CMS-2017-0163-1150-1-4",9,"3.75469235631424e-05","Section II Employer Group Waiver Plans",0.000207044385747007
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579940392e-07
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313883755e-06
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section I Validation Audits",7.80120548019659e-06
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section B.  Calculation of Fee for Service Cost",5.50936891099055e-06
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section G.  MA Employer Group Waiver Plans",8.42420574183442e-06
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section L.  Normalization Factors",1.14232413853471e-05
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045106181e-06
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section IV   Medicare Medicaid Plans",5.48787256309162e-06
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329726e-05
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section III CY 2019 Formulary Submission Window",1.21641982343067e-05
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351524e-05
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section E.  Clinical Trials",2.21636701369663e-05
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775255e-05
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section II Part C Cost Sharing Standards",1.48376036820581e-05
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section II Total Beneficiary Cost (TBC)",1.32115891376893e-05
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032523969e-05
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section C.  Part D Risk Sharing",2.55140908046386e-05
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505645e-05
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",0.0633793108705755
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section O.  Quality Payment Program",2.52847571990462e-05
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section II Health Related Supplemental Benefits",3.44788570211453e-05
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741368e-05
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928654e-05
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section III Improving Access to Part D Vaccines",2.62277505669594e-05
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868504e-05
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650496e-05
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section I Innovations in Health Plan Design",3.17543788246075e-05
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.2487850608102e-05
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section III Tier Composition",4.59243068332466e-05
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496432e-05
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649233e-05
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section III Expanding the Part D OTC Program",5.52438803782678e-05
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section D.  ESRD Rates",3.65706624378686e-05
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section I Plan Corrections",4.14166098663187e-05
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section A.  Update of the RxHCC Model",2.28230186141223e-05
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section II Tiered Cost Sharing of Medical Benefits",5.7502427551997e-05
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048513967e-05
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098668e-05
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724262958e-05
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section II Plans with Low Enrollment",5.12202792258135e-05
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273216e-05
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268875e-05
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598863e-05
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328357e-05
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669166e-05
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319153
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section B.  FFS Growth Percentage",4.04246404618603e-05
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section C.  IME Phase Out",7.3536633701141e-05
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114403e-05
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410043e-05
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000583e-05
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.1533056654313e-05
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078871
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897709e-05
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section II Cost Plan Competition Requirements",0.000117601526802608
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655976
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966492e-05
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.7896929609186e-05
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474102
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270583e-05
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559703
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734628e-05
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313591
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777678
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section II Outpatient Observation Services",0.000109941138994698
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156119
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777682
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section I Annual Calendar",5.38342337295222e-05
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section III Specialty Tiers",0.00012454381563509
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820222e-05
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section A.  MA Growth Percentage",0.00014610629255971
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.000202086368443959
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768407
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640232
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635087
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section III Benefit Review",0.000122732519844413
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.0001007530724741
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356355
"CMS-2017-0163-1150-1-4",10,"3.75469235631381e-05","Section II Employer Group Waiver Plans",0.000207044385747007
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418580170853e-07
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313877105e-06
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section I Validation Audits",7.80120548018659e-06
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section B.  Calculation of Fee for Service Cost",5.50936891098809e-06
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section G.  MA Employer Group Waiver Plans",8.42420574183367e-06
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section L.  Normalization Factors",1.142324138534e-05
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045105401e-06
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section IV   Medicare Medicaid Plans",0.328199830334311
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329727e-05
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section III CY 2019 Formulary Submission Window",1.2164198234295e-05
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351387e-05
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section E.  Clinical Trials",2.21636701369624e-05
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775207e-05
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section II Part C Cost Sharing Standards",1.48376036820471e-05
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section II Total Beneficiary Cost (TBC)",1.3211589137678e-05
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032523974e-05
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section C.  Part D Risk Sharing",2.55140908046316e-05
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505548e-05
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703434e-05
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section O.  Quality Payment Program",2.52847571990408e-05
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section II Health Related Supplemental Benefits",3.44788570211395e-05
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.0492278874127e-05
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928453e-05
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section III Improving Access to Part D Vaccines",2.62277505669535e-05
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868452e-05
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650516e-05
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section I Innovations in Health Plan Design",3.17543788245976e-05
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081068e-05
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section III Tier Composition",4.5924306833245e-05
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496448e-05
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649253e-05
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section III Expanding the Part D OTC Program",5.52438803782618e-05
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section D.  ESRD Rates",3.6570662437868e-05
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section I Plan Corrections",4.14166098663167e-05
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section A.  Update of the RxHCC Model",2.28230186141147e-05
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275520028e-05
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048513906e-05
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098592e-05
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724263025e-05
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section II Plans with Low Enrollment",5.12202792258004e-05
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273184e-05
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268787e-05
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598813e-05
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328354e-05
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.0466454466934e-05
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319153
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section B.  FFS Growth Percentage",4.04246404618529e-05
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section C.  IME Phase Out",7.35366337011384e-05
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114386e-05
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045409976e-05
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000583e-05
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543186e-05
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078871
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897702e-05
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section II Cost Plan Competition Requirements",0.000117601526802607
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655975
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966493e-05
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091837e-05
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474099
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270577e-05
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.00014610629255971
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734761e-05
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313587
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777683
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section II Outpatient Observation Services",0.000109941138994696
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156114
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777677
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section I Annual Calendar",5.3834233729517e-05
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section III Specialty Tiers",0.000124543815635083
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.9564379082018e-05
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section A.  MA Growth Percentage",0.000146106292559713
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.00020208636844396
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.0001209731537684
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640233
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635089
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section III Benefit Review",0.000122732519844409
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474102
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356359
"CMS-2017-0163-1150-1-4",11,"3.75469235631312e-05","Section II Employer Group Waiver Plans",0.000207044385747007
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579878636e-07
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313887796e-06
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section I Validation Audits",7.80120548018775e-06
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section B.  Calculation of Fee for Service Cost",5.50936891090178e-06
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section G.  MA Employer Group Waiver Plans",8.42420574184053e-06
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section L.  Normalization Factors",1.14232413853464e-05
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045105899e-06
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section IV   Medicare Medicaid Plans",5.4878725630879e-06
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.1532515932973e-05
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section III CY 2019 Formulary Submission Window",1.21641982343075e-05
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351526e-05
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section E.  Clinical Trials",2.21636701369639e-05
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775238e-05
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section II Part C Cost Sharing Standards",1.4837603682054e-05
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section II Total Beneficiary Cost (TBC)",0.581562735608136
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032523984e-05
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section C.  Part D Risk Sharing",2.55140908046341e-05
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505587e-05
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703444e-05
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section O.  Quality Payment Program",2.52847571990439e-05
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section II Health Related Supplemental Benefits",3.44788570211458e-05
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741334e-05
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.875389019285e-05
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section III Improving Access to Part D Vaccines",2.62277505669558e-05
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868486e-05
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.7781938965048e-05
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section I Innovations in Health Plan Design",3.17543788246044e-05
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081093e-05
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section III Tier Composition",4.59243068332405e-05
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496427e-05
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649306e-05
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section III Expanding the Part D OTC Program",5.52438803782656e-05
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section D.  ESRD Rates",3.65706624378809e-05
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section I Plan Corrections",4.14166098663229e-05
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section A.  Update of the RxHCC Model",2.28230186141222e-05
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275520032e-05
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048513983e-05
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098625e-05
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724262984e-05
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section II Plans with Low Enrollment",5.12202792258164e-05
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273244e-05
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268848e-05
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598845e-05
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328297e-05
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669157e-05
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319155
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section B.  FFS Growth Percentage",4.04246404618593e-05
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section C.  IME Phase Out",7.3536633701138e-05
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114398e-05
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410078e-05
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000585e-05
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543183e-05
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section D.  Retiree Drug Subsidy Amounts",0.00015411072607888
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897758e-05
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section II Cost Plan Competition Requirements",0.000117601526802609
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655975
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966487e-05
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091866e-05
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474099
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270557e-05
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559712
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734651e-05
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313592
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777684
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section II Outpatient Observation Services",0.000109941138994698
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156117
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.00010449577977768
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section I Annual Calendar",5.38342337295173e-05
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section III Specialty Tiers",0.000124543815635088
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820182e-05
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section A.  MA Growth Percentage",0.00014610629255971
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.000202086368443957
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768406
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640231
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635089
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section III Benefit Review",0.000122732519844425
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474097
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356355
"CMS-2017-0163-1150-1-4",12,"3.75469235631361e-05","Section II Employer Group Waiver Plans",0.000207044385747007
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579864525e-07
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313867794e-06
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section I Validation Audits",7.80120548019332e-06
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section B.  Calculation of Fee for Service Cost",5.50936891099209e-06
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section G.  MA Employer Group Waiver Plans",8.42420574185026e-06
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section L.  Normalization Factors",1.14232413853488e-05
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045106041e-06
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section IV   Medicare Medicaid Plans",5.48787256309027e-06
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329722e-05
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section III CY 2019 Formulary Submission Window",1.21641982343138e-05
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351552e-05
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section E.  Clinical Trials",2.21636701369651e-05
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775344e-05
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section II Part C Cost Sharing Standards",1.48376036820528e-05
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section II Total Beneficiary Cost (TBC)",1.32115891376959e-05
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032524139e-05
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section C.  Part D Risk Sharing",2.55140908046373e-05
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505599e-05
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703512e-05
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section O.  Quality Payment Program",2.52847571990463e-05
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section II Health Related Supplemental Benefits",3.44788570211561e-05
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741403e-05
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928539e-05
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section III Improving Access to Part D Vaccines",2.6227750566956e-05
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868577e-05
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650502e-05
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section I Innovations in Health Plan Design",3.17543788246063e-05
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081144e-05
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section III Tier Composition",4.59243068332447e-05
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496414e-05
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649272e-05
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section III Expanding the Part D OTC Program",5.52438803782765e-05
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section D.  ESRD Rates",3.65706624378739e-05
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section I Plan Corrections",4.14166098663227e-05
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section A.  Update of the RxHCC Model",2.28230186141247e-05
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275519951e-05
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048513981e-05
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",0.996800668458522
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724262965e-05
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section II Plans with Low Enrollment",5.12202792258164e-05
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273266e-05
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268828e-05
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598916e-05
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328423e-05
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669185e-05
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319154
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section B.  FFS Growth Percentage",4.04246404618571e-05
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section C.  IME Phase Out",7.35366337011366e-05
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.5450282411444e-05
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410094e-05
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000602e-05
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543184e-05
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078874
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897728e-05
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section II Cost Plan Competition Requirements",0.000117601526802604
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655975
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966439e-05
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091866e-05
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474103
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270638e-05
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.00014610629255971
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734727e-05
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313588
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777685
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section II Outpatient Observation Services",0.000109941138994696
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156118
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777678
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section I Annual Calendar",5.38342337295175e-05
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section III Specialty Tiers",0.000124543815635093
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820214e-05
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section A.  MA Growth Percentage",0.000146106292559715
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.000202086368443959
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768409
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640233
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635099
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section III Benefit Review",0.000122732519844414
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.00010075307247411
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356355
"CMS-2017-0163-1150-1-4",13,"3.75469235631483e-05","Section II Employer Group Waiver Plans",0.000207044385747009
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579879095e-07
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313888597e-06
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section I Validation Audits",7.80120548019212e-06
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section B.  Calculation of Fee for Service Cost",5.50936891097433e-06
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section G.  MA Employer Group Waiver Plans",8.4242057418359e-06
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section L.  Normalization Factors",1.14232413853512e-05
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045105876e-06
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section IV   Medicare Medicaid Plans",5.48787256309005e-06
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",0.230048891244117
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section III CY 2019 Formulary Submission Window",1.21641982343085e-05
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351487e-05
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section E.  Clinical Trials",2.21636701369617e-05
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775344e-05
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section II Part C Cost Sharing Standards",1.48376036820586e-05
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section II Total Beneficiary Cost (TBC)",1.3211589137691e-05
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032523931e-05
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section C.  Part D Risk Sharing",2.55140908046339e-05
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505557e-05
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.5493966770347e-05
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section O.  Quality Payment Program",2.52847571990424e-05
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section II Health Related Supplemental Benefits",3.44788570211537e-05
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741372e-05
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928547e-05
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section III Improving Access to Part D Vaccines",2.62277505669551e-05
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868462e-05
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650489e-05
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section I Innovations in Health Plan Design",3.17543788246041e-05
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081118e-05
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section III Tier Composition",4.5924306833243e-05
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496433e-05
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649264e-05
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section III Expanding the Part D OTC Program",5.52438803782585e-05
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section D.  ESRD Rates",3.65706624378778e-05
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section I Plan Corrections",4.14166098663164e-05
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section A.  Update of the RxHCC Model",2.28230186141257e-05
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275519968e-05
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048513982e-05
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098638e-05
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724262931e-05
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section II Plans with Low Enrollment",5.12202792258105e-05
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273305e-05
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268791e-05
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598889e-05
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328466e-05
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669166e-05
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319163
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section B.  FFS Growth Percentage",4.04246404618587e-05
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section C.  IME Phase Out",7.35366337011375e-05
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114451e-05
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.5186604541005e-05
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000615e-05
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543099e-05
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078874
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897706e-05
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section II Cost Plan Competition Requirements",0.000117601526802605
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655979
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966476e-05
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091896e-05
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474103
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270595e-05
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559711
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734647e-05
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313587
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777692
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section II Outpatient Observation Services",0.000109941138994698
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156119
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777682
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section I Annual Calendar",5.38342337295195e-05
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section III Specialty Tiers",0.000124543815635086
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.9564379082031e-05
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section A.  MA Growth Percentage",0.000146106292559708
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.000202086368443959
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768409
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640233
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.00012454381563509
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section III Benefit Review",0.000122732519844411
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.0001007530724741
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356357
"CMS-2017-0163-1150-1-4",14,"3.7546923563135e-05","Section II Employer Group Waiver Plans",0.00020704438574701
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579908889e-07
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313887032e-06
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section I Validation Audits",7.80120548019845e-06
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section B.  Calculation of Fee for Service Cost",5.50936891099133e-06
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section G.  MA Employer Group Waiver Plans",8.42420574183377e-06
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section L.  Normalization Factors",1.1423241385347e-05
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045106154e-06
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section IV   Medicare Medicaid Plans",5.48787256308859e-06
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.1532515932968e-05
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section III CY 2019 Formulary Submission Window",1.21641982343134e-05
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351531e-05
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section E.  Clinical Trials",2.21636701369746e-05
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775348e-05
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section II Part C Cost Sharing Standards",1.48376036820546e-05
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section II Total Beneficiary Cost (TBC)",1.32115891376958e-05
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032524176e-05
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section C.  Part D Risk Sharing",2.55140908046374e-05
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505634e-05
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703469e-05
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section O.  Quality Payment Program",2.52847571990445e-05
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section II Health Related Supplemental Benefits",3.44788570211533e-05
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741383e-05
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928574e-05
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section III Improving Access to Part D Vaccines",2.62277505669626e-05
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347866995e-05
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389649996e-05
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section I Innovations in Health Plan Design",3.17543788246061e-05
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081047e-05
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section III Tier Composition",4.59243068332497e-05
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496404e-05
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",0.947918512830763
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section III Expanding the Part D OTC Program",5.52438803782634e-05
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section D.  ESRD Rates",3.65706624378694e-05
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section I Plan Corrections",4.1416609866319e-05
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section A.  Update of the RxHCC Model",2.28230186141251e-05
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275520072e-05
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048513997e-05
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098683e-05
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724263062e-05
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section II Plans with Low Enrollment",5.12202792258189e-05
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.6054010927329e-05
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268854e-05
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598898e-05
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.5197887032845e-05
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669237e-05
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319153
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section B.  FFS Growth Percentage",4.04246404618611e-05
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section C.  IME Phase Out",7.35366337011434e-05
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114437e-05
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410207e-05
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000621e-05
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543273e-05
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078872
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.5035911989775e-05
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section II Cost Plan Competition Requirements",0.000117601526802609
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655995
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966557e-05
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.7896929609191e-05
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474103
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270598e-05
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559711
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734783e-05
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.00010197049231359
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777681
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section II Outpatient Observation Services",0.000109941138994702
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156118
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777677
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section I Annual Calendar",5.38342337295205e-05
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section III Specialty Tiers",0.000124543815635096
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820188e-05
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section A.  MA Growth Percentage",0.000146106292559713
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.000202086368443958
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768406
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640235
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635094
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section III Benefit Review",0.000122732519844421
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474114
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356359
"CMS-2017-0163-1150-1-4",15,"3.75469235631365e-05","Section II Employer Group Waiver Plans",0.000207044385747009
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579875763e-07
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313883486e-06
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section I Validation Audits",7.80120548019104e-06
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section B.  Calculation of Fee for Service Cost",5.50936891099533e-06
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section G.  MA Employer Group Waiver Plans",8.42420574184609e-06
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section L.  Normalization Factors",1.14232413853467e-05
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.5297404510588e-06
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section IV   Medicare Medicaid Plans",5.48787256284461e-06
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329728e-05
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section III CY 2019 Formulary Submission Window",1.21641982343114e-05
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370347779e-05
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section E.  Clinical Trials",2.21636701369668e-05
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775289e-05
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section II Part C Cost Sharing Standards",1.48376036820551e-05
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section II Total Beneficiary Cost (TBC)",1.3211589137691e-05
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032524064e-05
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section C.  Part D Risk Sharing",2.55140908046409e-05
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505575e-05
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703538e-05
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section O.  Quality Payment Program",2.52847571990493e-05
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section II Health Related Supplemental Benefits",3.44788570211524e-05
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741389e-05
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928507e-05
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section III Improving Access to Part D Vaccines",2.62277505669579e-05
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868492e-05
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650495e-05
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section I Innovations in Health Plan Design",3.17543788246082e-05
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081152e-05
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section III Tier Composition",4.59243068332498e-05
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496462e-05
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649269e-05
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section III Expanding the Part D OTC Program",5.52438803782652e-05
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section D.  ESRD Rates",3.65706624378707e-05
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section I Plan Corrections",0.996313921721897
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section A.  Update of the RxHCC Model",2.28230186141231e-05
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275519988e-05
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048514012e-05
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098667e-05
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724263011e-05
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section II Plans with Low Enrollment",5.12202792258176e-05
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273286e-05
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.7215762826882e-05
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598878e-05
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328299e-05
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669177e-05
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319158
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section B.  FFS Growth Percentage",4.04246404618599e-05
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section C.  IME Phase Out",7.353663370114e-05
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114377e-05
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.5186604541014e-05
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000638e-05
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543191e-05
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section D.  Retiree Drug Subsidy Amounts",0.00015411072607887
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897838e-05
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section II Cost Plan Competition Requirements",0.000117601526802605
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655977
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966481e-05
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091888e-05
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474115
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270618e-05
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559711
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734713e-05
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313591
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777684
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section II Outpatient Observation Services",0.000109941138994699
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156119
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777681
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section I Annual Calendar",5.38342337295272e-05
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section III Specialty Tiers",0.000124543815635094
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820226e-05
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section A.  MA Growth Percentage",0.000146106292559712
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.000202086368443962
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768406
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640236
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635093
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section III Benefit Review",0.000122732519844415
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.00010075307247411
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356356
"CMS-2017-0163-1150-1-4",16,"3.75469235631342e-05","Section II Employer Group Waiver Plans",0.00020704438574703
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579895736e-07
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313888359e-06
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section I Validation Audits",7.80120548019426e-06
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section B.  Calculation of Fee for Service Cost",5.50936891099143e-06
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section G.  MA Employer Group Waiver Plans",8.42420574183514e-06
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section L.  Normalization Factors",1.14232413853466e-05
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045105876e-06
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section IV   Medicare Medicaid Plans",5.48787256309412e-06
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329706e-05
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section III CY 2019 Formulary Submission Window",1.21641982343113e-05
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351522e-05
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section E.  Clinical Trials",2.21636701369777e-05
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775332e-05
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section II Part C Cost Sharing Standards",1.48376036817294e-05
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section II Total Beneficiary Cost (TBC)",1.32115891377008e-05
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032523991e-05
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section C.  Part D Risk Sharing",2.55140908046395e-05
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505671e-05
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703496e-05
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section O.  Quality Payment Program",2.5284757199047e-05
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section II Health Related Supplemental Benefits",3.44788570211566e-05
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741442e-05
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928585e-05
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section III Improving Access to Part D Vaccines",2.6227750566969e-05
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.2928234786855e-05
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650607e-05
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section I Innovations in Health Plan Design",3.175437882461e-05
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081126e-05
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section III Tier Composition",4.59243068332435e-05
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496438e-05
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649328e-05
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section III Expanding the Part D OTC Program",5.52438803782687e-05
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section D.  ESRD Rates",3.65706624378749e-05
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section I Plan Corrections",4.14166098663241e-05
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section A.  Update of the RxHCC Model",2.28230186141228e-05
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section II Tiered Cost Sharing of Medical Benefits",0.994882283947872
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048513985e-05
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098702e-05
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724263036e-05
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section II Plans with Low Enrollment",5.12202792258189e-05
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273248e-05
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268948e-05
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598865e-05
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328554e-05
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669198e-05
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319157
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section B.  FFS Growth Percentage",4.04246404618566e-05
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section C.  IME Phase Out",7.35366337011458e-05
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114381e-05
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410089e-05
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.6575108000072e-05
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543245e-05
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078877
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897732e-05
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section II Cost Plan Competition Requirements",0.000117601526802615
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655995
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966554e-05
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091862e-05
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474109
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270624e-05
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559706
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734648e-05
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313589
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777681
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section II Outpatient Observation Services",0.000109941138994703
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156118
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777679
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section I Annual Calendar",5.38342337295239e-05
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section III Specialty Tiers",0.000124543815635095
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820218e-05
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section A.  MA Growth Percentage",0.000146106292559714
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.00020208636844396
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768408
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.00011288233364024
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635102
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section III Benefit Review",0.000122732519844417
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474116
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356357
"CMS-2017-0163-1150-1-4",17,"3.75469235631541e-05","Section II Employer Group Waiver Plans",0.000207044385747001
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418580169842e-07
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313888018e-06
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section I Validation Audits",7.80120548019189e-06
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section B.  Calculation of Fee for Service Cost",0.783536606563324
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section G.  MA Employer Group Waiver Plans",8.42420574182367e-06
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section L.  Normalization Factors",1.14232413853549e-05
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045085223e-06
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section IV   Medicare Medicaid Plans",5.48787256308578e-06
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329705e-05
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section III CY 2019 Formulary Submission Window",1.21641982343028e-05
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351421e-05
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section E.  Clinical Trials",2.21636701369579e-05
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775247e-05
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section II Part C Cost Sharing Standards",1.48376036820481e-05
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section II Total Beneficiary Cost (TBC)",1.32115891376768e-05
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.0798103252402e-05
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section C.  Part D Risk Sharing",2.55140908046364e-05
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505586e-05
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703433e-05
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section O.  Quality Payment Program",2.5284757199044e-05
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section II Health Related Supplemental Benefits",3.44788570211399e-05
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741306e-05
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928509e-05
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section III Improving Access to Part D Vaccines",2.62277505669512e-05
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868482e-05
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650451e-05
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section I Innovations in Health Plan Design",3.17543788246062e-05
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.2487850608112e-05
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section III Tier Composition",4.59243068332398e-05
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496518e-05
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649225e-05
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section III Expanding the Part D OTC Program",5.52438803782587e-05
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section D.  ESRD Rates",3.65706624378429e-05
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section I Plan Corrections",4.14166098663165e-05
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section A.  Update of the RxHCC Model",2.28230186141295e-05
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275519934e-05
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048513968e-05
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098597e-05
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724262947e-05
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section II Plans with Low Enrollment",5.12202792258093e-05
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273227e-05
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268794e-05
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598884e-05
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328327e-05
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669103e-05
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319153
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section B.  FFS Growth Percentage",4.0424640461857e-05
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section C.  IME Phase Out",7.35366337011629e-05
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114359e-05
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410045e-05
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000594e-05
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543192e-05
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078872
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897717e-05
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section II Cost Plan Competition Requirements",0.000117601526802599
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655975
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966488e-05
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091863e-05
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474104
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270511e-05
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559709
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734625e-05
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313589
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777689
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section II Outpatient Observation Services",0.000109941138994699
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156115
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777678
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section I Annual Calendar",5.383423372952e-05
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section III Specialty Tiers",0.000124543815635086
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820249e-05
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section A.  MA Growth Percentage",0.000146106292559709
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.000202086368443959
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768408
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640233
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635093
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section III Benefit Review",0.000122732519844412
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.0001007530724741
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356358
"CMS-2017-0163-1150-1-4",18,"3.75469235631289e-05","Section II Employer Group Waiver Plans",0.000207044385747006
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",0.199153353125736
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313880682e-06
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section I Validation Audits",7.80120548018613e-06
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section B.  Calculation of Fee for Service Cost",5.50936891096864e-06
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section G.  MA Employer Group Waiver Plans",8.42420574182267e-06
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section L.  Normalization Factors",1.14232413853431e-05
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045103306e-06
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section IV   Medicare Medicaid Plans",5.4878725630773e-06
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329625e-05
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section III CY 2019 Formulary Submission Window",1.21641982342949e-05
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351354e-05
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section E.  Clinical Trials",2.21636701369613e-05
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775163e-05
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section II Part C Cost Sharing Standards",1.48376036820432e-05
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section II Total Beneficiary Cost (TBC)",1.32115891376669e-05
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032523875e-05
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section C.  Part D Risk Sharing",2.55140908046366e-05
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505463e-05
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703427e-05
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section O.  Quality Payment Program",2.52847571990391e-05
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section II Health Related Supplemental Benefits",3.44788570211308e-05
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741246e-05
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928469e-05
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section III Improving Access to Part D Vaccines",2.62277505669462e-05
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868459e-05
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.7781938965043e-05
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section I Innovations in Health Plan Design",3.17543788245873e-05
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506080928e-05
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section III Tier Composition",4.59243068332379e-05
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496399e-05
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649211e-05
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section III Expanding the Part D OTC Program",5.52438803782588e-05
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section D.  ESRD Rates",3.65706624378665e-05
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section I Plan Corrections",4.1416609866314e-05
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section A.  Update of the RxHCC Model",2.28230186141158e-05
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275519917e-05
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048513958e-05
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098591e-05
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724262902e-05
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section II Plans with Low Enrollment",5.12202792258097e-05
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273187e-05
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268706e-05
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598909e-05
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328309e-05
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669088e-05
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319153
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section B.  FFS Growth Percentage",4.04246404618609e-05
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section C.  IME Phase Out",7.35366337011402e-05
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114329e-05
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045409983e-05
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000523e-05
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543161e-05
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078869
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897655e-05
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section II Cost Plan Competition Requirements",0.000117601526802597
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655976
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966522e-05
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091776e-05
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section I Enforcement Actions for Provider Directories",0.0001007530724741
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270481e-05
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559714
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734712e-05
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313585
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777682
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section II Outpatient Observation Services",0.000109941138994691
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156112
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777675
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section I Annual Calendar",5.38342337295071e-05
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section III Specialty Tiers",0.000124543815635088
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820137e-05
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section A.  MA Growth Percentage",0.000146106292559706
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.000202086368443956
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768403
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640229
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635084
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section III Benefit Review",0.000122732519844411
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474097
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356354
"CMS-2017-0163-1150-1-4",19,"3.75469235631167e-05","Section II Employer Group Waiver Plans",0.000207044385747006
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579904725e-07
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313888126e-06
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section I Validation Audits",7.80120548019355e-06
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section B.  Calculation of Fee for Service Cost",5.50936891099125e-06
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section G.  MA Employer Group Waiver Plans",8.42420574183899e-06
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section L.  Normalization Factors",1.14232413853467e-05
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.529740451062e-06
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section IV   Medicare Medicaid Plans",5.48787256298657e-06
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329788e-05
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section III CY 2019 Formulary Submission Window",1.21641982343082e-05
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351514e-05
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section E.  Clinical Trials",2.2163670136972e-05
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775282e-05
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section II Part C Cost Sharing Standards",1.483760368205e-05
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section II Total Beneficiary Cost (TBC)",1.32115891376937e-05
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032523962e-05
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section C.  Part D Risk Sharing",2.55140908046369e-05
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505632e-05
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.5493966770347e-05
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section O.  Quality Payment Program",2.52847571990456e-05
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section II Health Related Supplemental Benefits",3.44788570211507e-05
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",0.997286187180202
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928553e-05
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section III Improving Access to Part D Vaccines",2.62277505669536e-05
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868485e-05
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650502e-05
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section I Innovations in Health Plan Design",3.17543788246081e-05
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081106e-05
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section III Tier Composition",4.59243068332466e-05
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.7474411449643e-05
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649254e-05
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section III Expanding the Part D OTC Program",5.524388037827e-05
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section D.  ESRD Rates",3.65706624378714e-05
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section I Plan Corrections",4.14166098663196e-05
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section A.  Update of the RxHCC Model",2.28230186141186e-05
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section II Tiered Cost Sharing of Medical Benefits",5.75024275520091e-05
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048514022e-05
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098609e-05
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section II Cost Plan Transition to MA under MACRA",7.75934724262974e-05
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section II Plans with Low Enrollment",5.12202792258163e-05
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273328e-05
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.7215762826887e-05
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598893e-05
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328467e-05
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669167e-05
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319154
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section B.  FFS Growth Percentage",4.04246404618565e-05
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section C.  IME Phase Out",7.35366337011403e-05
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114379e-05
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410102e-05
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000628e-05
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543177e-05
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078872
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897802e-05
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section II Cost Plan Competition Requirements",0.000117601526802609
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655973
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966485e-05
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091808e-05
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section I Enforcement Actions for Provider Directories",0.000100753072474109
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.4529948427064e-05
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559707
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section III Coordination of Benefits (COB) User Fee",7.68865316734745e-05
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313587
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777684
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section II Outpatient Observation Services",0.000109941138994698
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section II Part C Optional Supplemental Benefits",0.000114412744156121
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.00010449577977768
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section I Annual Calendar",5.38342337295262e-05
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section III Specialty Tiers",0.00012454381563509
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820182e-05
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section A.  MA Growth Percentage",0.000146106292559715
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.000202086368443959
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768408
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.00011288233364023
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635101
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section III Benefit Review",0.000122732519844414
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474101
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356355
"CMS-2017-0163-1150-1-4",20,"0.0559594278639901","Section II Employer Group Waiver Plans",0.000207044385747011
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.9941858013055e-07
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313882215e-06
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section I Validation Audits",0.999305692712264
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section B.  Calculation of Fee for Service Cost",5.50936891098936e-06
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section G.  MA Employer Group Waiver Plans",8.42420574183148e-06
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section L.  Normalization Factors",1.1423241385345e-05
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045106781e-06
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section IV   Medicare Medicaid Plans",5.48787256308948e-06
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329675e-05
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section III CY 2019 Formulary Submission Window",1.21641982343052e-05
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351475e-05
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section E.  Clinical Trials",2.21636701369657e-05
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775262e-05
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section II Part C Cost Sharing Standards",1.48376036820452e-05
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section II Total Beneficiary Cost (TBC)",1.32115891376822e-05
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032524053e-05
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section C.  Part D Risk Sharing",2.55140908046359e-05
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505519e-05
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667702435e-05
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section O.  Quality Payment Program",2.52847571990415e-05
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section II Health Related Supplemental Benefits",3.44788570211399e-05
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741342e-05
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928535e-05
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section III Improving Access to Part D Vaccines",2.62277505669586e-05
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.292823478685e-05
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650471e-05
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section I Innovations in Health Plan Design",3.17543788246059e-05
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081174e-05
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section III Tier Composition",4.59243068332423e-05
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496468e-05
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649221e-05
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section III Expanding the Part D OTC Program",5.5243880378265e-05
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section D.  ESRD Rates",3.65706624378614e-05
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section I Plan Corrections",4.14166098663198e-05
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section A.  Update of the RxHCC Model",2.28230186141197e-05
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section II Tiered Cost Sharing of Medical Benefits",5.7502427551995e-05
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.4018204851396e-05
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098605e-05
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724262916e-05
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section II Plans with Low Enrollment",5.12202792258045e-05
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273186e-05
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268779e-05
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598856e-05
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328353e-05
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669136e-05
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319154
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section B.  FFS Growth Percentage",4.04246404618511e-05
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section C.  IME Phase Out",7.35366337011384e-05
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114424e-05
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410178e-05
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000612e-05
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543163e-05
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section D.  Retiree Drug Subsidy Amounts",0.00015411072607887
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897757e-05
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section II Cost Plan Competition Requirements",0.000117601526802605
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655976
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966461e-05
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.7896929609188e-05
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474113
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270615e-05
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559707
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734671e-05
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313589
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777679
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section II Outpatient Observation Services",0.000109941138994698
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156119
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777677
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section I Annual Calendar",5.38342337295165e-05
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section III Specialty Tiers",0.000124543815635086
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820211e-05
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section A.  MA Growth Percentage",0.000146106292559711
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.000202086368443961
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768405
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640234
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635088
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section III Benefit Review",0.000122732519844411
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474101
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356357
"CMS-2017-0163-1150-1-4",21,"3.75469235631283e-05","Section II Employer Group Waiver Plans",0.000207044385747006
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579876566e-07
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313887603e-06
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section I Validation Audits",7.80120548019414e-06
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section B.  Calculation of Fee for Service Cost",5.50936891084744e-06
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section G.  MA Employer Group Waiver Plans",8.42420574184557e-06
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section L.  Normalization Factors",0.38042376741539
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045106456e-06
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section IV   Medicare Medicaid Plans",5.4878725630929e-06
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159326727e-05
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section III CY 2019 Formulary Submission Window",1.21641982343053e-05
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351477e-05
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section E.  Clinical Trials",2.21636701369617e-05
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775363e-05
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section II Part C Cost Sharing Standards",1.48376036820502e-05
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section II Total Beneficiary Cost (TBC)",1.32115891376985e-05
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032523994e-05
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section C.  Part D Risk Sharing",2.55140908046474e-05
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505591e-05
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703514e-05
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section O.  Quality Payment Program",2.52847571990534e-05
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section II Health Related Supplemental Benefits",3.44788570211453e-05
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741353e-05
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928536e-05
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section III Improving Access to Part D Vaccines",2.62277505669524e-05
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868522e-05
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650482e-05
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section I Innovations in Health Plan Design",3.17543788246098e-05
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081072e-05
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section III Tier Composition",4.59243068332422e-05
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496547e-05
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649234e-05
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section III Expanding the Part D OTC Program",5.52438803782575e-05
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section D.  ESRD Rates",3.65706624378846e-05
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section I Plan Corrections",4.14166098663144e-05
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section A.  Update of the RxHCC Model",2.28230186138367e-05
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275519946e-05
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048513986e-05
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098656e-05
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724262966e-05
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section II Plans with Low Enrollment",5.12202792258076e-05
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273208e-05
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268861e-05
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598881e-05
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328377e-05
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669186e-05
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319184
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section B.  FFS Growth Percentage",4.04246404618556e-05
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section C.  IME Phase Out",7.3536633701145e-05
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.5450282411441e-05
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410074e-05
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000572e-05
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543142e-05
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section D.  Retiree Drug Subsidy Amounts",0.00015411072607887
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897728e-05
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section II Cost Plan Competition Requirements",0.0001176015268026
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655977
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966469e-05
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091879e-05
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474102
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270585e-05
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.00014610629255971
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734612e-05
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313588
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777684
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section II Outpatient Observation Services",0.000109941138994697
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section II Part C Optional Supplemental Benefits",0.00011441274415612
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777678
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section I Annual Calendar",5.38342337295172e-05
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section III Specialty Tiers",0.000124543815635089
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820281e-05
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section A.  MA Growth Percentage",0.000146106292559712
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.000202086368443957
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768406
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640231
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635094
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section III Benefit Review",0.000122732519844413
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474099
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356373
"CMS-2017-0163-1150-1-4",22,"3.75469235631417e-05","Section II Employer Group Waiver Plans",0.00020704438574701
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",0.173996437566478
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313876912e-06
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section I Validation Audits",7.80120548020389e-06
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section B.  Calculation of Fee for Service Cost",5.5093689109747e-06
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section G.  MA Employer Group Waiver Plans",8.42420574183588e-06
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section L.  Normalization Factors",1.14232413853424e-05
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045102836e-06
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section IV   Medicare Medicaid Plans",5.48787256307348e-06
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329617e-05
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section III CY 2019 Formulary Submission Window",1.21641982342877e-05
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351319e-05
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section E.  Clinical Trials",2.21636701369586e-05
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775119e-05
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section II Part C Cost Sharing Standards",1.48376036820447e-05
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section II Total Beneficiary Cost (TBC)",1.32115891376781e-05
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032524003e-05
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section C.  Part D Risk Sharing",2.55140908046309e-05
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505461e-05
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703438e-05
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section O.  Quality Payment Program",2.52847571990375e-05
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section II Health Related Supplemental Benefits",3.44788570211309e-05
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.0492278874125e-05
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928524e-05
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section III Improving Access to Part D Vaccines",2.62277505669485e-05
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868397e-05
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650469e-05
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section I Innovations in Health Plan Design",3.17543788246018e-05
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081069e-05
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section III Tier Composition",4.59243068332354e-05
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496336e-05
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649136e-05
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section III Expanding the Part D OTC Program",5.52438803782585e-05
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section D.  ESRD Rates",3.65706624378648e-05
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section I Plan Corrections",4.14166098663189e-05
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section A.  Update of the RxHCC Model",2.28230186141138e-05
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section II Tiered Cost Sharing of Medical Benefits",5.75024275519907e-05
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048513934e-05
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098648e-05
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section II Cost Plan Transition to MA under MACRA",7.75934724262978e-05
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section II Plans with Low Enrollment",5.12202792258079e-05
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273251e-05
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268801e-05
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598881e-05
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328263e-05
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669105e-05
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319152
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section B.  FFS Growth Percentage",4.04246404618505e-05
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section C.  IME Phase Out",7.35366337011458e-05
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114343e-05
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section II Overview of CY 2019 Benefits and Bid Review",4.5186604540995e-05
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000538e-05
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543142e-05
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078867
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.5035911989775e-05
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section II Cost Plan Competition Requirements",0.000117601526802603
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655976
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966504e-05
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091833e-05
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section I Enforcement Actions for Provider Directories",0.000100753072474097
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270569e-05
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.00014610629255971
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section III Coordination of Benefits (COB) User Fee",7.68865316734708e-05
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.00010197049231359
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777685
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section II Outpatient Observation Services",0.000109941138994699
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section II Part C Optional Supplemental Benefits",0.000114412744156123
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777674
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section I Annual Calendar",5.38342337295086e-05
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section III Specialty Tiers",0.000124543815635087
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section N.  Encounter Data as a Diagnosis Source for 2019",9.956437908202e-05
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section A.  MA Growth Percentage",0.000146106292559708
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.000202086368443959
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768399
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640232
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635084
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section III Benefit Review",0.000122732519844406
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474098
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356354
"CMS-2017-0163-1150-1-4",23,"0.109645607709195","Section II Employer Group Waiver Plans",0.000207044385747007
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579915661e-07
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313887073e-06
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section I Validation Audits",7.8012054801928e-06
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section B.  Calculation of Fee for Service Cost",5.50936891098887e-06
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section G.  MA Employer Group Waiver Plans",8.42420574184455e-06
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section L.  Normalization Factors",1.14232413853454e-05
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045106549e-06
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section IV   Medicare Medicaid Plans",5.48787256308569e-06
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329701e-05
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section III CY 2019 Formulary Submission Window",1.21641982343057e-05
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section I Incomplete and Inaccurate Bid Submissions",0.535647291938435
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section E.  Clinical Trials",2.21636701369648e-05
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775299e-05
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section II Part C Cost Sharing Standards",1.48376036820566e-05
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section II Total Beneficiary Cost (TBC)",1.32115891376911e-05
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032524006e-05
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section C.  Part D Risk Sharing",2.55140908046402e-05
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.4985316250558e-05
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703517e-05
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section O.  Quality Payment Program",2.52847571990473e-05
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section II Health Related Supplemental Benefits",3.44788570211474e-05
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741352e-05
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928529e-05
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section III Improving Access to Part D Vaccines",2.62277505669596e-05
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868577e-05
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650557e-05
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section I Innovations in Health Plan Design",3.17543788246017e-05
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081046e-05
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section III Tier Composition",4.59243068332487e-05
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496405e-05
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649292e-05
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section III Expanding the Part D OTC Program",5.52438803782651e-05
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section D.  ESRD Rates",3.65706624378701e-05
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section I Plan Corrections",4.14166098663371e-05
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section A.  Update of the RxHCC Model",2.28230186141156e-05
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275519965e-05
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048514015e-05
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.5947545409872e-05
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724262999e-05
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section II Plans with Low Enrollment",5.12202792258126e-05
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273264e-05
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268849e-05
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598891e-05
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328442e-05
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669136e-05
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319154
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section B.  FFS Growth Percentage",4.04246404618559e-05
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section C.  IME Phase Out",7.35366337011402e-05
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.5450282411439e-05
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410093e-05
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.6575108000063e-05
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543142e-05
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078867
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.5035911989777e-05
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section II Cost Plan Competition Requirements",0.000117601526802609
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655973
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966477e-05
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091834e-05
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474112
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270599e-05
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559706
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section III Coordination of Benefits (COB) User Fee",7.6886531673472e-05
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313585
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.00010449577977768
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section II Outpatient Observation Services",0.000109941138994703
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section II Part C Optional Supplemental Benefits",0.00011441274415612
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777685
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section I Annual Calendar",5.38342337295195e-05
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section III Specialty Tiers",0.000124543815635096
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820211e-05
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section A.  MA Growth Percentage",0.000146106292559713
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.00020208636844396
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768407
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640232
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635092
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section III Benefit Review",0.000122732519844412
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474103
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356357
"CMS-2017-0163-1150-1-4",24,"3.75469235631366e-05","Section II Employer Group Waiver Plans",0.000207044385747008
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579863753e-07
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313888267e-06
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section I Validation Audits",7.80120548019547e-06
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section B.  Calculation of Fee for Service Cost",5.5093689109928e-06
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section G.  MA Employer Group Waiver Plans",8.42420574183519e-06
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section L.  Normalization Factors",1.14232413853491e-05
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045106433e-06
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section IV   Medicare Medicaid Plans",5.48787256309428e-06
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329759e-05
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section III CY 2019 Formulary Submission Window",1.21641982343083e-05
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351528e-05
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section E.  Clinical Trials",2.21636701369746e-05
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775386e-05
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section II Part C Cost Sharing Standards",1.4837603681707e-05
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section II Total Beneficiary Cost (TBC)",1.32115891376964e-05
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032524016e-05
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section C.  Part D Risk Sharing",2.55140908046389e-05
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505696e-05
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703489e-05
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section O.  Quality Payment Program",2.52847571990474e-05
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section II Health Related Supplemental Benefits",3.4478857021158e-05
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741378e-05
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928699e-05
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section III Improving Access to Part D Vaccines",2.62277505669652e-05
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.2928234786858e-05
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650553e-05
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section I Innovations in Health Plan Design",3.17543788246082e-05
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081161e-05
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section III Tier Composition",4.59243068332472e-05
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496399e-05
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649352e-05
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section III Expanding the Part D OTC Program",5.52438803782659e-05
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section D.  ESRD Rates",3.6570662437881e-05
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section I Plan Corrections",4.14166098663213e-05
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section A.  Update of the RxHCC Model",2.28230186141241e-05
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275520114e-05
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048513991e-05
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098704e-05
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section II Cost Plan Transition to MA under MACRA",7.7593472426295e-05
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section II Plans with Low Enrollment",5.12202792258098e-05
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273238e-05
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268965e-05
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598909e-05
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328511e-05
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669328e-05
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319156
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section B.  FFS Growth Percentage",4.04246404618594e-05
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section C.  IME Phase Out",7.35366337011424e-05
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114396e-05
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410204e-05
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000656e-05
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543189e-05
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section D.  Retiree Drug Subsidy Amounts",0.00015411072607888
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.5035911989773e-05
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section II Cost Plan Competition Requirements",0.00011760152680261
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655994
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.9794507696652e-05
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091889e-05
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474106
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270695e-05
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559714
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734659e-05
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313589
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777679
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section II Outpatient Observation Services",0.990215238629472
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156119
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777682
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section I Annual Calendar",5.38342337295239e-05
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section III Specialty Tiers",0.000124543815635088
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820209e-05
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section A.  MA Growth Percentage",0.000146106292559711
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.00020208636844396
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768409
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.00011288233364024
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635096
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section III Benefit Review",0.000122732519844427
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474105
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356356
"CMS-2017-0163-1150-1-4",25,"3.75469235631387e-05","Section II Employer Group Waiver Plans",0.000207044385747009
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579896366e-07
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313887679e-06
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section I Validation Audits",7.80120548019545e-06
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section B.  Calculation of Fee for Service Cost",5.50936891097546e-06
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section G.  MA Employer Group Waiver Plans",8.42420574184613e-06
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section L.  Normalization Factors",1.14232413853524e-05
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045107016e-06
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section IV   Medicare Medicaid Plans",5.487872563011e-06
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329764e-05
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section III CY 2019 Formulary Submission Window",1.21641982343113e-05
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351489e-05
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section E.  Clinical Trials",2.21636701369632e-05
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775394e-05
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section II Part C Cost Sharing Standards",1.48376036820547e-05
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section II Total Beneficiary Cost (TBC)",1.32115891376977e-05
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032524009e-05
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section C.  Part D Risk Sharing",2.5514090804636e-05
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505622e-05
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703455e-05
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section O.  Quality Payment Program",2.52847571990473e-05
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section II Health Related Supplemental Benefits",3.44788570211493e-05
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741391e-05
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.8753890192856e-05
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section III Improving Access to Part D Vaccines",2.62277505669579e-05
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868527e-05
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650507e-05
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section I Innovations in Health Plan Design",3.17543788246152e-05
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081092e-05
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section III Tier Composition",4.59243068332439e-05
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",0.995774777380982
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649235e-05
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section III Expanding the Part D OTC Program",5.52438803782638e-05
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section D.  ESRD Rates",3.65706624378839e-05
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section I Plan Corrections",4.1416609866323e-05
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section A.  Update of the RxHCC Model",2.28230186141302e-05
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275519976e-05
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.4018204851399e-05
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098684e-05
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724262954e-05
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section II Plans with Low Enrollment",5.1220279225814e-05
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273288e-05
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268868e-05
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598942e-05
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328397e-05
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.0466454466916e-05
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319162
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section B.  FFS Growth Percentage",4.04246404618571e-05
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section C.  IME Phase Out",7.35366337011468e-05
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114464e-05
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410091e-05
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000575e-05
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543105e-05
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078869
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897725e-05
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section II Cost Plan Competition Requirements",0.000117601526802606
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655976
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966555e-05
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091898e-05
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474099
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270648e-05
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559708
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734621e-05
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.00010197049231359
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777694
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section II Outpatient Observation Services",0.000109941138994695
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156119
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777678
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section I Annual Calendar",5.38342337295201e-05
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section III Specialty Tiers",0.000124543815635088
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820274e-05
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section A.  MA Growth Percentage",0.000146106292559712
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.00020208636844396
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768409
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640234
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.00012454381563509
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section III Benefit Review",0.000122732519844416
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474102
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356353
"CMS-2017-0163-1150-1-4",26,"3.75469235631359e-05","Section II Employer Group Waiver Plans",0.000207044385747012
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418580065062e-07
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313887381e-06
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section I Validation Audits",7.80120548019234e-06
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section B.  Calculation of Fee for Service Cost",5.50936891099202e-06
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section G.  MA Employer Group Waiver Plans",8.42420574184212e-06
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section L.  Normalization Factors",1.14232413853481e-05
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045106269e-06
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section IV   Medicare Medicaid Plans",5.48787256293319e-06
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329724e-05
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section III CY 2019 Formulary Submission Window",1.21641982343056e-05
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351548e-05
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section E.  Clinical Trials",2.21636701369671e-05
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775271e-05
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section II Part C Cost Sharing Standards",1.48376036820506e-05
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section II Total Beneficiary Cost (TBC)",1.32115891376888e-05
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032523985e-05
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section C.  Part D Risk Sharing",2.55140908046356e-05
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505601e-05
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703485e-05
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section O.  Quality Payment Program",2.52847571990488e-05
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section II Health Related Supplemental Benefits",3.44788570211445e-05
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741359e-05
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928468e-05
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section III Improving Access to Part D Vaccines",2.6227750566954e-05
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868519e-05
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650518e-05
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section I Innovations in Health Plan Design",0.99717386028461
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081072e-05
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section III Tier Composition",4.59243068332452e-05
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496427e-05
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.5643882464929e-05
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section III Expanding the Part D OTC Program",5.52438803782631e-05
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section D.  ESRD Rates",3.65706624378744e-05
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section I Plan Corrections",4.14166098663233e-05
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section A.  Update of the RxHCC Model",2.28230186141255e-05
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275520029e-05
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048513985e-05
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098639e-05
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724262939e-05
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section II Plans with Low Enrollment",5.12202792258109e-05
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273312e-05
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268864e-05
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598902e-05
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328393e-05
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669258e-05
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319151
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section B.  FFS Growth Percentage",4.04246404618599e-05
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section C.  IME Phase Out",7.35366337011406e-05
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114476e-05
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410069e-05
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000648e-05
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543198e-05
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078872
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897684e-05
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section II Cost Plan Competition Requirements",0.000117601526802605
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655973
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.9794507696651e-05
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091922e-05
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section I Enforcement Actions for Provider Directories",0.0001007530724741
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270599e-05
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559707
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734729e-05
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313587
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777681
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section II Outpatient Observation Services",0.000109941138994701
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156117
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777676
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section I Annual Calendar",0.639641783707989
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section III Specialty Tiers",0.000124543815635088
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820197e-05
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section A.  MA Growth Percentage",0.000146106292559711
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.000202086368443955
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768407
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640229
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635091
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section III Benefit Review",0.000122732519844416
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474096
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356357
"CMS-2017-0163-1150-1-4",27,"3.75469235631393e-05","Section II Employer Group Waiver Plans",0.000207044385747007
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.9941857987579e-07
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313867034e-06
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section I Validation Audits",7.80120548019132e-06
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section B.  Calculation of Fee for Service Cost",5.5093689109671e-06
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section G.  MA Employer Group Waiver Plans",8.4242057418411e-06
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section L.  Normalization Factors",1.1423241385349e-05
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045106576e-06
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section IV   Medicare Medicaid Plans",5.48787256303403e-06
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329706e-05
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section III CY 2019 Formulary Submission Window",1.21641982343112e-05
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351495e-05
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section E.  Clinical Trials",2.21636701369679e-05
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775391e-05
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section II Part C Cost Sharing Standards",1.48376036820599e-05
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section II Total Beneficiary Cost (TBC)",1.32115891376881e-05
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032524124e-05
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section C.  Part D Risk Sharing",2.55140908046381e-05
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505672e-05
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703532e-05
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section O.  Quality Payment Program",2.52847571990454e-05
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section II Health Related Supplemental Benefits",3.44788570211562e-05
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741416e-05
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928627e-05
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section III Improving Access to Part D Vaccines",2.62277505669593e-05
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868658e-05
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650658e-05
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section I Innovations in Health Plan Design",3.17543788246039e-05
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081108e-05
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section III Tier Composition",4.59243068332426e-05
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496414e-05
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649411e-05
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section III Expanding the Part D OTC Program",5.5243880378274e-05
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section D.  ESRD Rates",3.65706624378728e-05
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section I Plan Corrections",4.14166098663285e-05
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section A.  Update of the RxHCC Model",2.28230186141283e-05
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section II Tiered Cost Sharing of Medical Benefits",5.75024275520085e-05
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048513989e-05
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098699e-05
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section II Cost Plan Transition to MA under MACRA",7.75934724263041e-05
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section II Plans with Low Enrollment",5.1220279225819e-05
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section III Low Enrollment Plans (Stand alone PDPs only)",6.605401092733e-05
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.7215762826886e-05
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598901e-05
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328494e-05
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669215e-05
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319153
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section B.  FFS Growth Percentage",4.04246404618579e-05
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section C.  IME Phase Out",7.35366337011385e-05
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114416e-05
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410124e-05
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000685e-05
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",0.995413557957766
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078871
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897795e-05
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section II Cost Plan Competition Requirements",0.000117601526802611
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655974
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966488e-05
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091892e-05
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section I Enforcement Actions for Provider Directories",0.0001007530724741
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270687e-05
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559706
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section III Coordination of Benefits (COB) User Fee",7.68865316734805e-05
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313587
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777682
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section II Outpatient Observation Services",0.000109941138994696
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section II Part C Optional Supplemental Benefits",0.000114412744156115
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777691
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section I Annual Calendar",5.38342337295222e-05
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section III Specialty Tiers",0.000124543815635102
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820204e-05
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section A.  MA Growth Percentage",0.000146106292559713
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.000202086368443958
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.00012097315376841
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640239
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635093
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section III Benefit Review",0.000122732519844423
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474116
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356356
"CMS-2017-0163-1150-1-4",28,"0.032773625633817","Section II Employer Group Waiver Plans",0.000207044385747008
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",0.212219855421494
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313880975e-06
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section I Validation Audits",7.80120548017968e-06
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section B.  Calculation of Fee for Service Cost",5.50936891095013e-06
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section G.  MA Employer Group Waiver Plans",8.42420574182148e-06
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section L.  Normalization Factors",1.14232413853394e-05
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045103761e-06
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section IV   Medicare Medicaid Plans",5.48787256307552e-06
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329585e-05
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section III CY 2019 Formulary Submission Window",1.21641982342975e-05
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351342e-05
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section E.  Clinical Trials",2.21636701369517e-05
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775133e-05
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section II Part C Cost Sharing Standards",1.48376036820477e-05
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section II Total Beneficiary Cost (TBC)",1.32115891376916e-05
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032523952e-05
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section C.  Part D Risk Sharing",2.55140908046338e-05
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505536e-05
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703431e-05
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section O.  Quality Payment Program",2.52847571990383e-05
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section II Health Related Supplemental Benefits",3.44788570211389e-05
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741263e-05
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928453e-05
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section III Improving Access to Part D Vaccines",2.62277505669504e-05
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868406e-05
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650474e-05
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section I Innovations in Health Plan Design",3.1754378824582e-05
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506080939e-05
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section III Tier Composition",4.59243068332359e-05
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496372e-05
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649168e-05
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section III Expanding the Part D OTC Program",5.52438803782526e-05
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section D.  ESRD Rates",3.65706624378743e-05
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section I Plan Corrections",4.14166098663079e-05
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section A.  Update of the RxHCC Model",2.28230186141084e-05
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275519949e-05
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048513987e-05
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098539e-05
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724262927e-05
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section II Plans with Low Enrollment",5.12202792258e-05
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273195e-05
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.7215762826879e-05
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598879e-05
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328311e-05
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669059e-05
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319151
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section B.  FFS Growth Percentage",4.04246404618568e-05
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section C.  IME Phase Out",7.35366337011312e-05
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114382e-05
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410066e-05
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000504e-05
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543157e-05
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section D.  Retiree Drug Subsidy Amounts",0.00015411072607887
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897771e-05
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section II Cost Plan Competition Requirements",0.000117601526802607
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655977
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966542e-05
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091758e-05
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474095
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270502e-05
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559709
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734576e-05
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313584
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777684
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section II Outpatient Observation Services",0.000109941138994695
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156119
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777679
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section I Annual Calendar",5.38342337295085e-05
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section III Specialty Tiers",0.000124543815635083
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820128e-05
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section A.  MA Growth Percentage",0.000146106292559707
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.000202086368443957
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768398
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640228
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635093
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section III Benefit Review",0.000122732519844408
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474096
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356356
"CMS-2017-0163-1150-1-4",29,"3.75469235632196e-05","Section II Employer Group Waiver Plans",0.000207044385747007
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579872165e-07
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313888249e-06
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section I Validation Audits",7.80120548019917e-06
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section B.  Calculation of Fee for Service Cost",5.50936891099437e-06
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section G.  MA Employer Group Waiver Plans",8.42420574184821e-06
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section L.  Normalization Factors",1.14232413853484e-05
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045106478e-06
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section IV   Medicare Medicaid Plans",5.48787256309116e-06
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329699e-05
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section III CY 2019 Formulary Submission Window",1.21641982343103e-05
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351604e-05
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section E.  Clinical Trials",2.21636701369677e-05
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775395e-05
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section II Part C Cost Sharing Standards",1.48376036820497e-05
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section II Total Beneficiary Cost (TBC)",1.32115891376968e-05
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.0798103252399e-05
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section C.  Part D Risk Sharing",2.55140908046357e-05
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505676e-05
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703493e-05
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section O.  Quality Payment Program",2.52847571990476e-05
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section II Health Related Supplemental Benefits",3.44788570211603e-05
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741366e-05
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928514e-05
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section III Improving Access to Part D Vaccines",2.62277505669602e-05
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868601e-05
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650594e-05
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section I Innovations in Health Plan Design",3.17543788246046e-05
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081138e-05
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section III Tier Composition",4.59243068332394e-05
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496452e-05
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649344e-05
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section III Expanding the Part D OTC Program",5.524388037826e-05
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section D.  ESRD Rates",3.65706624378767e-05
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section I Plan Corrections",4.14166098663355e-05
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section A.  Update of the RxHCC Model",2.28230186141226e-05
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275520046e-05
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048514e-05
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098699e-05
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724262963e-05
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section II Plans with Low Enrollment",5.12202792258187e-05
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273348e-05
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268939e-05
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598909e-05
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328481e-05
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669189e-05
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319156
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section B.  FFS Growth Percentage",4.04246404618609e-05
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section C.  IME Phase Out",7.35366337011391e-05
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114478e-05
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410185e-05
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.6575108000062e-05
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543215e-05
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078874
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897756e-05
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section II Cost Plan Competition Requirements",0.000117601526802612
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655979
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.9794507696648e-05
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091943e-05
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474105
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270614e-05
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559718
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section III Coordination of Benefits (COB) User Fee",7.6886531673471e-05
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313596
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777683
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section II Outpatient Observation Services",0.000109941138994699
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section II Part C Optional Supplemental Benefits",0.254712361026909
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777681
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section I Annual Calendar",5.38342337295221e-05
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section III Specialty Tiers",0.000124543815635096
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820225e-05
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section A.  MA Growth Percentage",0.000146106292559712
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.000202086368443961
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768408
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640239
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635092
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section III Benefit Review",0.000122732519844423
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474114
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356357
"CMS-2017-0163-1150-1-4",30,"3.75469235631364e-05","Section II Employer Group Waiver Plans",0.000207044385747017
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579871441e-07
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313885723e-06
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section I Validation Audits",7.8012054801948e-06
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section B.  Calculation of Fee for Service Cost",5.5093689107014e-06
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section G.  MA Employer Group Waiver Plans",8.42420574184916e-06
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section L.  Normalization Factors",1.14232413853637e-05
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045107164e-06
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section IV   Medicare Medicaid Plans",5.48787256308964e-06
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329786e-05
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section III CY 2019 Formulary Submission Window",1.21641982343073e-05
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351541e-05
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section E.  Clinical Trials",2.2163670136965e-05
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775315e-05
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section II Part C Cost Sharing Standards",1.48376036820492e-05
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section II Total Beneficiary Cost (TBC)",1.32115891376934e-05
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032523994e-05
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section C.  Part D Risk Sharing",2.55140908046487e-05
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505589e-05
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703499e-05
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section O.  Quality Payment Program",2.52847571990461e-05
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section II Health Related Supplemental Benefits",3.44788570211501e-05
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741374e-05
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928523e-05
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section III Improving Access to Part D Vaccines",2.62277505669589e-05
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868519e-05
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650521e-05
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section I Innovations in Health Plan Design",3.17543788246039e-05
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081194e-05
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section III Tier Composition",4.59243068332418e-05
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496484e-05
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649267e-05
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section III Expanding the Part D OTC Program",5.524388037826e-05
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section D.  ESRD Rates",3.65706624378834e-05
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section I Plan Corrections",4.1416609866318e-05
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section A.  Update of the RxHCC Model",2.28230186141354e-05
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275519964e-05
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048513985e-05
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098655e-05
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724262975e-05
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section II Plans with Low Enrollment",5.12202792258104e-05
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273268e-05
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268859e-05
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598893e-05
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328359e-05
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669175e-05
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.990463710491595
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section B.  FFS Growth Percentage",4.04246404618739e-05
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section C.  IME Phase Out",7.35366337011513e-05
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114432e-05
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410045e-05
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000571e-05
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543123e-05
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section D.  Retiree Drug Subsidy Amounts",0.00015411072607887
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897719e-05
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section II Cost Plan Competition Requirements",0.000117601526802605
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655978
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966464e-05
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091873e-05
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474104
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270613e-05
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559708
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734655e-05
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313589
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777683
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section II Outpatient Observation Services",0.000109941138994696
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156121
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777681
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section I Annual Calendar",5.38342337295215e-05
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section III Specialty Tiers",0.000124543815635087
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",0.9911387702617
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section A.  MA Growth Percentage",0.000146106292559713
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.000202086368443961
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768407
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640231
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635093
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section III Benefit Review",0.000122732519844417
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474098
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.981109589501284
"CMS-2017-0163-1150-1-4",31,"3.75469235631449e-05","Section II Employer Group Waiver Plans",0.000207044385747008
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579898182e-07
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313885526e-06
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section I Validation Audits",7.80120548019922e-06
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section B.  Calculation of Fee for Service Cost",5.50936891099279e-06
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section G.  MA Employer Group Waiver Plans",8.42420574184201e-06
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section L.  Normalization Factors",1.14232413853496e-05
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045106275e-06
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section IV   Medicare Medicaid Plans",5.48787256304555e-06
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329714e-05
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section III CY 2019 Formulary Submission Window",1.21641982343091e-05
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351547e-05
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section E.  Clinical Trials",2.21636701369761e-05
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775324e-05
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section II Part C Cost Sharing Standards",1.48376036820576e-05
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section II Total Beneficiary Cost (TBC)",1.32115891377026e-05
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032524017e-05
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section C.  Part D Risk Sharing",2.55140908046376e-05
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505571e-05
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703515e-05
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section O.  Quality Payment Program",2.52847571990458e-05
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section II Health Related Supplemental Benefits",3.44788570211492e-05
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741381e-05
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928584e-05
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section III Improving Access to Part D Vaccines",2.622775056696e-05
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868575e-05
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650546e-05
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section I Innovations in Health Plan Design",3.17543788246056e-05
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081142e-05
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section III Tier Composition",4.59243068332447e-05
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496471e-05
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649352e-05
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section III Expanding the Part D OTC Program",5.52438803782687e-05
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section D.  ESRD Rates",3.6570662437886e-05
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section I Plan Corrections",4.14166098663217e-05
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section A.  Update of the RxHCC Model",2.2823018614123e-05
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275520026e-05
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048514069e-05
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098668e-05
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724263074e-05
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section II Plans with Low Enrollment",5.12202792258277e-05
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273312e-05
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268885e-05
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598929e-05
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328465e-05
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669228e-05
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319156
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section B.  FFS Growth Percentage",4.04246404618576e-05
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section C.  IME Phase Out",7.35366337011396e-05
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114411e-05
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.5186604541023e-05
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000804e-05
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.1533056654321e-05
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078876
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897821e-05
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section II Cost Plan Competition Requirements",0.989533464114568
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655988
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966535e-05
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091903e-05
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474102
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270652e-05
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559708
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734722e-05
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313591
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.00010449577977768
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section II Outpatient Observation Services",0.000109941138994708
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156121
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777682
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section I Annual Calendar",5.38342337295237e-05
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section III Specialty Tiers",0.0001245438156351
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820204e-05
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section A.  MA Growth Percentage",0.000146106292559713
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.00020208636844396
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768406
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640228
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635102
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section III Benefit Review",0.000122732519844418
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474106
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356355
"CMS-2017-0163-1150-1-4",32,"3.75469235631402e-05","Section II Employer Group Waiver Plans",0.000207044385747005
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",0.118834161047422
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.964433138811e-06
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section I Validation Audits",7.80120548018666e-06
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section B.  Calculation of Fee for Service Cost",5.50936891084646e-06
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section G.  MA Employer Group Waiver Plans",8.42420574183368e-06
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section L.  Normalization Factors",1.14232413853446e-05
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045105911e-06
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section IV   Medicare Medicaid Plans",5.48787256307799e-06
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329579e-05
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section III CY 2019 Formulary Submission Window",1.21641982342877e-05
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351362e-05
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section E.  Clinical Trials",2.2163670136955e-05
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775212e-05
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section II Part C Cost Sharing Standards",1.48376036820453e-05
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section II Total Beneficiary Cost (TBC)",1.32115891376681e-05
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032523872e-05
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section C.  Part D Risk Sharing",2.55140908046331e-05
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505567e-05
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703448e-05
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section O.  Quality Payment Program",2.52847571990368e-05
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section II Health Related Supplemental Benefits",3.44788570211399e-05
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741279e-05
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928499e-05
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section III Improving Access to Part D Vaccines",2.62277505669471e-05
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868388e-05
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650474e-05
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section I Innovations in Health Plan Design",3.17543788245905e-05
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.2487850608096e-05
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section III Tier Composition",4.59243068332408e-05
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496437e-05
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649228e-05
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section III Expanding the Part D OTC Program",5.52438803782627e-05
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section D.  ESRD Rates",3.65706624378643e-05
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section I Plan Corrections",4.14166098663202e-05
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section A.  Update of the RxHCC Model",2.28230186141079e-05
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section II Tiered Cost Sharing of Medical Benefits",5.75024275519947e-05
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048513993e-05
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098585e-05
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section II Cost Plan Transition to MA under MACRA",7.75934724262931e-05
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section II Plans with Low Enrollment",5.12202792258063e-05
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273209e-05
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268686e-05
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598924e-05
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328366e-05
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669183e-05
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319153
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section B.  FFS Growth Percentage",4.0424640461856e-05
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section C.  IME Phase Out",7.35366337011408e-05
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114353e-05
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410037e-05
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000578e-05
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543136e-05
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078869
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897703e-05
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section II Cost Plan Competition Requirements",0.000117601526802598
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655975
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966499e-05
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091771e-05
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section I Enforcement Actions for Provider Directories",0.0001007530724741
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270461e-05
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.00014610629255971
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section III Coordination of Benefits (COB) User Fee",7.68865316734697e-05
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313584
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777685
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section II Outpatient Observation Services",0.000109941138994694
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section II Part C Optional Supplemental Benefits",0.000114412744156116
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777677
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section I Annual Calendar",5.38342337295037e-05
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section III Specialty Tiers",0.000124543815635086
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820173e-05
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section A.  MA Growth Percentage",0.000146106292559708
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.000202086368443958
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768393
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640224
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635083
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section III Benefit Review",0.000122732519844408
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474098
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356351
"CMS-2017-0163-1150-1-4",33,"0.131848085319832","Section II Employer Group Waiver Plans",0.000207044385747008
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579865254e-07
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313867828e-06
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section I Validation Audits",7.801205480191e-06
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section B.  Calculation of Fee for Service Cost",5.50936891099187e-06
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section G.  MA Employer Group Waiver Plans",8.42420574183462e-06
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section L.  Normalization Factors",1.14232413853493e-05
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045106502e-06
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section IV   Medicare Medicaid Plans",5.48787256305225e-06
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.1532515932971e-05
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section III CY 2019 Formulary Submission Window",1.21641982343174e-05
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351572e-05
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section E.  Clinical Trials",2.2163670136968e-05
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.5157402877534e-05
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section II Part C Cost Sharing Standards",1.48376036820582e-05
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section II Total Beneficiary Cost (TBC)",1.32115891376902e-05
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032524038e-05
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section C.  Part D Risk Sharing",2.55140908046469e-05
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505619e-05
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703517e-05
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section O.  Quality Payment Program",2.52847571990456e-05
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section II Health Related Supplemental Benefits",3.44788570211483e-05
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741364e-05
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928564e-05
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section III Improving Access to Part D Vaccines",2.62277505669707e-05
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868579e-05
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650597e-05
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section I Innovations in Health Plan Design",3.17543788246062e-05
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081151e-05
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section III Tier Composition",4.5924306833252e-05
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496416e-05
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649347e-05
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section III Expanding the Part D OTC Program",5.52438803782701e-05
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section D.  ESRD Rates",3.65706624378708e-05
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section I Plan Corrections",4.14166098663272e-05
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section A.  Update of the RxHCC Model",2.28230186141319e-05
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275520051e-05
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.4018204851399e-05
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098714e-05
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724262973e-05
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section II Plans with Low Enrollment",5.12202792258156e-05
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273281e-05
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.7215762826892e-05
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598869e-05
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328353e-05
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669177e-05
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319154
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section B.  FFS Growth Percentage",4.04246404618563e-05
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section C.  IME Phase Out",7.3536633701139e-05
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114419e-05
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410028e-05
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.6575108000059e-05
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543308e-05
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078872
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897715e-05
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section II Cost Plan Competition Requirements",0.000117601526802609
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655977
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.9794507696643e-05
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091897e-05
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section I Enforcement Actions for Provider Directories",0.0001007530724741
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270612e-05
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559709
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734796e-05
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313596
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777681
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section II Outpatient Observation Services",0.000109941138994698
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156117
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777679
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section I Annual Calendar",5.38342337295189e-05
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section III Specialty Tiers",0.988915600408477
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.9564379082023e-05
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section A.  MA Growth Percentage",0.000146106292559715
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.000202086368443961
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768408
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640236
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635093
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section III Benefit Review",0.000122732519844423
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474117
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356357
"CMS-2017-0163-1150-1-4",34,"3.75469235631331e-05","Section II Employer Group Waiver Plans",0.000207044385747007
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579886274e-07
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313888668e-06
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section I Validation Audits",7.80120548019804e-06
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section B.  Calculation of Fee for Service Cost",5.509368910952e-06
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section G.  MA Employer Group Waiver Plans",8.42420574184305e-06
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section L.  Normalization Factors",1.14232413853537e-05
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045106195e-06
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section IV   Medicare Medicaid Plans",5.48787256309506e-06
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section I.  ESRD Risk Adjustment Model for CY 2019",0.768936247353783
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section III CY 2019 Formulary Submission Window",1.21641982343109e-05
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351499e-05
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section E.  Clinical Trials",2.21636701369609e-05
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775319e-05
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section II Part C Cost Sharing Standards",1.48376036820519e-05
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section II Total Beneficiary Cost (TBC)",1.32115891376889e-05
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032524045e-05
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section C.  Part D Risk Sharing",2.55140908046357e-05
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505595e-05
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703468e-05
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section O.  Quality Payment Program",2.52847571990406e-05
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section II Health Related Supplemental Benefits",3.44788570211491e-05
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741356e-05
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928504e-05
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section III Improving Access to Part D Vaccines",2.62277505669544e-05
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868515e-05
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.778193896505e-05
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section I Innovations in Health Plan Design",3.17543788246058e-05
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081078e-05
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section III Tier Composition",4.59243068332408e-05
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496438e-05
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649258e-05
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section III Expanding the Part D OTC Program",5.52438803782565e-05
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section D.  ESRD Rates",3.65706624378904e-05
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section I Plan Corrections",4.14166098663179e-05
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section A.  Update of the RxHCC Model",2.28230186141258e-05
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section II Tiered Cost Sharing of Medical Benefits",5.75024275519985e-05
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048513975e-05
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098628e-05
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section II Cost Plan Transition to MA under MACRA",7.75934724262984e-05
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section II Plans with Low Enrollment",5.12202792258124e-05
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273269e-05
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268862e-05
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section M.  Medical Loss Ratio Credibility Adjustment",8.7216522859888e-05
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328467e-05
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669169e-05
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319166
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section B.  FFS Growth Percentage",4.04246404618688e-05
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section C.  IME Phase Out",7.35366337011375e-05
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114347e-05
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410022e-05
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000627e-05
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543139e-05
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078867
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897699e-05
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section II Cost Plan Competition Requirements",0.000117601526802605
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655979
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966468e-05
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091834e-05
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section I Enforcement Actions for Provider Directories",0.000100753072474101
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270598e-05
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559707
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section III Coordination of Benefits (COB) User Fee",7.68865316734738e-05
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.00010197049231359
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777687
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section II Outpatient Observation Services",0.000109941138994699
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section II Part C Optional Supplemental Benefits",0.000114412744156118
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777682
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section I Annual Calendar",5.38342337295194e-05
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section III Specialty Tiers",0.000124543815635091
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820179e-05
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section A.  MA Growth Percentage",0.00014610629255971
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.00020208636844396
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768409
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640232
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635091
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section III Benefit Review",0.000122732519844412
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474104
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356356
"CMS-2017-0163-1150-1-4",35,"0.22891796647016","Section II Employer Group Waiver Plans",0.000207044385747007
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.9941858012219e-07
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313888004e-06
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section I Validation Audits",7.80120548019074e-06
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section B.  Calculation of Fee for Service Cost",5.50936891065562e-06
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section G.  MA Employer Group Waiver Plans",8.4242057418485e-06
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section L.  Normalization Factors",1.14232413853532e-05
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045077062e-06
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section IV   Medicare Medicaid Plans",5.48787256309028e-06
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329836e-05
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section III CY 2019 Formulary Submission Window",1.21641982343073e-05
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351469e-05
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section E.  Clinical Trials",2.21636701369678e-05
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775284e-05
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section II Part C Cost Sharing Standards",1.48376036820591e-05
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section II Total Beneficiary Cost (TBC)",1.32115891376953e-05
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.0798103252398e-05
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section C.  Part D Risk Sharing",2.55140908046363e-05
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505646e-05
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703482e-05
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section O.  Quality Payment Program",2.5284757199043e-05
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section II Health Related Supplemental Benefits",3.44788570211509e-05
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741385e-05
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928582e-05
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section III Improving Access to Part D Vaccines",2.62277505669561e-05
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868571e-05
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650557e-05
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section I Innovations in Health Plan Design",3.1754378824608e-05
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081091e-05
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section III Tier Composition",4.59243068332421e-05
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496537e-05
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649321e-05
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section III Expanding the Part D OTC Program",5.52438803782713e-05
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section D.  ESRD Rates",3.65706624378805e-05
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section I Plan Corrections",4.14166098663246e-05
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section A.  Update of the RxHCC Model",2.2823018614123e-05
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section II Tiered Cost Sharing of Medical Benefits",5.75024275519959e-05
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048513999e-05
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098672e-05
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section II Cost Plan Transition to MA under MACRA",7.75934724262942e-05
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section II Plans with Low Enrollment",5.12202792258124e-05
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273291e-05
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268829e-05
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598959e-05
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328322e-05
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.0466454466914e-05
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section B.  Encounter Data as a Diagnosis Source for 2019",0.00010714932031916
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section B.  FFS Growth Percentage",0.996402206998895
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section C.  IME Phase Out",7.35366337011597e-05
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114429e-05
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410142e-05
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000584e-05
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543165e-05
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078873
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897748e-05
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section II Cost Plan Competition Requirements",0.000117601526802603
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655975
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966477e-05
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.7896929609187e-05
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section I Enforcement Actions for Provider Directories",0.000100753072474104
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270602e-05
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559709
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section III Coordination of Benefits (COB) User Fee",7.68865316734681e-05
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313587
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section K.  Medicare Advantage Coding Pattern Adjustment",0.00010449577977769
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section II Outpatient Observation Services",0.000109941138994696
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section II Part C Optional Supplemental Benefits",0.000114412744156118
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777677
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section I Annual Calendar",5.38342337295218e-05
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section III Specialty Tiers",0.000124543815635086
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820308e-05
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section A.  MA Growth Percentage",0.000146106292559708
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.000202086368443962
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.00012097315376842
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640235
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635092
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section III Benefit Review",0.000122732519844425
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474097
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.00021225180335635
"CMS-2017-0163-1150-1-4",36,"0.17148966707849","Section II Employer Group Waiver Plans",0.000207044385747011
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579917814e-07
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313884493e-06
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section I Validation Audits",7.80120548019359e-06
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section B.  Calculation of Fee for Service Cost",5.50936891098714e-06
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section G.  MA Employer Group Waiver Plans",8.42420574183313e-06
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section L.  Normalization Factors",1.14232413853467e-05
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045106139e-06
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section IV   Medicare Medicaid Plans",5.48787256309485e-06
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329723e-05
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section III CY 2019 Formulary Submission Window",1.21641982343037e-05
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section I Incomplete and Inaccurate Bid Submissions",2.2639337035152e-05
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section E.  Clinical Trials",0.99802743335781
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.5157402877536e-05
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section II Part C Cost Sharing Standards",1.48376036820614e-05
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section II Total Beneficiary Cost (TBC)",1.32115891376931e-05
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032524003e-05
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section C.  Part D Risk Sharing",2.55140908046395e-05
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505599e-05
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703466e-05
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section O.  Quality Payment Program",2.52847571990481e-05
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section II Health Related Supplemental Benefits",3.44788570211591e-05
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741384e-05
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928543e-05
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section III Improving Access to Part D Vaccines",2.62277505669613e-05
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868509e-05
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650548e-05
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section I Innovations in Health Plan Design",3.17543788246083e-05
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081082e-05
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section III Tier Composition",4.59243068332459e-05
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496422e-05
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.5643882464943e-05
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section III Expanding the Part D OTC Program",5.52438803782722e-05
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section D.  ESRD Rates",3.6570662437868e-05
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section I Plan Corrections",4.14166098663192e-05
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section A.  Update of the RxHCC Model",2.28230186141194e-05
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section II Tiered Cost Sharing of Medical Benefits",5.75024275520014e-05
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048514008e-05
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098662e-05
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section II Cost Plan Transition to MA under MACRA",7.75934724263057e-05
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section II Plans with Low Enrollment",5.1220279225816e-05
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273229e-05
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268887e-05
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598891e-05
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328501e-05
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669148e-05
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319154
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section B.  FFS Growth Percentage",4.04246404618536e-05
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section C.  IME Phase Out",7.3536633701137e-05
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114433e-05
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section II Overview of CY 2019 Benefits and Bid Review",4.5186604541018e-05
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000705e-05
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543151e-05
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078874
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897722e-05
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section II Cost Plan Competition Requirements",0.000117601526802618
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section II Medicare Advantage (MA) Segmented Service Area Options",0.00012833167265598
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966479e-05
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.7896929609181e-05
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section I Enforcement Actions for Provider Directories",0.000100753072474107
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270592e-05
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559708
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section III Coordination of Benefits (COB) User Fee",7.68865316734758e-05
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313592
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777685
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section II Outpatient Observation Services",0.000109941138994704
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section II Part C Optional Supplemental Benefits",0.000114412744156119
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777688
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section I Annual Calendar",5.38342337295204e-05
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section III Specialty Tiers",0.000124543815635087
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820214e-05
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section A.  MA Growth Percentage",0.000146106292559713
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.000202086368443959
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768406
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640226
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635103
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section III Benefit Review",0.000122732519844416
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474105
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356358
"CMS-2017-0163-1150-1-4",37,"0.021996749951628","Section II Employer Group Waiver Plans",0.000207044385747009
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579910282e-07
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313882927e-06
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section I Validation Audits",7.80120548018964e-06
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section B.  Calculation of Fee for Service Cost",5.50936891098816e-06
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section G.  MA Employer Group Waiver Plans",8.42420574183307e-06
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section L.  Normalization Factors",1.14232413853527e-05
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045106513e-06
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section IV   Medicare Medicaid Plans",5.48787256284271e-06
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329752e-05
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section III CY 2019 Formulary Submission Window",1.21641982343061e-05
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351497e-05
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section E.  Clinical Trials",2.21636701369617e-05
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",0.9986509911439
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section II Part C Cost Sharing Standards",1.48376036820515e-05
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section II Total Beneficiary Cost (TBC)",1.32115891376884e-05
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032524052e-05
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section C.  Part D Risk Sharing",2.55140908046361e-05
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505606e-05
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703441e-05
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section O.  Quality Payment Program",2.52847571990467e-05
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section II Health Related Supplemental Benefits",3.44788570211426e-05
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.0492278874126e-05
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928535e-05
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section III Improving Access to Part D Vaccines",2.62277505669583e-05
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868542e-05
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650517e-05
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section I Innovations in Health Plan Design",3.17543788246147e-05
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081112e-05
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section III Tier Composition",4.59243068332438e-05
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496518e-05
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649285e-05
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section III Expanding the Part D OTC Program",5.52438803782695e-05
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section D.  ESRD Rates",3.65706624378682e-05
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section I Plan Corrections",4.14166098663189e-05
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section A.  Update of the RxHCC Model",2.28230186141192e-05
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275520012e-05
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048514066e-05
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098644e-05
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section II Cost Plan Transition to MA under MACRA",7.7593472426303e-05
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section II Plans with Low Enrollment",5.12202792258188e-05
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273239e-05
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268882e-05
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598893e-05
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328358e-05
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669185e-05
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319153
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section B.  FFS Growth Percentage",4.04246404618579e-05
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section C.  IME Phase Out",7.35366337011411e-05
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114543e-05
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410047e-05
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000541e-05
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543173e-05
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078868
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897739e-05
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section II Cost Plan Competition Requirements",0.000117601526802609
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655973
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966495e-05
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091821e-05
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474106
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270649e-05
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559724
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734789e-05
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313586
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777681
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section II Outpatient Observation Services",0.000109941138994698
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156112
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777678
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section I Annual Calendar",5.3834233729505e-05
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section III Specialty Tiers",0.000124543815635087
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820215e-05
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section A.  MA Growth Percentage",0.000146106292559712
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.00020208636844396
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768402
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640233
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.00012454381563509
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section III Benefit Review",0.00012273251984441
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.0001007530724741
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356356
"CMS-2017-0163-1150-1-4",38,"3.75469235631267e-05","Section II Employer Group Waiver Plans",0.000207044385747009
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.9941857987293e-07
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313886331e-06
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section I Validation Audits",7.80120548019945e-06
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section B.  Calculation of Fee for Service Cost",5.50936891099045e-06
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section G.  MA Employer Group Waiver Plans",8.42420574183647e-06
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section L.  Normalization Factors",1.14232413853498e-05
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045106253e-06
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section IV   Medicare Medicaid Plans",5.48787256308632e-06
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329717e-05
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section III CY 2019 Formulary Submission Window",1.21641982343088e-05
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351514e-05
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section E.  Clinical Trials",2.21636701369708e-05
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775318e-05
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section II Part C Cost Sharing Standards",1.48376036820528e-05
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section II Total Beneficiary Cost (TBC)",1.32115891376944e-05
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032524006e-05
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section C.  Part D Risk Sharing",2.55140908046406e-05
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505646e-05
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703516e-05
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section O.  Quality Payment Program",2.5284757199041e-05
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section II Health Related Supplemental Benefits",3.4478857021149e-05
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741355e-05
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928636e-05
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section III Improving Access to Part D Vaccines",2.6227750566978e-05
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868507e-05
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650666e-05
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section I Innovations in Health Plan Design",3.17543788246075e-05
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081116e-05
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section III Tier Composition",4.59243068332366e-05
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496431e-05
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649369e-05
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section III Expanding the Part D OTC Program",5.52438803782728e-05
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section D.  ESRD Rates",3.65706624378801e-05
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section I Plan Corrections",4.14166098663291e-05
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section A.  Update of the RxHCC Model",2.28230186141244e-05
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275520088e-05
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.4018204851398e-05
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098688e-05
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724262979e-05
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section II Plans with Low Enrollment",5.12202792258103e-05
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273292e-05
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",0.582930175722689
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.7216522859886e-05
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328489e-05
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669204e-05
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319157
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section B.  FFS Growth Percentage",4.04246404618556e-05
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section C.  IME Phase Out",7.35366337011411e-05
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114455e-05
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410172e-05
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.657510800006e-05
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543192e-05
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078873
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897728e-05
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section II Cost Plan Competition Requirements",0.000117601526802611
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655983
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966436e-05
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091915e-05
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474103
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270599e-05
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559708
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734818e-05
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.00010197049231359
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777681
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section II Outpatient Observation Services",0.000109941138994707
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156117
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777687
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section I Annual Calendar",5.38342337295278e-05
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section III Specialty Tiers",0.000124543815635096
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820187e-05
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section A.  MA Growth Percentage",0.000146106292559711
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.000202086368443961
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768406
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640234
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635095
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section III Benefit Review",0.000122732519844427
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474107
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356355
"CMS-2017-0163-1150-1-4",39,"3.75469235631423e-05","Section II Employer Group Waiver Plans",0.000207044385747012
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579909966e-07
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313884892e-06
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section I Validation Audits",7.80120548019825e-06
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section B.  Calculation of Fee for Service Cost",5.50936891099249e-06
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section G.  MA Employer Group Waiver Plans",8.42420574161828e-06
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section L.  Normalization Factors",1.1423241385351e-05
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045105989e-06
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section IV   Medicare Medicaid Plans",5.48787256308683e-06
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.1532515932976e-05
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section III CY 2019 Formulary Submission Window",1.21641982343119e-05
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351476e-05
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section E.  Clinical Trials",2.21636701369653e-05
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775291e-05
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section II Part C Cost Sharing Standards",1.48376036820577e-05
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section II Total Beneficiary Cost (TBC)",1.32115891376946e-05
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032523985e-05
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section C.  Part D Risk Sharing",2.55140908046409e-05
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505671e-05
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.549396677035e-05
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section O.  Quality Payment Program",2.52847571990472e-05
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section II Health Related Supplemental Benefits",3.4478857021149e-05
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.0492278874137e-05
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928516e-05
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section III Improving Access to Part D Vaccines",2.62277505669621e-05
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868658e-05
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650586e-05
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section I Innovations in Health Plan Design",3.17543788246099e-05
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081053e-05
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section III Tier Composition",4.59243068332534e-05
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496463e-05
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649301e-05
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section III Expanding the Part D OTC Program",5.52438803782654e-05
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section D.  ESRD Rates",3.6570662437883e-05
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section I Plan Corrections",4.14166098663212e-05
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section A.  Update of the RxHCC Model",2.28230186141201e-05
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275520012e-05
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048514001e-05
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098768e-05
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724262975e-05
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section II Plans with Low Enrollment",5.12202792258096e-05
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.6054010927322e-05
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268879e-05
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598926e-05
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328406e-05
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669167e-05
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319154
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section B.  FFS Growth Percentage",4.04246404618585e-05
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section C.  IME Phase Out",7.35366337011392e-05
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114419e-05
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410112e-05
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000576e-05
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543215e-05
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section D.  Retiree Drug Subsidy Amounts",0.479908339944446
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897736e-05
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section II Cost Plan Competition Requirements",0.000117601526802608
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655977
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.9794507696648e-05
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091925e-05
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474101
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270608e-05
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559707
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734799e-05
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.99092462618409
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777693
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section II Outpatient Observation Services",0.000109941138994698
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156119
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777677
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section I Annual Calendar",5.38342337295229e-05
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section III Specialty Tiers",0.000124543815635098
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820208e-05
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section A.  MA Growth Percentage",0.000146106292559711
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.982014313208488
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768408
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640233
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635094
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section III Benefit Review",0.000122732519844422
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474099
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356356
"CMS-2017-0163-1150-1-4",40,"3.75469235631352e-05","Section II Employer Group Waiver Plans",0.000207044385747008
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579891495e-07
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313888723e-06
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section I Validation Audits",7.801205480186e-06
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section B.  Calculation of Fee for Service Cost",5.50936891075151e-06
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section G.  MA Employer Group Waiver Plans",0.117804072742736
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section L.  Normalization Factors",1.14232413853503e-05
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045082001e-06
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section IV   Medicare Medicaid Plans",5.48787256308555e-06
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329694e-05
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section III CY 2019 Formulary Submission Window",1.21641982343018e-05
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351507e-05
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section E.  Clinical Trials",2.2163670136961e-05
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.5157402877529e-05
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section II Part C Cost Sharing Standards",1.48376036820519e-05
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section II Total Beneficiary Cost (TBC)",1.32115891376922e-05
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032523983e-05
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section C.  Part D Risk Sharing",2.55140908046363e-05
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505549e-05
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703516e-05
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section O.  Quality Payment Program",2.52847571990468e-05
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section II Health Related Supplemental Benefits",3.4478857021138e-05
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741353e-05
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928548e-05
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section III Improving Access to Part D Vaccines",2.62277505669529e-05
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868524e-05
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.7781938965046e-05
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section I Innovations in Health Plan Design",3.1754378824597e-05
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081082e-05
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section III Tier Composition",4.59243068332423e-05
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496507e-05
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649261e-05
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section III Expanding the Part D OTC Program",5.52438803782571e-05
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section D.  ESRD Rates",3.65706624378805e-05
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section I Plan Corrections",4.14166098663277e-05
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section A.  Update of the RxHCC Model",2.28230186141196e-05
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275519978e-05
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048513997e-05
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098774e-05
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724263018e-05
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section II Plans with Low Enrollment",5.12202792258093e-05
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273274e-05
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268837e-05
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598866e-05
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328472e-05
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669184e-05
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319162
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section B.  FFS Growth Percentage",4.04246404618578e-05
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section C.  IME Phase Out",7.3536633701143e-05
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114387e-05
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410207e-05
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000687e-05
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.1533056654314e-05
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078872
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897838e-05
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section II Cost Plan Competition Requirements",0.000117601526802604
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655974
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966549e-05
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091991e-05
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474099
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270642e-05
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559727
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734616e-05
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313591
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777694
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section II Outpatient Observation Services",0.000109941138994698
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156123
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777681
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section I Annual Calendar",5.38342337295205e-05
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section III Specialty Tiers",0.000124543815635091
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820194e-05
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section A.  MA Growth Percentage",0.000146106292559707
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.000202086368443966
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768408
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640234
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635093
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section III Benefit Review",0.000122732519844415
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474105
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356354
"CMS-2017-0163-1150-1-4",41,"3.75469235631349e-05","Section II Employer Group Waiver Plans",0.000207044385747012
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579859918e-07
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.9644331386755e-06
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section I Validation Audits",7.80120548019562e-06
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section B.  Calculation of Fee for Service Cost",5.50936891099429e-06
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section G.  MA Employer Group Waiver Plans",8.42420574183283e-06
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section L.  Normalization Factors",1.14232413853467e-05
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045106329e-06
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section IV   Medicare Medicaid Plans",5.48787256308819e-06
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329753e-05
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section III CY 2019 Formulary Submission Window",1.21641982343035e-05
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351476e-05
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section E.  Clinical Trials",2.2163670136968e-05
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775336e-05
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section II Part C Cost Sharing Standards",1.48376036820574e-05
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section II Total Beneficiary Cost (TBC)",1.32115891376887e-05
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032524127e-05
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section C.  Part D Risk Sharing",2.55140908046412e-05
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505629e-05
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703533e-05
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section O.  Quality Payment Program",2.52847571990447e-05
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section II Health Related Supplemental Benefits",3.4478857021156e-05
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741377e-05
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928534e-05
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section III Improving Access to Part D Vaccines",2.62277505669608e-05
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868504e-05
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.7781938965053e-05
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section I Innovations in Health Plan Design",3.17543788246081e-05
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081094e-05
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section III Tier Composition",4.59243068332486e-05
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496449e-05
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649361e-05
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section III Expanding the Part D OTC Program",0.995083294646334
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section D.  ESRD Rates",3.65706624378719e-05
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section I Plan Corrections",4.14166098663288e-05
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section A.  Update of the RxHCC Model",2.28230186141243e-05
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275520052e-05
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048513982e-05
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098807e-05
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724262954e-05
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section II Plans with Low Enrollment",5.12202792258103e-05
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273288e-05
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268963e-05
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598898e-05
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328494e-05
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669214e-05
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319154
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section B.  FFS Growth Percentage",4.04246404618598e-05
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section C.  IME Phase Out",7.35366337011374e-05
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114475e-05
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.518660454101e-05
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000668e-05
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543284e-05
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078875
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897792e-05
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section II Cost Plan Competition Requirements",0.000117601526802609
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655973
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966485e-05
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091862e-05
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section I Enforcement Actions for Provider Directories",0.0001007530724741
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270655e-05
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559706
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734826e-05
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313599
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777681
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section II Outpatient Observation Services",0.000109941138994697
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156115
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777688
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section I Annual Calendar",5.38342337295266e-05
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section III Specialty Tiers",0.000124543815635095
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820219e-05
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section A.  MA Growth Percentage",0.000146106292559712
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.000202086368443959
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768409
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640237
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635106
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section III Benefit Review",0.000122732519844413
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474112
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356355
"CMS-2017-0163-1150-1-4",42,"3.7546923563131e-05","Section II Employer Group Waiver Plans",0.000207044385747009
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579906391e-07
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.9644331387168e-06
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section I Validation Audits",7.80120548018971e-06
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section B.  Calculation of Fee for Service Cost",5.50936891098781e-06
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section G.  MA Employer Group Waiver Plans",8.42420574183457e-06
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section L.  Normalization Factors",1.14232413853436e-05
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045105827e-06
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section IV   Medicare Medicaid Plans",5.48787256284894e-06
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.1532515932971e-05
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section III CY 2019 Formulary Submission Window",0.26860842990041
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351326e-05
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section E.  Clinical Trials",2.21636701369666e-05
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775338e-05
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section II Part C Cost Sharing Standards",1.48376036820538e-05
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section II Total Beneficiary Cost (TBC)",1.32115891376892e-05
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032524016e-05
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section C.  Part D Risk Sharing",2.55140908046345e-05
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505591e-05
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.5493966770345e-05
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section O.  Quality Payment Program",2.5284757199045e-05
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section II Health Related Supplemental Benefits",3.44788570211448e-05
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741307e-05
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928512e-05
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section III Improving Access to Part D Vaccines",2.62277505669574e-05
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868514e-05
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650524e-05
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section I Innovations in Health Plan Design",3.17543788246069e-05
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081122e-05
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section III Tier Composition",4.59243068332546e-05
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496431e-05
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649284e-05
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section III Expanding the Part D OTC Program",5.52438803782678e-05
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section D.  ESRD Rates",3.6570662437869e-05
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section I Plan Corrections",4.14166098663146e-05
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section A.  Update of the RxHCC Model",2.28230186141173e-05
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275519933e-05
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.4018204851397e-05
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.594754540986e-05
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724262922e-05
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section II Plans with Low Enrollment",5.12202792258072e-05
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273233e-05
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268915e-05
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598865e-05
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.5197887032828e-05
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669113e-05
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319153
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section B.  FFS Growth Percentage",4.04246404618551e-05
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section C.  IME Phase Out",7.35366337011374e-05
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114393e-05
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410066e-05
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000589e-05
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543212e-05
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section D.  Retiree Drug Subsidy Amounts",0.00015411072607887
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897724e-05
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section II Cost Plan Competition Requirements",0.000117601526802601
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655977
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966426e-05
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091906e-05
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474104
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270578e-05
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559709
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section III Coordination of Benefits (COB) User Fee",7.6886531673476e-05
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.00010197049231359
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777679
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section II Outpatient Observation Services",0.000109941138994697
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156118
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777681
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section I Annual Calendar",5.3834233729516e-05
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section III Specialty Tiers",0.000124543815635099
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820172e-05
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section A.  MA Growth Percentage",0.000146106292559714
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.00020208636844396
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768408
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640231
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635091
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section III Benefit Review",0.000122732519844419
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474099
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356354
"CMS-2017-0163-1150-1-4",43,"3.75469235631301e-05","Section II Employer Group Waiver Plans",0.000207044385747008
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.9941857990426e-07
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313887584e-06
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section I Validation Audits",7.8012054801938e-06
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section B.  Calculation of Fee for Service Cost",5.50936891125773e-06
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section G.  MA Employer Group Waiver Plans",8.42420574183517e-06
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section L.  Normalization Factors",1.14232413853568e-05
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045106951e-06
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section IV   Medicare Medicaid Plans",5.48787256309266e-06
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159326195e-05
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section III CY 2019 Formulary Submission Window",1.21641982343078e-05
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351512e-05
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section E.  Clinical Trials",2.21636701369684e-05
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.5157402877525e-05
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section II Part C Cost Sharing Standards",1.48376036820499e-05
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section II Total Beneficiary Cost (TBC)",1.32115891376981e-05
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032524058e-05
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section C.  Part D Risk Sharing",2.55140908046389e-05
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505632e-05
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703479e-05
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section O.  Quality Payment Program",2.52847571990485e-05
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section II Health Related Supplemental Benefits",3.44788570211432e-05
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741396e-05
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928496e-05
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section III Improving Access to Part D Vaccines",2.62277505669581e-05
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868563e-05
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.778193896505e-05
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section I Innovations in Health Plan Design",3.17543788246063e-05
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.2487850608113e-05
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section III Tier Composition",4.59243068332409e-05
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496574e-05
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649233e-05
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section III Expanding the Part D OTC Program",5.52438803782565e-05
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section D.  ESRD Rates",0.996745211043029
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section I Plan Corrections",4.14166098663192e-05
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section A.  Update of the RxHCC Model",2.28230186141328e-05
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section II Tiered Cost Sharing of Medical Benefits",5.75024275519945e-05
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.4018204851399e-05
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098678e-05
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section II Cost Plan Transition to MA under MACRA",7.75934724262998e-05
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section II Plans with Low Enrollment",5.12202792258114e-05
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section III Low Enrollment Plans (Stand alone PDPs only)",6.6054010927332e-05
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268844e-05
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598888e-05
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328349e-05
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669174e-05
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section B.  Encounter Data as a Diagnosis Source for 2019",0.00010714932031916
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section B.  FFS Growth Percentage",4.04246404618737e-05
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section C.  IME Phase Out",7.35366337011511e-05
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114424e-05
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410061e-05
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000594e-05
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543176e-05
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078872
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897734e-05
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section II Cost Plan Competition Requirements",0.000117601526802602
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655977
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.9794507696647e-05
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091912e-05
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section I Enforcement Actions for Provider Directories",0.000100753072474102
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270579e-05
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559705
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section III Coordination of Benefits (COB) User Fee",7.68865316734698e-05
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313589
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777693
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section II Outpatient Observation Services",0.000109941138994699
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section II Part C Optional Supplemental Benefits",0.000114412744156119
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.00010449577977768
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section I Annual Calendar",5.3834233729521e-05
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section III Specialty Tiers",0.000124543815635087
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820339e-05
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section A.  MA Growth Percentage",0.000146106292559709
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.000202086368443959
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768408
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640233
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635092
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section III Benefit Review",0.000122732519844415
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474095
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356356
"CMS-2017-0163-1150-1-4",44,"0.033355142839393","Section II Employer Group Waiver Plans",0.00020704438574701
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579871019e-07
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313877295e-06
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section I Validation Audits",7.80120548019677e-06
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section B.  Calculation of Fee for Service Cost",5.50936891099439e-06
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section G.  MA Employer Group Waiver Plans",8.42420574184547e-06
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section L.  Normalization Factors",1.14232413853476e-05
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045106521e-06
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section IV   Medicare Medicaid Plans",5.48787256308967e-06
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329738e-05
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section III CY 2019 Formulary Submission Window",1.21641982343107e-05
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351559e-05
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section E.  Clinical Trials",2.21636701369668e-05
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.5157402877538e-05
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section II Part C Cost Sharing Standards",1.48376036820605e-05
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section II Total Beneficiary Cost (TBC)",1.32115891376966e-05
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032524144e-05
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section C.  Part D Risk Sharing",2.55140908046406e-05
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505785e-05
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703534e-05
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section O.  Quality Payment Program",2.52847571990478e-05
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section II Health Related Supplemental Benefits",3.44788570211554e-05
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741444e-05
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928731e-05
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section III Improving Access to Part D Vaccines",2.6227750566961e-05
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868651e-05
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650644e-05
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section I Innovations in Health Plan Design",3.17543788246076e-05
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081113e-05
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section III Tier Composition",4.59243068332422e-05
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.7474411449648e-05
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649357e-05
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section III Expanding the Part D OTC Program",5.52438803782764e-05
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section D.  ESRD Rates",3.65706624378792e-05
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section I Plan Corrections",4.14166098663321e-05
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section A.  Update of the RxHCC Model",2.28230186141322e-05
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275520123e-05
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048513998e-05
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098791e-05
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724263022e-05
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section II Plans with Low Enrollment",5.12202792258123e-05
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.6054010927326e-05
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268938e-05
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598877e-05
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328463e-05
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669196e-05
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319155
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section B.  FFS Growth Percentage",4.04246404618584e-05
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section C.  IME Phase Out",7.35366337011379e-05
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114416e-05
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410135e-05
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000608e-05
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543275e-05
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078877
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897729e-05
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section II Cost Plan Competition Requirements",0.000117601526802611
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655982
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966444e-05
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091905e-05
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474105
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270598e-05
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559706
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734785e-05
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313587
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777681
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section II Outpatient Observation Services",0.000109941138994706
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156119
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777686
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section I Annual Calendar",5.38342337295218e-05
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section III Specialty Tiers",0.000124543815635099
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820214e-05
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section A.  MA Growth Percentage",0.000146106292559711
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.000202086368443961
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768407
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.00011288233364024
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635097
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section III Benefit Review",0.000122732519844419
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.991032976549805
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356355
"CMS-2017-0163-1150-1-4",45,"3.7546923563138e-05","Section II Employer Group Waiver Plans",0.000207044385747011
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418580160022e-07
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313888442e-06
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section I Validation Audits",7.80120548019176e-06
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section B.  Calculation of Fee for Service Cost",5.50936891073584e-06
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section G.  MA Employer Group Waiver Plans",8.42420574171177e-06
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section L.  Normalization Factors",1.14232413853532e-05
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",0.20602385901024
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section IV   Medicare Medicaid Plans",5.48787256308778e-06
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329698e-05
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section III CY 2019 Formulary Submission Window",1.2164198234299e-05
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351466e-05
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section E.  Clinical Trials",2.21636701369646e-05
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775214e-05
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section II Part C Cost Sharing Standards",1.48376036820569e-05
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section II Total Beneficiary Cost (TBC)",1.32115891376877e-05
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032523954e-05
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section C.  Part D Risk Sharing",2.55140908046388e-05
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505615e-05
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703451e-05
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section O.  Quality Payment Program",2.52847571990486e-05
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section II Health Related Supplemental Benefits",3.44788570211438e-05
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741371e-05
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928572e-05
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section III Improving Access to Part D Vaccines",2.62277505669504e-05
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868599e-05
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650591e-05
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section I Innovations in Health Plan Design",3.17543788246036e-05
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081079e-05
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section III Tier Composition",4.59243068332397e-05
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496503e-05
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649232e-05
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section III Expanding the Part D OTC Program",5.52438803782582e-05
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section D.  ESRD Rates",3.65706624378759e-05
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section I Plan Corrections",4.14166098663172e-05
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section A.  Update of the RxHCC Model",2.28230186141221e-05
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275519968e-05
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048513925e-05
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098639e-05
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724262943e-05
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section II Plans with Low Enrollment",5.12202792258117e-05
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273208e-05
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268987e-05
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598892e-05
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328285e-05
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669165e-05
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319152
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section B.  FFS Growth Percentage",4.04246404618647e-05
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section C.  IME Phase Out",7.35366337011364e-05
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114415e-05
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410071e-05
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000601e-05
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543201e-05
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078871
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897755e-05
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section II Cost Plan Competition Requirements",0.000117601526802605
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655973
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966553e-05
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091895e-05
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474101
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270567e-05
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559714
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734596e-05
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313589
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777683
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section II Outpatient Observation Services",0.0001099411389947
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156118
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.00010449577977769
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section I Annual Calendar",5.38342337295147e-05
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section III Specialty Tiers",0.000124543815635088
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820243e-05
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section A.  MA Growth Percentage",0.000146106292559708
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.000202086368443961
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768406
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640233
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635089
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section III Benefit Review",0.000122732519844414
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.0001007530724741
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356357
"CMS-2017-0163-1150-1-4",46,"3.75469235631382e-05","Section II Employer Group Waiver Plans",0.000207044385747009
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579870311e-07
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313888007e-06
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section I Validation Audits",7.80120548019214e-06
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section B.  Calculation of Fee for Service Cost",5.50936891098415e-06
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section G.  MA Employer Group Waiver Plans",8.42420574183841e-06
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section L.  Normalization Factors",1.14232413853448e-05
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045106036e-06
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section IV   Medicare Medicaid Plans",5.48787256308293e-06
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section I.  ESRD Risk Adjustment Model for CY 2019",1.1532515932972e-05
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section III CY 2019 Formulary Submission Window",1.21641982343125e-05
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351506e-05
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section E.  Clinical Trials",2.21636701369595e-05
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775269e-05
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section II Part C Cost Sharing Standards",1.4837603682061e-05
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section II Total Beneficiary Cost (TBC)",1.3211589137692e-05
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032524027e-05
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section C.  Part D Risk Sharing",2.55140908046377e-05
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505646e-05
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703508e-05
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section O.  Quality Payment Program",2.52847571990411e-05
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section II Health Related Supplemental Benefits",3.44788570211532e-05
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741346e-05
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928552e-05
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section III Improving Access to Part D Vaccines",2.62277505669538e-05
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",0.99884938710397
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.7781938965068e-05
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section I Innovations in Health Plan Design",3.17543788246014e-05
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.2487850608104e-05
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section III Tier Composition",4.59243068332471e-05
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496399e-05
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649433e-05
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section III Expanding the Part D OTC Program",5.52438803782649e-05
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section D.  ESRD Rates",3.65706624378765e-05
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section I Plan Corrections",4.14166098663155e-05
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section A.  Update of the RxHCC Model",2.28230186141266e-05
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section II Tiered Cost Sharing of Medical Benefits",5.75024275520049e-05
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048513975e-05
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098661e-05
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section II Cost Plan Transition to MA under MACRA",7.75934724262969e-05
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section II Plans with Low Enrollment",5.12202792258104e-05
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273297e-05
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268889e-05
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598873e-05
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328378e-05
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.0466454466919e-05
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319154
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section B.  FFS Growth Percentage",4.042464046186e-05
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section C.  IME Phase Out",7.35366337011369e-05
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114392e-05
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section II Overview of CY 2019 Benefits and Bid Review",4.5186604541009e-05
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000589e-05
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543158e-05
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section D.  Retiree Drug Subsidy Amounts",0.213661162356704
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897763e-05
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section II Cost Plan Competition Requirements",0.000117601526802606
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655977
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966475e-05
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091865e-05
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section I Enforcement Actions for Provider Directories",0.000100753072474102
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270617e-05
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559706
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section III Coordination of Benefits (COB) User Fee",7.68865316734822e-05
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313597
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777683
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section II Outpatient Observation Services",0.000109941138994702
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section II Part C Optional Supplemental Benefits",0.000114412744156118
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777686
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section I Annual Calendar",5.38342337295216e-05
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section III Specialty Tiers",0.000124543815635091
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820197e-05
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section A.  MA Growth Percentage",0.000146106292559706
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.00020208636844396
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768403
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640236
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635091
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section III Benefit Review",0.000122732519844424
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474106
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356356
"CMS-2017-0163-1150-1-4",47,"0.00523029566052335","Section II Employer Group Waiver Plans",0.00020704438574701
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579883121e-07
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.9644331388735e-06
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section I Validation Audits",7.80120548019351e-06
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section B.  Calculation of Fee for Service Cost",5.50936891072142e-06
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section G.  MA Employer Group Waiver Plans",8.42420574184366e-06
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section L.  Normalization Factors",1.14232413853535e-05
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045106041e-06
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section IV   Medicare Medicaid Plans",5.48787256308947e-06
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329856e-05
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section III CY 2019 Formulary Submission Window",1.21641982343126e-05
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section I Incomplete and Inaccurate Bid Submissions",2.2639337035154e-05
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section E.  Clinical Trials",2.21636701369667e-05
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775313e-05
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section II Part C Cost Sharing Standards",1.48376036820465e-05
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section II Total Beneficiary Cost (TBC)",1.32115891377008e-05
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032523958e-05
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section C.  Part D Risk Sharing",2.55140908046377e-05
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505599e-05
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703506e-05
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section O.  Quality Payment Program",2.52847571990451e-05
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section II Health Related Supplemental Benefits",3.44788570211491e-05
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741383e-05
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928574e-05
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section III Improving Access to Part D Vaccines",2.62277505669556e-05
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868533e-05
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650566e-05
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section I Innovations in Health Plan Design",3.17543788246067e-05
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081119e-05
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section III Tier Composition",4.59243068332462e-05
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496437e-05
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649288e-05
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section III Expanding the Part D OTC Program",5.52438803782718e-05
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section D.  ESRD Rates",3.65706624378776e-05
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section I Plan Corrections",4.14166098663178e-05
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section A.  Update of the RxHCC Model",0.997968751343343
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275519968e-05
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048513977e-05
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098676e-05
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724262953e-05
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section II Plans with Low Enrollment",5.12202792258114e-05
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273309e-05
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268923e-05
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598923e-05
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328471e-05
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669207e-05
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319153
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section B.  FFS Growth Percentage",4.04246404618576e-05
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section C.  IME Phase Out",7.35366337011402e-05
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114488e-05
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.518660454101e-05
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000621e-05
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543193e-05
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078871
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897729e-05
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section II Cost Plan Competition Requirements",0.000117601526802606
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655975
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966502e-05
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.789692960919e-05
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474104
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270552e-05
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559705
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734821e-05
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313588
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777685
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section II Outpatient Observation Services",0.000109941138994698
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156119
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777683
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section I Annual Calendar",5.38342337295238e-05
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section III Specialty Tiers",0.000124543815635095
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.9564379082025e-05
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section A.  MA Growth Percentage",0.00014610629255971
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.000202086368443961
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768408
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640233
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635091
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section III Benefit Review",0.000122732519844414
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474111
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356351
"CMS-2017-0163-1150-1-4",48,"3.75469235631366e-05","Section II Employer Group Waiver Plans",0.000207044385747007
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418580154876e-07
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",0.504344774637497
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section I Validation Audits",7.80120548018278e-06
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section B.  Calculation of Fee for Service Cost",5.50936891098855e-06
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section G.  MA Employer Group Waiver Plans",8.42420574182159e-06
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section L.  Normalization Factors",1.14232413853493e-05
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045105755e-06
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section IV   Medicare Medicaid Plans",5.48787256308289e-06
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329648e-05
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section III CY 2019 Formulary Submission Window",1.21641982342965e-05
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351427e-05
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section E.  Clinical Trials",2.21636701369571e-05
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775196e-05
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section II Part C Cost Sharing Standards",1.48376036820477e-05
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section II Total Beneficiary Cost (TBC)",1.32115891376858e-05
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032524072e-05
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section C.  Part D Risk Sharing",2.55140908046416e-05
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505471e-05
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703432e-05
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section O.  Quality Payment Program",2.52847571990418e-05
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section II Health Related Supplemental Benefits",3.44788570211393e-05
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741269e-05
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928517e-05
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section III Improving Access to Part D Vaccines",2.62277505669517e-05
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868516e-05
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.7781938965051e-05
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section I Innovations in Health Plan Design",3.17543788245989e-05
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081021e-05
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section III Tier Composition",4.59243068332436e-05
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496412e-05
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649223e-05
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section III Expanding the Part D OTC Program",5.52438803782666e-05
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section D.  ESRD Rates",3.65706624378616e-05
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section I Plan Corrections",4.14166098663207e-05
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section A.  Update of the RxHCC Model",2.28230186141189e-05
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section II Tiered Cost Sharing of Medical Benefits",5.7502427551989e-05
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048513978e-05
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098576e-05
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724262923e-05
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section II Plans with Low Enrollment",5.12202792258074e-05
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273137e-05
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268746e-05
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598825e-05
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328369e-05
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669124e-05
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319158
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section B.  FFS Growth Percentage",4.04246404618487e-05
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section C.  IME Phase Out",7.35366337011366e-05
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114342e-05
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.5186604541e-05
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000569e-05
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543126e-05
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078868
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897722e-05
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section II Cost Plan Competition Requirements",0.000117601526802604
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655976
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.9794507696643e-05
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091808e-05
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474099
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270516e-05
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559709
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734685e-05
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313587
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777682
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section II Outpatient Observation Services",0.000109941138994697
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156117
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777676
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section I Annual Calendar",5.38342337295138e-05
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section III Specialty Tiers",0.000124543815635086
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820181e-05
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section A.  MA Growth Percentage",0.000146106292559707
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.000202086368443959
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768403
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640227
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.00012454381563509
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section III Benefit Review",0.00012273251984441
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474105
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356356
"CMS-2017-0163-1150-1-4",49,"3.7546923563139e-05","Section II Employer Group Waiver Plans",0.000207044385747007
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418580163518e-07
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",0.225601028226337
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section I Validation Audits",7.80120548018666e-06
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section B.  Calculation of Fee for Service Cost",5.50936891099212e-06
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section G.  MA Employer Group Waiver Plans",8.42420574182967e-06
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section L.  Normalization Factors",1.14232413853471e-05
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045104858e-06
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section IV   Medicare Medicaid Plans",5.48787256308436e-06
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329591e-05
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section III CY 2019 Formulary Submission Window",1.21641982343053e-05
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351398e-05
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section E.  Clinical Trials",2.21636701369543e-05
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775227e-05
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section II Part C Cost Sharing Standards",1.48376036820415e-05
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section II Total Beneficiary Cost (TBC)",1.32115891376809e-05
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032523916e-05
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section C.  Part D Risk Sharing",2.55140908046346e-05
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505492e-05
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703421e-05
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section O.  Quality Payment Program",2.5284757199037e-05
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section II Health Related Supplemental Benefits",3.44788570211368e-05
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741302e-05
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.8753890192846e-05
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section III Improving Access to Part D Vaccines",2.62277505669462e-05
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868422e-05
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.7781938965046e-05
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section I Innovations in Health Plan Design",3.17543788245911e-05
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081069e-05
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section III Tier Composition",4.59243068332424e-05
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.7474411449635e-05
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649224e-05
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section III Expanding the Part D OTC Program",5.52438803782599e-05
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section D.  ESRD Rates",3.65706624378636e-05
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section I Plan Corrections",4.14166098663127e-05
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section A.  Update of the RxHCC Model",2.28230186141107e-05
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275519948e-05
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048513934e-05
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098644e-05
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724262931e-05
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section II Plans with Low Enrollment",5.12202792258036e-05
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273196e-05
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268756e-05
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598836e-05
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328412e-05
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669124e-05
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319153
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section B.  FFS Growth Percentage",4.04246404618511e-05
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section C.  IME Phase Out",7.35366337011362e-05
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114339e-05
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410082e-05
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000537e-05
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543143e-05
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078872
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897695e-05
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section II Cost Plan Competition Requirements",0.000117601526802602
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655981
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966491e-05
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091778e-05
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474097
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270513e-05
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559714
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734684e-05
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313582
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777677
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section II Outpatient Observation Services",0.000109941138994699
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156116
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777679
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section I Annual Calendar",5.38342337295133e-05
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section III Specialty Tiers",0.000124543815635087
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.956437908202e-05
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section A.  MA Growth Percentage",0.00014610629255971
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.000202086368443957
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768398
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640224
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635087
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section III Benefit Review",0.000122732519844408
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474099
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356357
"CMS-2017-0163-1150-1-4",50,"3.75469235631417e-05","Section II Employer Group Waiver Plans",0.000207044385747006
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579884097e-07
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313881808e-06
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section I Validation Audits",7.80120548020013e-06
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section B.  Calculation of Fee for Service Cost",5.50936891099276e-06
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section G.  MA Employer Group Waiver Plans",8.42420574185156e-06
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section L.  Normalization Factors",1.14232413853551e-05
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045106429e-06
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section IV   Medicare Medicaid Plans",5.48787256278177e-06
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329821e-05
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section III CY 2019 Formulary Submission Window",1.21641982343119e-05
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351625e-05
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section E.  Clinical Trials",2.21636701369761e-05
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775433e-05
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section II Part C Cost Sharing Standards",1.48376036820615e-05
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section II Total Beneficiary Cost (TBC)",1.32115891377029e-05
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032524063e-05
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section C.  Part D Risk Sharing",2.55140908046386e-05
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505645e-05
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703542e-05
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section O.  Quality Payment Program",2.52847571990497e-05
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section II Health Related Supplemental Benefits",3.44788570211584e-05
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741482e-05
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928629e-05
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section III Improving Access to Part D Vaccines",2.62277505669689e-05
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868705e-05
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650653e-05
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section I Innovations in Health Plan Design",3.17543788246099e-05
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081097e-05
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section III Tier Composition",4.59243068332436e-05
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496467e-05
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649398e-05
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section III Expanding the Part D OTC Program",5.52438803782868e-05
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section D.  ESRD Rates",3.65706624378783e-05
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section I Plan Corrections",4.14166098663296e-05
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section A.  Update of the RxHCC Model",2.28230186141245e-05
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275520097e-05
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048513983e-05
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098708e-05
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724263135e-05
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section II Plans with Low Enrollment",5.12202792258232e-05
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273305e-05
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268936e-05
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598902e-05
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328572e-05
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669181e-05
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319155
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section B.  FFS Growth Percentage",4.04246404618622e-05
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section C.  IME Phase Out",7.35366337011404e-05
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114492e-05
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410178e-05
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000747e-05
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.1533056654335e-05
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078884
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897757e-05
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section II Cost Plan Competition Requirements",0.000117601526802618
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655984
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966539e-05
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091924e-05
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474101
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270815e-05
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559707
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734797e-05
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313594
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777682
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section II Outpatient Observation Services",0.000109941138994706
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156129
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777691
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section I Annual Calendar",0.172503132185671
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section III Specialty Tiers",0.000124543815635097
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820217e-05
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section A.  MA Growth Percentage",0.000146106292559713
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.00020208636844396
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768419
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640241
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635105
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section III Benefit Review",0.000122732519844425
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.00010075307247411
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356356
"CMS-2017-0163-1150-1-4",51,"3.75469235631451e-05","Section II Employer Group Waiver Plans",0.000207044385747007
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579899336e-07
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313888785e-06
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section I Validation Audits",7.80120548019134e-06
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section B.  Calculation of Fee for Service Cost",5.50936891098746e-06
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section G.  MA Employer Group Waiver Plans",8.42420574184104e-06
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section L.  Normalization Factors",1.14232413853436e-05
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045106369e-06
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section IV   Medicare Medicaid Plans",5.48787256308485e-06
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329703e-05
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section III CY 2019 Formulary Submission Window",1.21641982343098e-05
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351542e-05
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section E.  Clinical Trials",2.21636701369676e-05
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775348e-05
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section II Part C Cost Sharing Standards",1.48376036816804e-05
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section II Total Beneficiary Cost (TBC)",1.32115891376928e-05
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032523966e-05
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section C.  Part D Risk Sharing",2.5514090804637e-05
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section II Maximum Out of Pocket (MOOP) Limits",0.9977763068537
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703464e-05
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section O.  Quality Payment Program",2.52847571990452e-05
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section II Health Related Supplemental Benefits",3.44788570211533e-05
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741329e-05
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928686e-05
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section III Improving Access to Part D Vaccines",2.62277505669529e-05
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868632e-05
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650595e-05
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section I Innovations in Health Plan Design",3.17543788246066e-05
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081096e-05
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section III Tier Composition",4.59243068332462e-05
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496391e-05
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.5643882464938e-05
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section III Expanding the Part D OTC Program",5.52438803782646e-05
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section D.  ESRD Rates",3.65706624378744e-05
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section I Plan Corrections",4.14166098663155e-05
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section A.  Update of the RxHCC Model",2.28230186141175e-05
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section II Tiered Cost Sharing of Medical Benefits",5.75024275520096e-05
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048513983e-05
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098621e-05
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section II Cost Plan Transition to MA under MACRA",7.75934724263028e-05
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section II Plans with Low Enrollment",5.12202792258164e-05
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section III Low Enrollment Plans (Stand alone PDPs only)",6.6054010927331e-05
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268825e-05
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598855e-05
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328447e-05
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669211e-05
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319155
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section B.  FFS Growth Percentage",4.04246404618582e-05
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section C.  IME Phase Out",7.35366337011364e-05
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.5450282411442e-05
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410103e-05
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000637e-05
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543246e-05
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section D.  Retiree Drug Subsidy Amounts",0.0701678860221711
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897764e-05
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section II Cost Plan Competition Requirements",0.000117601526802609
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655979
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966437e-05
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091815e-05
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section I Enforcement Actions for Provider Directories",0.000100753072474101
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270591e-05
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559708
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section III Coordination of Benefits (COB) User Fee",7.68865316734639e-05
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313585
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section K.  Medicare Advantage Coding Pattern Adjustment",0.00010449577977768
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section II Outpatient Observation Services",0.000109941138994707
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section II Part C Optional Supplemental Benefits",0.00011441274415612
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777679
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section I Annual Calendar",5.38342337295146e-05
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section III Specialty Tiers",0.000124543815635088
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820192e-05
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section A.  MA Growth Percentage",0.000146106292559713
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.000202086368443959
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.00012097315376841
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640236
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635095
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section III Benefit Review",0.000122732519844421
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474112
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356357
"CMS-2017-0163-1150-1-4",52,"0.0348963833706282","Section II Employer Group Waiver Plans",0.000207044385747008
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579867325e-07
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.9644331387834e-06
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section I Validation Audits",7.80120548019078e-06
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section B.  Calculation of Fee for Service Cost",5.50936891099121e-06
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section G.  MA Employer Group Waiver Plans",8.42420574183583e-06
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section L.  Normalization Factors",1.14232413853443e-05
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045106099e-06
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section IV   Medicare Medicaid Plans",5.48787256308628e-06
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329698e-05
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section III CY 2019 Formulary Submission Window",1.21641982343118e-05
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351539e-05
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section E.  Clinical Trials",2.21636701369617e-05
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775296e-05
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section II Part C Cost Sharing Standards",1.48376036820563e-05
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section II Total Beneficiary Cost (TBC)",1.32115891376904e-05
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032524021e-05
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section C.  Part D Risk Sharing",2.55140908046431e-05
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.4985316250562e-05
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703491e-05
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section O.  Quality Payment Program",2.52847571990426e-05
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section II Health Related Supplemental Benefits",3.44788570211506e-05
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741375e-05
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928568e-05
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section III Improving Access to Part D Vaccines",2.62277505669546e-05
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868558e-05
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650563e-05
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section I Innovations in Health Plan Design",3.17543788246064e-05
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.2487850608114e-05
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section III Tier Composition",0.995912736691841
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496383e-05
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.5643882464934e-05
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section III Expanding the Part D OTC Program",5.52438803782654e-05
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section D.  ESRD Rates",3.65706624378675e-05
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section I Plan Corrections",4.14166098663262e-05
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section A.  Update of the RxHCC Model",2.28230186141218e-05
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275520014e-05
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048513974e-05
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098714e-05
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724262961e-05
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section II Plans with Low Enrollment",5.12202792258123e-05
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273228e-05
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268819e-05
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598906e-05
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328392e-05
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669161e-05
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319156
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section B.  FFS Growth Percentage",4.04246404618577e-05
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section C.  IME Phase Out",7.3536633701138e-05
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114414e-05
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410137e-05
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000624e-05
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543165e-05
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078872
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897692e-05
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section II Cost Plan Competition Requirements",0.000117601526802607
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655973
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966484e-05
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091838e-05
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474104
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270612e-05
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559707
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section III Coordination of Benefits (COB) User Fee",0.993157098681061
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313592
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777681
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section II Outpatient Observation Services",0.000109941138994698
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156115
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777689
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section I Annual Calendar",5.38342337295168e-05
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section III Specialty Tiers",0.0001245438156351
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820202e-05
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section A.  MA Growth Percentage",0.000146106292559711
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.00020208636844396
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768407
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640235
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.00012454381563509
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section III Benefit Review",0.989076805733847
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474113
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356359
"CMS-2017-0163-1150-1-4",53,"3.75469235631355e-05","Section II Employer Group Waiver Plans",0.00020704438574701
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579871371e-07
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313877597e-06
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section I Validation Audits",7.80120548019863e-06
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section B.  Calculation of Fee for Service Cost",5.50936891099446e-06
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section G.  MA Employer Group Waiver Plans",8.42420574184225e-06
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section L.  Normalization Factors",1.14232413853484e-05
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.5297404510661e-06
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section IV   Medicare Medicaid Plans",5.48787256307878e-06
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.1532515932972e-05
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section III CY 2019 Formulary Submission Window",1.21641982343074e-05
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351571e-05
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section E.  Clinical Trials",2.21636701369764e-05
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775294e-05
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section II Part C Cost Sharing Standards",1.48376036820545e-05
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section II Total Beneficiary Cost (TBC)",1.32115891376954e-05
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032524026e-05
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section C.  Part D Risk Sharing",2.5514090804638e-05
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505619e-05
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703503e-05
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section O.  Quality Payment Program",2.52847571990487e-05
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section II Health Related Supplemental Benefits",3.44788570211542e-05
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741445e-05
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928529e-05
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section III Improving Access to Part D Vaccines",2.62277505669602e-05
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868501e-05
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650487e-05
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section I Innovations in Health Plan Design",3.17543788246081e-05
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081119e-05
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section III Tier Composition",4.5924306833242e-05
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.7474411449643e-05
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649263e-05
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section III Expanding the Part D OTC Program",5.52438803782669e-05
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section D.  ESRD Rates",3.65706624378681e-05
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section I Plan Corrections",4.14166098663245e-05
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section A.  Update of the RxHCC Model",2.28230186141236e-05
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275520052e-05
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048514045e-05
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098672e-05
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724263047e-05
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section II Plans with Low Enrollment",5.12202792258228e-05
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273315e-05
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.7215762826884e-05
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598941e-05
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328484e-05
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669195e-05
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319153
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section B.  FFS Growth Percentage",4.04246404618572e-05
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section C.  IME Phase Out",7.35366337011351e-05
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114483e-05
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410168e-05
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section II Transparency   Timeliness with Prior Authorization Processes",0.994074815387994
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543294e-05
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078871
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897815e-05
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section II Cost Plan Competition Requirements",0.000117601526802616
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655971
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966593e-05
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091907e-05
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474112
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270625e-05
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559706
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734823e-05
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313589
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777681
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section II Outpatient Observation Services",0.000109941138994701
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156116
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777678
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section I Annual Calendar",5.38342337295262e-05
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section III Specialty Tiers",0.00012454381563509
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820223e-05
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section A.  MA Growth Percentage",0.000146106292559714
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.00020208636844396
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768409
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640228
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635104
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section III Benefit Review",0.000122732519844416
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.0001007530724741
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356356
"CMS-2017-0163-1150-1-4",54,"3.75469235631329e-05","Section II Employer Group Waiver Plans",0.000207044385747007
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579876067e-07
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313882967e-06
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section I Validation Audits",7.80120548019363e-06
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section B.  Calculation of Fee for Service Cost",5.50936891099218e-06
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section G.  MA Employer Group Waiver Plans",8.42420574183786e-06
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section L.  Normalization Factors",1.14232413853441e-05
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045106807e-06
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section IV   Medicare Medicaid Plans",5.48787256308753e-06
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329688e-05
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section III CY 2019 Formulary Submission Window",1.21641982343061e-05
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section I Incomplete and Inaccurate Bid Submissions",2.2639337035152e-05
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section E.  Clinical Trials",2.21636701369679e-05
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775321e-05
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section II Part C Cost Sharing Standards",1.48376036820533e-05
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section II Total Beneficiary Cost (TBC)",1.3211589137697e-05
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032524074e-05
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section C.  Part D Risk Sharing",2.55140908046377e-05
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505614e-05
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.5493966770352e-05
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section O.  Quality Payment Program",2.52847571990482e-05
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section II Health Related Supplemental Benefits",3.44788570211488e-05
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741353e-05
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928533e-05
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section III Improving Access to Part D Vaccines",2.62277505669488e-05
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.2928234786861e-05
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650579e-05
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section I Innovations in Health Plan Design",3.17543788246085e-05
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081082e-05
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section III Tier Composition",4.59243068332499e-05
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496513e-05
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649381e-05
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section III Expanding the Part D OTC Program",5.52438803782668e-05
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section D.  ESRD Rates",3.65706624378803e-05
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section I Plan Corrections",4.14166098663257e-05
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section A.  Update of the RxHCC Model",2.28230186141249e-05
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275520007e-05
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048514016e-05
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098689e-05
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724262966e-05
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section II Plans with Low Enrollment",5.12202792258191e-05
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273264e-05
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",0.413794837148545
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598915e-05
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328376e-05
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669182e-05
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319157
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section B.  FFS Growth Percentage",4.04246404618569e-05
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section C.  IME Phase Out",7.35366337011414e-05
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114421e-05
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410125e-05
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000658e-05
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543264e-05
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078877
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897695e-05
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section II Cost Plan Competition Requirements",0.000117601526802612
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655971
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966501e-05
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091891e-05
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474104
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.452994842706e-05
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559708
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734696e-05
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313592
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777682
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section II Outpatient Observation Services",0.000109941138994699
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156116
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777689
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section I Annual Calendar",5.38342337295183e-05
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section III Specialty Tiers",0.000124543815635103
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820185e-05
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section A.  MA Growth Percentage",0.000146106292559712
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.000202086368443959
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768407
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640237
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635105
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section III Benefit Review",0.000122732519844422
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474113
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356357
"CMS-2017-0163-1150-1-4",55,"3.75469235631355e-05","Section II Employer Group Waiver Plans",0.000207044385747009
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",0.204025565687738
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313880461e-06
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section I Validation Audits",7.80120548018316e-06
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section B.  Calculation of Fee for Service Cost",5.50936891098072e-06
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section G.  MA Employer Group Waiver Plans",8.42420574183312e-06
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section L.  Normalization Factors",1.14232413853415e-05
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045106032e-06
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section IV   Medicare Medicaid Plans",5.48787256303972e-06
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329601e-05
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section III CY 2019 Formulary Submission Window",1.21641982342958e-05
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351386e-05
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section E.  Clinical Trials",2.21636701369601e-05
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775168e-05
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section II Part C Cost Sharing Standards",1.48376036820413e-05
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section II Total Beneficiary Cost (TBC)",1.32115891376826e-05
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032523994e-05
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section C.  Part D Risk Sharing",2.55140908046375e-05
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505551e-05
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703453e-05
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section O.  Quality Payment Program",2.52847571990367e-05
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section II Health Related Supplemental Benefits",3.44788570211315e-05
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741266e-05
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928461e-05
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section III Improving Access to Part D Vaccines",2.62277505669486e-05
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868488e-05
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650436e-05
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section I Innovations in Health Plan Design",3.17543788245981e-05
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081044e-05
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section III Tier Composition",4.592430683324e-05
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496431e-05
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649203e-05
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section III Expanding the Part D OTC Program",5.52438803782555e-05
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section D.  ESRD Rates",3.65706624378723e-05
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section I Plan Corrections",4.14166098663185e-05
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section A.  Update of the RxHCC Model",2.28230186141193e-05
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275519905e-05
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048513989e-05
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098638e-05
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724262928e-05
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section II Plans with Low Enrollment",5.1220279225803e-05
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273243e-05
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268709e-05
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598892e-05
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328261e-05
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669119e-05
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319156
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section B.  FFS Growth Percentage",4.04246404618502e-05
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section C.  IME Phase Out",7.35366337011323e-05
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114398e-05
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410055e-05
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000575e-05
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543085e-05
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078868
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.5035911989773e-05
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section II Cost Plan Competition Requirements",0.000117601526802608
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655978
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966492e-05
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091828e-05
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474101
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270504e-05
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559709
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734637e-05
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313583
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777692
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section II Outpatient Observation Services",0.000109941138994692
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156128
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777677
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section I Annual Calendar",5.38342337295058e-05
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section III Specialty Tiers",0.000124543815635088
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820171e-05
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section A.  MA Growth Percentage",0.000146106292559707
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.000202086368443958
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768399
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640224
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635088
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section III Benefit Review",0.000122732519844409
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474095
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356356
"CMS-2017-0163-1150-1-4",56,"3.75469235631275e-05","Section II Employer Group Waiver Plans",0.000207044385747006
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.9941857989234e-07
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313889444e-06
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section I Validation Audits",7.8012054801901e-06
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section B.  Calculation of Fee for Service Cost",5.50936891075707e-06
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section G.  MA Employer Group Waiver Plans",0.881454597151983
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section L.  Normalization Factors",1.14232413853516e-05
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045082299e-06
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section IV   Medicare Medicaid Plans",5.48787256308371e-06
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329728e-05
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section III CY 2019 Formulary Submission Window",1.21641982343006e-05
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351521e-05
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section E.  Clinical Trials",2.21636701369625e-05
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775272e-05
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section II Part C Cost Sharing Standards",1.48376036820555e-05
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section II Total Beneficiary Cost (TBC)",1.3211589137693e-05
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032523994e-05
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section C.  Part D Risk Sharing",2.55140908046427e-05
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.4985316250559e-05
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703463e-05
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section O.  Quality Payment Program",2.52847571990441e-05
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section II Health Related Supplemental Benefits",3.44788570211434e-05
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.049227887413e-05
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928524e-05
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section III Improving Access to Part D Vaccines",2.62277505669549e-05
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868522e-05
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650482e-05
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section I Innovations in Health Plan Design",3.17543788246046e-05
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081034e-05
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section III Tier Composition",4.59243068332451e-05
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496547e-05
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649208e-05
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section III Expanding the Part D OTC Program",5.52438803782622e-05
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section D.  ESRD Rates",3.65706624378825e-05
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section I Plan Corrections",4.14166098663255e-05
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section A.  Update of the RxHCC Model",2.28230186141223e-05
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275519979e-05
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.4018204851399e-05
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098709e-05
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724262975e-05
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section II Plans with Low Enrollment",5.12202792258135e-05
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273295e-05
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268827e-05
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598896e-05
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.5197887032837e-05
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669179e-05
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.00010714932031916
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section B.  FFS Growth Percentage",4.04246404618595e-05
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section C.  IME Phase Out",7.3536633701144e-05
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114384e-05
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410247e-05
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000599e-05
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543134e-05
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078871
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897741e-05
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section II Cost Plan Competition Requirements",0.000117601526802601
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655974
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966528e-05
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.7896929609201e-05
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section I Enforcement Actions for Provider Directories",0.0001007530724741
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270586e-05
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559704
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734608e-05
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313587
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777692
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section II Outpatient Observation Services",0.000109941138994697
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section II Part C Optional Supplemental Benefits",0.00011441274415612
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777677
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section I Annual Calendar",5.38342337295353e-05
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section III Specialty Tiers",0.000124543815635085
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820168e-05
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section A.  MA Growth Percentage",0.000146106292559708
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.000202086368443957
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768407
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640235
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635092
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section III Benefit Review",0.000122732519844416
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474107
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356352
"CMS-2017-0163-1150-1-4",57,"3.75469235631406e-05","Section II Employer Group Waiver Plans",0.000207044385747005
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579960477e-07
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313884664e-06
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section I Validation Audits",7.80120548019598e-06
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section B.  Calculation of Fee for Service Cost",5.50936891071059e-06
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section G.  MA Employer Group Waiver Plans",8.42420574184664e-06
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section L.  Normalization Factors",1.14232413853505e-05
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045106621e-06
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section IV   Medicare Medicaid Plans",5.48787256309106e-06
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329761e-05
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section III CY 2019 Formulary Submission Window",1.2164198234309e-05
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351473e-05
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section E.  Clinical Trials",2.21636701369661e-05
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775321e-05
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section II Part C Cost Sharing Standards",1.48376036820512e-05
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section II Total Beneficiary Cost (TBC)",1.32115891376982e-05
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032524001e-05
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section C.  Part D Risk Sharing",2.55140908046379e-05
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505563e-05
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703473e-05
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section O.  Quality Payment Program",2.52847571990478e-05
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section II Health Related Supplemental Benefits",3.44788570211464e-05
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741409e-05
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928529e-05
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section III Improving Access to Part D Vaccines",2.62277505669554e-05
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868568e-05
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650516e-05
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section I Innovations in Health Plan Design",3.17543788246101e-05
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081115e-05
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section III Tier Composition",4.59243068332463e-05
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.7474411449651e-05
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649288e-05
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section III Expanding the Part D OTC Program",5.52438803782624e-05
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section D.  ESRD Rates",3.65706624378876e-05
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section I Plan Corrections",4.14166098663203e-05
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section A.  Update of the RxHCC Model",2.28230186141258e-05
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section II Tiered Cost Sharing of Medical Benefits",5.7502427551998e-05
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048513996e-05
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.5947545409873e-05
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724262969e-05
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section II Plans with Low Enrollment",5.12202792258136e-05
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273318e-05
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268893e-05
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598886e-05
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328323e-05
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.0466454466916e-05
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319156
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section B.  FFS Growth Percentage",4.04246404618613e-05
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section C.  IME Phase Out",7.35366337011481e-05
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114419e-05
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410082e-05
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000602e-05
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543116e-05
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section D.  Retiree Drug Subsidy Amounts",0.00015411072607887
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897717e-05
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section II Cost Plan Competition Requirements",0.000117601526802602
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655978
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966525e-05
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091886e-05
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474103
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270621e-05
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559708
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734663e-05
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313589
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.990699875599786
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section II Outpatient Observation Services",0.000109941138994699
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section II Part C Optional Supplemental Benefits",0.00011441274415612
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777678
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section I Annual Calendar",5.3834233729519e-05
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section III Specialty Tiers",0.00012454381563509
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.9564379082019e-05
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section A.  MA Growth Percentage",0.000146106292559714
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.00020208636844396
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.989233389314612
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.00011288233364023
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635092
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section III Benefit Review",0.00012273251984441
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474097
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356355
"CMS-2017-0163-1150-1-4",58,"3.75469235631386e-05","Section II Employer Group Waiver Plans",0.000207044385747009
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579897369e-07
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313887873e-06
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section I Validation Audits",7.80120548019536e-06
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section B.  Calculation of Fee for Service Cost",5.50936891099474e-06
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section G.  MA Employer Group Waiver Plans",8.42420574184167e-06
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section L.  Normalization Factors",1.14232413853499e-05
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045106905e-06
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section IV   Medicare Medicaid Plans",5.48787256308505e-06
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329694e-05
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section III CY 2019 Formulary Submission Window",1.21641982343081e-05
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351592e-05
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section E.  Clinical Trials",2.21636701369679e-05
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775375e-05
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section II Part C Cost Sharing Standards",1.48376036820507e-05
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section II Total Beneficiary Cost (TBC)",1.3211589137693e-05
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032524005e-05
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section C.  Part D Risk Sharing",2.55140908046375e-05
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505618e-05
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703457e-05
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section O.  Quality Payment Program",2.52847571990461e-05
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section II Health Related Supplemental Benefits",3.44788570211495e-05
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741401e-05
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.8753890192852e-05
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section III Improving Access to Part D Vaccines",2.62277505669584e-05
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868555e-05
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650508e-05
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section I Innovations in Health Plan Design",3.17543788246076e-05
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081089e-05
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section III Tier Composition",4.59243068332397e-05
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.7474411449647e-05
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.564388246493e-05
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section III Expanding the Part D OTC Program",5.52438803782705e-05
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section D.  ESRD Rates",3.65706624378746e-05
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section I Plan Corrections",4.14166098663291e-05
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section A.  Update of the RxHCC Model",2.28230186141204e-05
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275520085e-05
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048513976e-05
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098719e-05
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724263031e-05
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section II Plans with Low Enrollment",5.12202792258148e-05
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273293e-05
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268848e-05
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section M.  Medical Loss Ratio Credibility Adjustment",0.99223772946547
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328361e-05
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.0466454466916e-05
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319155
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section B.  FFS Growth Percentage",4.04246404618636e-05
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section C.  IME Phase Out",7.35366337011429e-05
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114437e-05
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410203e-05
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000737e-05
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.1533056654317e-05
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078869
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897765e-05
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section II Cost Plan Competition Requirements",0.000117601526802611
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655976
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966558e-05
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.7896929609184e-05
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section I Enforcement Actions for Provider Directories",0.991032976549805
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270603e-05
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559707
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734656e-05
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313587
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777684
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section II Outpatient Observation Services",0.000109941138994699
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156117
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777678
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section I Annual Calendar",5.38342337295327e-05
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section III Specialty Tiers",0.000124543815635089
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820215e-05
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section A.  MA Growth Percentage",0.000146106292559712
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.000202086368443961
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768408
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640235
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635101
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section III Benefit Review",0.000122732519844413
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474099
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356356
"CMS-2017-0163-1150-1-4",59,"3.75469235631348e-05","Section II Employer Group Waiver Plans",0.000207044385747007
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579852681e-07
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",0.109517394676244
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section I Validation Audits",7.80120548018476e-06
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section B.  Calculation of Fee for Service Cost",5.50936891099173e-06
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section G.  MA Employer Group Waiver Plans",8.42420574183081e-06
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section L.  Normalization Factors",1.14232413853444e-05
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045105048e-06
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section IV   Medicare Medicaid Plans",5.48787256307627e-06
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329648e-05
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section III CY 2019 Formulary Submission Window",1.2164198234295e-05
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351475e-05
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section E.  Clinical Trials",2.21636701369578e-05
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775207e-05
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section II Part C Cost Sharing Standards",1.48376036820461e-05
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section II Total Beneficiary Cost (TBC)",1.32115891376787e-05
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032523934e-05
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section C.  Part D Risk Sharing",2.55140908046307e-05
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505501e-05
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703369e-05
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section O.  Quality Payment Program",2.52847571990366e-05
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section II Health Related Supplemental Benefits",3.44788570211441e-05
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741256e-05
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928456e-05
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section III Improving Access to Part D Vaccines",2.62277505669476e-05
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868496e-05
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650497e-05
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section I Innovations in Health Plan Design",3.17543788246004e-05
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506080982e-05
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section III Tier Composition",4.59243068332353e-05
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.7474411449635e-05
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649221e-05
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section III Expanding the Part D OTC Program",5.52438803782615e-05
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section D.  ESRD Rates",3.65706624378645e-05
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section I Plan Corrections",4.14166098663118e-05
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section A.  Update of the RxHCC Model",2.28230186141157e-05
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275519926e-05
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048513951e-05
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098571e-05
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section II Cost Plan Transition to MA under MACRA",7.7593472426294e-05
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section II Plans with Low Enrollment",5.12202792258015e-05
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273156e-05
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268698e-05
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598849e-05
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328326e-05
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669077e-05
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319156
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section B.  FFS Growth Percentage",4.04246404618506e-05
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section C.  IME Phase Out",7.3536633701137e-05
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114343e-05
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410017e-05
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000569e-05
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566542987e-05
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078871
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897776e-05
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section II Cost Plan Competition Requirements",0.000117601526802606
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655974
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966421e-05
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091808e-05
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474098
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270551e-05
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559709
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734703e-05
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313587
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777685
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section II Outpatient Observation Services",0.000109941138994694
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section II Part C Optional Supplemental Benefits",0.00011441274415612
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777676
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section I Annual Calendar",5.38342337295179e-05
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section III Specialty Tiers",0.000124543815635089
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820163e-05
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section A.  MA Growth Percentage",0.000146106292559713
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.000202086368443957
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768403
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640229
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635086
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section III Benefit Review",0.000122732519844413
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474096
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356359
"CMS-2017-0163-1150-1-4",60,"3.75469235631456e-05","Section II Employer Group Waiver Plans",0.000207044385747006
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579870155e-07
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313888251e-06
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section I Validation Audits",7.80120548019809e-06
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section B.  Calculation of Fee for Service Cost",5.50936891098613e-06
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section G.  MA Employer Group Waiver Plans",8.42420574183118e-06
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section L.  Normalization Factors",1.14232413853445e-05
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045106425e-06
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section IV   Medicare Medicaid Plans",5.48787256309396e-06
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329705e-05
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section III CY 2019 Formulary Submission Window",1.21641982343069e-05
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section I Incomplete and Inaccurate Bid Submissions",2.2639337035153e-05
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section E.  Clinical Trials",2.21636701369662e-05
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775309e-05
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section II Part C Cost Sharing Standards",1.48376036820602e-05
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section II Total Beneficiary Cost (TBC)",1.32115891376929e-05
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032523983e-05
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section C.  Part D Risk Sharing",2.55140908046417e-05
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505641e-05
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703491e-05
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section O.  Quality Payment Program",2.52847571990426e-05
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section II Health Related Supplemental Benefits",3.4478857021148e-05
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741383e-05
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928648e-05
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section III Improving Access to Part D Vaccines",0.997665730199541
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868515e-05
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650638e-05
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section I Innovations in Health Plan Design",3.17543788246035e-05
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.2487850608112e-05
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section III Tier Composition",4.59243068332506e-05
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496401e-05
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649281e-05
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section III Expanding the Part D OTC Program",5.52438803782676e-05
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section D.  ESRD Rates",3.65706624378764e-05
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section I Plan Corrections",4.14166098663296e-05
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section A.  Update of the RxHCC Model",2.2823018614124e-05
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275519933e-05
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048513937e-05
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098631e-05
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724262951e-05
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section II Plans with Low Enrollment",5.12202792258098e-05
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273234e-05
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268799e-05
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.7216522859889e-05
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328539e-05
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669182e-05
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319155
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section B.  FFS Growth Percentage",4.04246404618529e-05
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section C.  IME Phase Out",7.35366337011388e-05
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114417e-05
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410133e-05
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000609e-05
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543181e-05
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078871
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897737e-05
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section II Cost Plan Competition Requirements",0.000117601526802609
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655982
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966434e-05
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091931e-05
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474103
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270543e-05
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559708
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734741e-05
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313594
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777683
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section II Outpatient Observation Services",0.000109941138994704
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156118
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777682
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section I Annual Calendar",5.38342337295212e-05
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section III Specialty Tiers",0.000124543815635097
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820177e-05
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section A.  MA Growth Percentage",0.000146106292559713
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.000202086368443959
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768402
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640234
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635093
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section III Benefit Review",0.000122732519844412
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474114
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356357
"CMS-2017-0163-1150-1-4",61,"3.75469235631364e-05","Section II Employer Group Waiver Plans",0.000207044385747009
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579867454e-07
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313888164e-06
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section I Validation Audits",7.80120548019555e-06
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section B.  Calculation of Fee for Service Cost",5.50936891073924e-06
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section G.  MA Employer Group Waiver Plans",8.42420574184148e-06
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section L.  Normalization Factors",1.14232413853532e-05
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045081388e-06
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section IV   Medicare Medicaid Plans",5.48787256307974e-06
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329769e-05
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section III CY 2019 Formulary Submission Window",1.21641982343078e-05
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351516e-05
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section E.  Clinical Trials",2.2163670136971e-05
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775283e-05
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section II Part C Cost Sharing Standards",1.48376036820605e-05
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section II Total Beneficiary Cost (TBC)",1.32115891377031e-05
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032524022e-05
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section C.  Part D Risk Sharing",2.55140908046415e-05
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505641e-05
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703489e-05
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section O.  Quality Payment Program",2.52847571990459e-05
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section II Health Related Supplemental Benefits",3.44788570211447e-05
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741317e-05
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928581e-05
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section III Improving Access to Part D Vaccines",2.62277505669591e-05
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868745e-05
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650603e-05
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section I Innovations in Health Plan Design",3.17543788246034e-05
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081074e-05
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section III Tier Composition",4.59243068332403e-05
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496525e-05
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649351e-05
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section III Expanding the Part D OTC Program",5.52438803782585e-05
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section D.  ESRD Rates",3.65706624378898e-05
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section I Plan Corrections",4.1416609866322e-05
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section A.  Update of the RxHCC Model",2.28230186141288e-05
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275519963e-05
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048514001e-05
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098694e-05
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724262983e-05
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section II Plans with Low Enrollment",5.12202792258135e-05
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273379e-05
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268865e-05
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598939e-05
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328331e-05
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669201e-05
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319155
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section B.  FFS Growth Percentage",4.04246404618695e-05
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section C.  IME Phase Out",7.35366337011415e-05
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114418e-05
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410182e-05
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000636e-05
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543148e-05
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section D.  Retiree Drug Subsidy Amounts",0.00015411072607887
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897748e-05
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section II Cost Plan Competition Requirements",0.000117601526802609
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655979
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966501e-05
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091864e-05
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474103
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270614e-05
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559707
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734644e-05
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313591
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777685
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section II Outpatient Observation Services",0.000109941138994696
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156119
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777682
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section I Annual Calendar",5.38342337295185e-05
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section III Specialty Tiers",0.000124543815635094
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820208e-05
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section A.  MA Growth Percentage",0.986996539962186
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.00020208636844396
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768424
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640231
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635091
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section III Benefit Review",0.000122732519844416
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.0001007530724741
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356356
"CMS-2017-0163-1150-1-4",62,"3.75469235631356e-05","Section II Employer Group Waiver Plans",0.000207044385747011
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579883993e-07
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313888384e-06
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section I Validation Audits",7.80120548018939e-06
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section B.  Calculation of Fee for Service Cost",5.50936891096621e-06
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section G.  MA Employer Group Waiver Plans",8.42420574184018e-06
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section L.  Normalization Factors",0.618570987342699
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045105737e-06
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section IV   Medicare Medicaid Plans",5.48787256308918e-06
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159326772e-05
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section III CY 2019 Formulary Submission Window",1.21641982343057e-05
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351503e-05
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section E.  Clinical Trials",2.21636701369656e-05
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775341e-05
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section II Part C Cost Sharing Standards",1.48376036820551e-05
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section II Total Beneficiary Cost (TBC)",1.32115891376975e-05
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032523968e-05
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section C.  Part D Risk Sharing",2.55140908046357e-05
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505573e-05
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703483e-05
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section O.  Quality Payment Program",2.52847571990506e-05
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section II Health Related Supplemental Benefits",3.44788570211524e-05
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741355e-05
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928544e-05
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section III Improving Access to Part D Vaccines",2.62277505669499e-05
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.2928234786857e-05
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650484e-05
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section I Innovations in Health Plan Design",3.1754378824611e-05
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081066e-05
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section III Tier Composition",4.59243068332385e-05
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496487e-05
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649224e-05
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section III Expanding the Part D OTC Program",5.52438803782623e-05
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section D.  ESRD Rates",3.65706624378884e-05
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section I Plan Corrections",4.14166098663176e-05
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section A.  Update of the RxHCC Model",2.28230186141438e-05
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section II Tiered Cost Sharing of Medical Benefits",5.75024275519964e-05
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048513986e-05
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098687e-05
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section II Cost Plan Transition to MA under MACRA",7.75934724262978e-05
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section II Plans with Low Enrollment",5.12202792258133e-05
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273236e-05
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268764e-05
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598852e-05
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328407e-05
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669192e-05
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319154
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section B.  FFS Growth Percentage",4.04246404618615e-05
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section C.  IME Phase Out",7.35366337011391e-05
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114512e-05
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410051e-05
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000607e-05
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543113e-05
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078871
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897744e-05
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section II Cost Plan Competition Requirements",0.000117601526802603
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655976
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966459e-05
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091879e-05
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section I Enforcement Actions for Provider Directories",0.000100753072474103
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270597e-05
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559707
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section III Coordination of Benefits (COB) User Fee",7.68865316734603e-05
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313589
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777694
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section II Outpatient Observation Services",0.000109941138994698
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section II Part C Optional Supplemental Benefits",0.000114412744156116
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777681
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section I Annual Calendar",5.38342337295202e-05
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section III Specialty Tiers",0.000124543815635087
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820389e-05
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section A.  MA Growth Percentage",0.000146106292559711
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.00020208636844396
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768402
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.00011288233364023
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635091
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section III Benefit Review",0.000122732519844411
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474099
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356374
"CMS-2017-0163-1150-1-4",63,"0.00925402214465007","Section II Employer Group Waiver Plans",0.000207044385747011
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579899336e-07
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313884385e-06
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section I Validation Audits",7.80120548019225e-06
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section B.  Calculation of Fee for Service Cost",5.50936891099751e-06
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section G.  MA Employer Group Waiver Plans",8.42420574184395e-06
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section L.  Normalization Factors",1.14232413853491e-05
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.5297404507774e-06
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section IV   Medicare Medicaid Plans",5.48787256308518e-06
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329777e-05
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section III CY 2019 Formulary Submission Window",1.21641982343111e-05
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351569e-05
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section E.  Clinical Trials",2.21636701369694e-05
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775367e-05
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section II Part C Cost Sharing Standards",1.48376036820546e-05
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section II Total Beneficiary Cost (TBC)",1.32115891376937e-05
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032523993e-05
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section C.  Part D Risk Sharing",2.55140908046383e-05
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505619e-05
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703485e-05
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section O.  Quality Payment Program",2.52847571990525e-05
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section II Health Related Supplemental Benefits",3.44788570211484e-05
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741397e-05
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928556e-05
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section III Improving Access to Part D Vaccines",2.62277505669589e-05
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868567e-05
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650521e-05
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section I Innovations in Health Plan Design",3.1754378824606e-05
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081118e-05
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section III Tier Composition",4.592430683324e-05
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496515e-05
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649377e-05
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section III Expanding the Part D OTC Program",5.52438803782704e-05
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section D.  ESRD Rates",3.65706624378834e-05
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section I Plan Corrections",4.14166098663203e-05
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section A.  Update of the RxHCC Model",2.28230186141241e-05
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275520028e-05
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048514073e-05
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098715e-05
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724263006e-05
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section II Plans with Low Enrollment",5.12202792258137e-05
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273385e-05
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268855e-05
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598957e-05
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328492e-05
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669175e-05
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319157
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section B.  FFS Growth Percentage",4.04246404618621e-05
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section C.  IME Phase Out",7.35366337011508e-05
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114417e-05
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410147e-05
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000664e-05
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543236e-05
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078872
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897749e-05
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section II Cost Plan Competition Requirements",0.000117601526802613
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.00012833167265598
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",0.992898288814998
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091919e-05
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474104
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270635e-05
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559711
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734694e-05
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.00010197049231359
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777698
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section II Outpatient Observation Services",0.000109941138994698
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156119
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777686
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section I Annual Calendar",5.38342337295238e-05
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section III Specialty Tiers",0.000124543815635095
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820176e-05
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section A.  MA Growth Percentage",0.000146106292559715
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.00020208636844396
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768419
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640232
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635101
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section III Benefit Review",0.000122732519844415
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474099
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356353
"CMS-2017-0163-1150-1-4",64,"3.754692356315e-05","Section II Employer Group Waiver Plans",0.00020704438574701
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579858969e-07
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313887446e-06
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section I Validation Audits",7.80120548019311e-06
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section B.  Calculation of Fee for Service Cost",5.50936891098826e-06
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section G.  MA Employer Group Waiver Plans",8.42420574183845e-06
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section L.  Normalization Factors",1.14232413853483e-05
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045106295e-06
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section IV   Medicare Medicaid Plans",5.48787256309135e-06
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329726e-05
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section III CY 2019 Formulary Submission Window",1.21641982343066e-05
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351498e-05
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section E.  Clinical Trials",2.21636701369621e-05
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775268e-05
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section II Part C Cost Sharing Standards",1.48376036820512e-05
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section II Total Beneficiary Cost (TBC)",1.32115891376904e-05
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032523985e-05
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section C.  Part D Risk Sharing",2.55140908046384e-05
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505622e-05
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703466e-05
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section O.  Quality Payment Program",2.52847571990427e-05
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section II Health Related Supplemental Benefits",3.44788570211474e-05
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741363e-05
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928512e-05
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section III Improving Access to Part D Vaccines",2.6227750566954e-05
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.2928234786855e-05
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650487e-05
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section I Innovations in Health Plan Design",3.17543788246042e-05
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081064e-05
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section III Tier Composition",4.59243068332445e-05
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496436e-05
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649283e-05
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section III Expanding the Part D OTC Program",5.52438803782625e-05
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section D.  ESRD Rates",3.65706624378761e-05
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section I Plan Corrections",4.14166098663246e-05
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section A.  Update of the RxHCC Model",2.28230186141245e-05
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section II Tiered Cost Sharing of Medical Benefits",5.75024275520015e-05
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048513978e-05
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098655e-05
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section II Cost Plan Transition to MA under MACRA",7.75934724262999e-05
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section II Plans with Low Enrollment",0.995441395148903
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section III Low Enrollment Plans (Stand alone PDPs only)",0.994121193027468
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268798e-05
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598828e-05
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328428e-05
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669147e-05
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319154
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section B.  FFS Growth Percentage",4.04246404618579e-05
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section C.  IME Phase Out",7.35366337011388e-05
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114447e-05
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410178e-05
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000606e-05
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.1533056654321e-05
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section D.  Retiree Drug Subsidy Amounts",0.00015411072607887
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897823e-05
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section II Cost Plan Competition Requirements",0.000117601526802612
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655974
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966479e-05
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091888e-05
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section I Enforcement Actions for Provider Directories",0.0001007530724741
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270624e-05
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559726
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section III Coordination of Benefits (COB) User Fee",7.68865316734611e-05
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313585
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777682
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section II Outpatient Observation Services",0.000109941138994697
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section II Part C Optional Supplemental Benefits",0.00011441274415612
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.00010449577977768
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section I Annual Calendar",5.38342337295252e-05
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section III Specialty Tiers",0.000124543815635093
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820198e-05
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section A.  MA Growth Percentage",0.000146106292559714
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.000202086368443959
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768403
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640235
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635091
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section III Benefit Review",0.000122732519844416
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474104
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356357
"CMS-2017-0163-1150-1-4",65,"0.0497728546864481","Section II Employer Group Waiver Plans",0.000207044385747006
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.9941857987357e-07
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.964433138832e-06
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section I Validation Audits",7.80120548019477e-06
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section B.  Calculation of Fee for Service Cost",5.50936891099034e-06
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section G.  MA Employer Group Waiver Plans",8.42420574184613e-06
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section L.  Normalization Factors",1.14232413853464e-05
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045106399e-06
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section IV   Medicare Medicaid Plans",5.48787256309245e-06
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329717e-05
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section III CY 2019 Formulary Submission Window",1.21641982343086e-05
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351525e-05
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section E.  Clinical Trials",2.2163670136968e-05
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775434e-05
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section II Part C Cost Sharing Standards",1.48376036820548e-05
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section II Total Beneficiary Cost (TBC)",1.32115891376938e-05
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032524029e-05
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section C.  Part D Risk Sharing",2.55140908046398e-05
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505667e-05
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703522e-05
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section O.  Quality Payment Program",2.52847571990462e-05
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section II Health Related Supplemental Benefits",3.44788570211547e-05
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741343e-05
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928606e-05
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section III Improving Access to Part D Vaccines",2.62277505669553e-05
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868589e-05
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650499e-05
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section I Innovations in Health Plan Design",3.17543788246073e-05
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081128e-05
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section III Tier Composition",4.59243068332469e-05
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496477e-05
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649299e-05
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section III Expanding the Part D OTC Program",5.52438803782612e-05
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section D.  ESRD Rates",3.65706624378716e-05
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section I Plan Corrections",4.14166098663329e-05
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section A.  Update of the RxHCC Model",2.28230186141256e-05
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275520051e-05
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048514092e-05
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098697e-05
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724263061e-05
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section II Plans with Low Enrollment",5.12202792258238e-05
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273379e-05
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268872e-05
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598883e-05
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328463e-05
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669189e-05
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319154
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section B.  FFS Growth Percentage",4.04246404618637e-05
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section C.  IME Phase Out",7.3536633701141e-05
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114667e-05
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410188e-05
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000669e-05
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543124e-05
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section D.  Retiree Drug Subsidy Amounts",0.00015411072607887
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897732e-05
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section II Cost Plan Competition Requirements",0.000117601526802605
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655975
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966502e-05
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091824e-05
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474098
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270647e-05
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.986996539962186
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734785e-05
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313587
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777681
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section II Outpatient Observation Services",0.000109941138994699
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156123
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777677
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section I Annual Calendar",5.38342337295211e-05
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section III Specialty Tiers",0.000124543815635092
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820231e-05
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section A.  MA Growth Percentage",0.000146106292559712
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.00020208636844396
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.00012097315376841
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640231
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635093
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section III Benefit Review",0.000122732519844422
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.0001007530724741
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356354
"CMS-2017-0163-1150-1-4",66,"3.7546923563144e-05","Section II Employer Group Waiver Plans",0.949643134207174
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579876529e-07
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313885976e-06
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section I Validation Audits",7.80120548019677e-06
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section B.  Calculation of Fee for Service Cost",5.50936891099226e-06
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section G.  MA Employer Group Waiver Plans",8.42420574184743e-06
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section L.  Normalization Factors",1.14232413853472e-05
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.5297404510686e-06
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section IV   Medicare Medicaid Plans",5.48787256292088e-06
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329686e-05
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section III CY 2019 Formulary Submission Window",1.21641982343184e-05
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section I Incomplete and Inaccurate Bid Submissions",0.462360446402472
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section E.  Clinical Trials",2.21636701369629e-05
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775351e-05
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section II Part C Cost Sharing Standards",1.48376036820511e-05
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section II Total Beneficiary Cost (TBC)",1.32115891376915e-05
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032523995e-05
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section C.  Part D Risk Sharing",2.55140908046357e-05
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505567e-05
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703478e-05
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section O.  Quality Payment Program",2.52847571990472e-05
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section II Health Related Supplemental Benefits",3.4478857021149e-05
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741308e-05
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928575e-05
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section III Improving Access to Part D Vaccines",2.62277505669614e-05
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868526e-05
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650499e-05
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section I Innovations in Health Plan Design",3.17543788246024e-05
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081107e-05
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section III Tier Composition",4.5924306833242e-05
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496493e-05
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649302e-05
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section III Expanding the Part D OTC Program",5.52438803782682e-05
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section D.  ESRD Rates",3.6570662437871e-05
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section I Plan Corrections",4.14166098661949e-05
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section A.  Update of the RxHCC Model",2.28230186141214e-05
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275519959e-05
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048513979e-05
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098702e-05
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724262968e-05
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section II Plans with Low Enrollment",5.12202792258096e-05
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273276e-05
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268846e-05
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598928e-05
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328335e-05
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669173e-05
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319155
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section B.  FFS Growth Percentage",4.04246404618579e-05
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section C.  IME Phase Out",7.35366337011399e-05
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114465e-05
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410063e-05
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000624e-05
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543084e-05
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section D.  Retiree Drug Subsidy Amounts",0.00015411072607887
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897743e-05
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section II Cost Plan Competition Requirements",0.000117601526802605
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655975
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966486e-05
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091899e-05
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474095
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270596e-05
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559708
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734814e-05
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313586
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.00010449577977768
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section II Outpatient Observation Services",0.000109941138994699
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156137
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777679
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section I Annual Calendar",0.183171505771872
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section III Specialty Tiers",0.00012454381563509
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820207e-05
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section A.  MA Growth Percentage",0.000146106292559711
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.000202086368443959
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768405
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640235
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635092
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section III Benefit Review",0.000122732519844421
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474102
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356353
"CMS-2017-0163-1150-1-4",67,"3.7546923563132e-05","Section II Employer Group Waiver Plans",0.000207044385747008
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579868787e-07
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313889069e-06
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section I Validation Audits",7.80120548019505e-06
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section B.  Calculation of Fee for Service Cost",5.50936891099409e-06
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section G.  MA Employer Group Waiver Plans",8.42420574183161e-06
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section L.  Normalization Factors",1.14232413853474e-05
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045107051e-06
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section IV   Medicare Medicaid Plans",5.48787256309212e-06
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329749e-05
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section III CY 2019 Formulary Submission Window",1.21641982343056e-05
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351563e-05
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section E.  Clinical Trials",2.2163670136965e-05
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775445e-05
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section II Part C Cost Sharing Standards",1.48376036820483e-05
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section II Total Beneficiary Cost (TBC)",1.32115891376962e-05
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032524003e-05
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section C.  Part D Risk Sharing",2.55140908046389e-05
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.4985316250568e-05
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703516e-05
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section O.  Quality Payment Program",2.52847571990477e-05
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section II Health Related Supplemental Benefits",3.44788570211502e-05
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741396e-05
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928506e-05
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section III Improving Access to Part D Vaccines",2.62277505669555e-05
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868575e-05
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.7781938965053e-05
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section I Innovations in Health Plan Design",3.17543788246053e-05
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081058e-05
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section III Tier Composition",4.59243068332407e-05
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496488e-05
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649314e-05
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section III Expanding the Part D OTC Program",5.52438803782717e-05
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section D.  ESRD Rates",3.65706624378722e-05
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section I Plan Corrections",4.14166098663297e-05
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section A.  Update of the RxHCC Model",2.2823018614122e-05
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275519968e-05
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",0.991632379768225
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098703e-05
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724263026e-05
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section II Plans with Low Enrollment",5.12202792258259e-05
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273252e-05
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268849e-05
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598946e-05
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328364e-05
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.0466454466916e-05
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319154
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section B.  FFS Growth Percentage",4.04246404618573e-05
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section C.  IME Phase Out",7.35366337011395e-05
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114664e-05
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410193e-05
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000677e-05
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543171e-05
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section D.  Retiree Drug Subsidy Amounts",0.00015411072607887
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897707e-05
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section II Cost Plan Competition Requirements",0.000117601526802609
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655978
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966608e-05
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091857e-05
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474106
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270658e-05
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559739
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section III Coordination of Benefits (COB) User Fee",7.6886531673464e-05
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313592
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777684
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section II Outpatient Observation Services",0.000109941138994698
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156121
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777679
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section I Annual Calendar",5.38342337295206e-05
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section III Specialty Tiers",0.000124543815635088
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820211e-05
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section A.  MA Growth Percentage",0.000146106292559713
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.00020208636844396
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768409
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640231
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635103
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section III Benefit Review",0.000122732519844415
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.0001007530724741
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356357
"CMS-2017-0163-1150-1-4",68,"3.75469235631391e-05","Section II Employer Group Waiver Plans",0.000207044385747009
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579894207e-07
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313858366e-06
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section I Validation Audits",7.80120548019174e-06
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section B.  Calculation of Fee for Service Cost",5.50936891092449e-06
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section G.  MA Employer Group Waiver Plans",8.42420574184521e-06
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section L.  Normalization Factors",1.14232413853522e-05
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045103591e-06
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section IV   Medicare Medicaid Plans",5.48787256280531e-06
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.1532515932973e-05
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section III CY 2019 Formulary Submission Window",1.21641982343117e-05
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351523e-05
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section E.  Clinical Trials",2.21636701369643e-05
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.5157402877534e-05
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section II Part C Cost Sharing Standards",1.48376036820596e-05
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section II Total Beneficiary Cost (TBC)",1.32115891376936e-05
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032524373e-05
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section C.  Part D Risk Sharing",2.55140908046377e-05
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505666e-05
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703573e-05
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section O.  Quality Payment Program",2.52847571990501e-05
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section II Health Related Supplemental Benefits",3.44788570211479e-05
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741374e-05
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928587e-05
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section III Improving Access to Part D Vaccines",2.62277505669666e-05
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868617e-05
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650635e-05
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section I Innovations in Health Plan Design",3.17543788246086e-05
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081197e-05
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section III Tier Composition",4.59243068332589e-05
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496598e-05
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649518e-05
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section III Expanding the Part D OTC Program",5.52438803782728e-05
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section D.  ESRD Rates",3.65706624378749e-05
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section I Plan Corrections",4.14166098663347e-05
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section A.  Update of the RxHCC Model",2.282301861413e-05
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275520011e-05
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048513986e-05
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098719e-05
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724263023e-05
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section II Plans with Low Enrollment",5.12202792258327e-05
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273334e-05
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.7215762826896e-05
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598945e-05
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328463e-05
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669186e-05
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319154
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section B.  FFS Growth Percentage",4.04246404618581e-05
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section C.  IME Phase Out",7.3536633701143e-05
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114459e-05
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410195e-05
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000562e-05
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543115e-05
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078885
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897869e-05
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section II Cost Plan Competition Requirements",0.000117601526802613
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655988
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966629e-05
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091983e-05
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474121
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.4529948427078e-05
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559714
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734803e-05
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313599
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777685
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section II Outpatient Observation Services",0.000109941138994706
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156133
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.00010449577977769
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section I Annual Calendar",5.38342337295558e-05
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section III Specialty Tiers",0.000124543815635108
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820215e-05
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section A.  MA Growth Percentage",0.000146106292559713
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.000202086368443959
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768417
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640237
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635115
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section III Benefit Review",0.000122732519844417
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474124
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356356
"CMS-2017-0163-1150-1-4",69,"3.75469235631424e-05","Section II Employer Group Waiver Plans",0.000207044385747003
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579910369e-07
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",0.0801581135846888
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section I Validation Audits",7.80120548018512e-06
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section B.  Calculation of Fee for Service Cost",5.50936891098293e-06
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section G.  MA Employer Group Waiver Plans",8.42420574182737e-06
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section L.  Normalization Factors",1.14232413853389e-05
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045106216e-06
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section IV   Medicare Medicaid Plans",5.48787256308912e-06
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329674e-05
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section III CY 2019 Formulary Submission Window",1.21641982342946e-05
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351402e-05
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section E.  Clinical Trials",2.21636701369594e-05
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775248e-05
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section II Part C Cost Sharing Standards",1.48376036820468e-05
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section II Total Beneficiary Cost (TBC)",1.32115891376877e-05
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032524002e-05
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section C.  Part D Risk Sharing",2.55140908046355e-05
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505483e-05
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703419e-05
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section O.  Quality Payment Program",2.52847571990375e-05
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section II Health Related Supplemental Benefits",3.44788570211397e-05
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741316e-05
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928499e-05
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section III Improving Access to Part D Vaccines",2.62277505669491e-05
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868452e-05
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650561e-05
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section I Innovations in Health Plan Design",3.17543788245996e-05
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081074e-05
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section III Tier Composition",4.59243068332417e-05
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496391e-05
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649289e-05
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section III Expanding the Part D OTC Program",5.52438803782567e-05
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section D.  ESRD Rates",3.65706624378683e-05
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section I Plan Corrections",4.14166098663155e-05
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section A.  Update of the RxHCC Model",2.28230186141166e-05
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275519955e-05
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048513992e-05
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.5947545409868e-05
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section II Cost Plan Transition to MA under MACRA",7.7593472426294e-05
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section II Plans with Low Enrollment",5.12202792258011e-05
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273178e-05
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268806e-05
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598844e-05
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328378e-05
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669161e-05
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319155
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section B.  FFS Growth Percentage",4.0424640461855e-05
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section C.  IME Phase Out",7.35366337011332e-05
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114357e-05
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410003e-05
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000542e-05
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.1533056654318e-05
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078874
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897743e-05
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section II Cost Plan Competition Requirements",0.000117601526802601
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655978
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966372e-05
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091764e-05
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474099
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270556e-05
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559706
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734666e-05
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313586
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777679
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section II Outpatient Observation Services",0.000109941138994691
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156113
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777683
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section I Annual Calendar",5.38342337295137e-05
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section III Specialty Tiers",0.0001245438156351
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.9564379082017e-05
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section A.  MA Growth Percentage",0.000146106292559713
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.000202086368443958
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.0001209731537684
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640228
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635087
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section III Benefit Review",0.000122732519844411
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474098
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356357
"CMS-2017-0163-1150-1-4",70,"3.7546923563134e-05","Section II Employer Group Waiver Plans",0.000207044385747006
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579877113e-07
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313886967e-06
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section I Validation Audits",7.80120548019496e-06
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section B.  Calculation of Fee for Service Cost",5.50936891098445e-06
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section G.  MA Employer Group Waiver Plans",8.42420574184843e-06
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section L.  Normalization Factors",1.14232413853475e-05
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045106249e-06
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section IV   Medicare Medicaid Plans",5.48787256309333e-06
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329691e-05
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section III CY 2019 Formulary Submission Window",1.21641982343038e-05
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351488e-05
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section E.  Clinical Trials",2.21636701369785e-05
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775319e-05
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section II Part C Cost Sharing Standards",1.48376036820461e-05
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section II Total Beneficiary Cost (TBC)",1.32115891377046e-05
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032523948e-05
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section C.  Part D Risk Sharing",2.5514090804638e-05
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505695e-05
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703508e-05
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section O.  Quality Payment Program",2.52847571990457e-05
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section II Health Related Supplemental Benefits",3.44788570211494e-05
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.0492278874143e-05
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928446e-05
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section III Improving Access to Part D Vaccines",2.62277505669574e-05
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868548e-05
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650525e-05
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section I Innovations in Health Plan Design",3.17543788246058e-05
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081079e-05
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section III Tier Composition",4.59243068332443e-05
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496418e-05
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649362e-05
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section III Expanding the Part D OTC Program",5.52438803782647e-05
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section D.  ESRD Rates",3.6570662437875e-05
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section I Plan Corrections",4.14166098663231e-05
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section A.  Update of the RxHCC Model",2.28230186141196e-05
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275520085e-05
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048513962e-05
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098663e-05
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724263048e-05
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section II Plans with Low Enrollment",5.12202792258221e-05
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273281e-05
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268906e-05
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598879e-05
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328432e-05
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.0466454466919e-05
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319153
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section B.  FFS Growth Percentage",4.0424640461861e-05
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section C.  IME Phase Out",7.35366337011388e-05
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114405e-05
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section II Overview of CY 2019 Benefits and Bid Review",0.99597839219585
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000667e-05
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543165e-05
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078875
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.503591198978e-05
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section II Cost Plan Competition Requirements",0.000117601526802614
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.00012833167265598
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966446e-05
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091888e-05
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474113
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270615e-05
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559712
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734751e-05
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313587
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777682
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section II Outpatient Observation Services",0.000109941138994706
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156116
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777681
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section I Annual Calendar",5.38342337295156e-05
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section III Specialty Tiers",0.000124543815635089
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.9564379082018e-05
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section A.  MA Growth Percentage",0.000146106292559714
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.000202086368443962
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768408
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640228
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635108
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section III Benefit Review",0.000122732519844425
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.0001007530724741
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356357
"CMS-2017-0163-1150-1-4",71,"3.75469235631352e-05","Section II Employer Group Waiver Plans",0.000207044385747005
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579874499e-07
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313882725e-06
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section I Validation Audits",7.8012054796485e-06
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section B.  Calculation of Fee for Service Cost",5.50936891099043e-06
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section G.  MA Employer Group Waiver Plans",8.4242057418338e-06
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section L.  Normalization Factors",1.14232413853466e-05
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.5297404510631e-06
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section IV   Medicare Medicaid Plans",5.48787256308668e-06
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329707e-05
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section III CY 2019 Formulary Submission Window",1.21641982343085e-05
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351623e-05
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section E.  Clinical Trials",2.21636701369651e-05
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775312e-05
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section II Part C Cost Sharing Standards",1.48376036820539e-05
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section II Total Beneficiary Cost (TBC)",1.32115891376876e-05
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032524096e-05
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section C.  Part D Risk Sharing",2.55140908046389e-05
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505595e-05
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",0.933497220053634
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section O.  Quality Payment Program",2.52847571990497e-05
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section II Health Related Supplemental Benefits",3.44788570211512e-05
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741442e-05
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928524e-05
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section III Improving Access to Part D Vaccines",2.62277505669559e-05
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868544e-05
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650497e-05
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section I Innovations in Health Plan Design",3.1754378824615e-05
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081162e-05
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section III Tier Composition",4.59243068332488e-05
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496511e-05
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649255e-05
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section III Expanding the Part D OTC Program",5.52438803782809e-05
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section D.  ESRD Rates",3.65706624378683e-05
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section I Plan Corrections",4.14166098663308e-05
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section A.  Update of the RxHCC Model",2.28230186141182e-05
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275519969e-05
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048514085e-05
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098695e-05
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724262988e-05
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section II Plans with Low Enrollment",5.12202792258151e-05
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.6054010927324e-05
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268857e-05
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598859e-05
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328305e-05
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669162e-05
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319156
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section B.  FFS Growth Percentage",4.04246404618591e-05
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section C.  IME Phase Out",7.35366337011417e-05
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114395e-05
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410111e-05
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000624e-05
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543222e-05
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078869
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.5035911989803e-05
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section II Cost Plan Competition Requirements",0.000117601526802601
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655975
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.9794507696647e-05
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091928e-05
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474108
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270704e-05
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559707
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734804e-05
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.0001019704923136
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.00010449577977768
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section II Outpatient Observation Services",0.000109941138994698
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section II Part C Optional Supplemental Benefits",0.00011441274415612
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777678
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section I Annual Calendar",5.38342337295211e-05
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section III Specialty Tiers",0.0001245438156351
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820208e-05
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section A.  MA Growth Percentage",0.000146106292559711
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.000202086368443962
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768405
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640231
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635112
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section III Benefit Review",0.000122732519844412
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.00010075307247411
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356356
"CMS-2017-0163-1150-1-4",72,"3.75469235631325e-05","Section II Employer Group Waiver Plans",0.000207044385747003
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579878502e-07
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.9644331388758e-06
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section I Validation Audits",7.801205480201e-06
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section B.  Calculation of Fee for Service Cost",5.50936891099283e-06
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section G.  MA Employer Group Waiver Plans",8.42420574184076e-06
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section L.  Normalization Factors",1.14232413853463e-05
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045106438e-06
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section IV   Medicare Medicaid Plans",5.48787256306575e-06
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329719e-05
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section III CY 2019 Formulary Submission Window",1.21641982343082e-05
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351607e-05
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section E.  Clinical Trials",2.21636701369699e-05
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775394e-05
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section II Part C Cost Sharing Standards",1.48376036820647e-05
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section II Total Beneficiary Cost (TBC)",1.32115891376938e-05
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032523992e-05
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section C.  Part D Risk Sharing",2.55140908046396e-05
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505666e-05
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.5493966770352e-05
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section O.  Quality Payment Program",2.52847571990507e-05
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section II Health Related Supplemental Benefits",3.44788570211512e-05
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741412e-05
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928596e-05
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section III Improving Access to Part D Vaccines",2.62277505669617e-05
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868574e-05
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650533e-05
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section I Innovations in Health Plan Design",3.17543788246103e-05
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081104e-05
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section III Tier Composition",4.59243068332424e-05
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496427e-05
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649334e-05
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section III Expanding the Part D OTC Program",5.52438803782671e-05
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section D.  ESRD Rates",3.65706624378707e-05
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section I Plan Corrections",4.14166098663288e-05
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section A.  Update of the RxHCC Model",2.28230186141229e-05
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275520058e-05
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048514056e-05
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098673e-05
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section II Cost Plan Transition to MA under MACRA",0.993094180954059
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section II Plans with Low Enrollment",5.12202792258213e-05
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273376e-05
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268881e-05
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.7216522859896e-05
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328456e-05
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669183e-05
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319153
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section B.  FFS Growth Percentage",4.04246404618578e-05
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section C.  IME Phase Out",7.35366337011403e-05
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114404e-05
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410206e-05
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000655e-05
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543181e-05
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078883
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897796e-05
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section II Cost Plan Competition Requirements",0.000117601526802623
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.00012833167265598
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966579e-05
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091917e-05
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474103
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270674e-05
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559709
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734684e-05
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313588
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777681
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section II Outpatient Observation Services",0.000109941138994702
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156127
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777681
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section I Annual Calendar",5.38342337295302e-05
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section III Specialty Tiers",0.000124543815635089
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820216e-05
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section A.  MA Growth Percentage",0.000146106292559712
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.00020208636844396
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768413
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640237
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635106
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section III Benefit Review",0.000122732519844417
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474105
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356357
"CMS-2017-0163-1150-1-4",73,"3.75469235631354e-05","Section II Employer Group Waiver Plans",0.000207044385747015
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579927528e-07
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313877033e-06
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section I Validation Audits",7.80120548020172e-06
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section B.  Calculation of Fee for Service Cost",5.50936891098836e-06
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section G.  MA Employer Group Waiver Plans",8.42420574183344e-06
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section L.  Normalization Factors",1.1423241385343e-05
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045106126e-06
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section IV   Medicare Medicaid Plans",5.48787256285375e-06
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329706e-05
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section III CY 2019 Formulary Submission Window",0.730321120654971
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section I Incomplete and Inaccurate Bid Submissions",2.263933703515e-05
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section E.  Clinical Trials",2.21636701369616e-05
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775305e-05
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section II Part C Cost Sharing Standards",1.48376036820487e-05
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section II Total Beneficiary Cost (TBC)",1.32115891376852e-05
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032523997e-05
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section C.  Part D Risk Sharing",2.55140908046355e-05
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505578e-05
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703492e-05
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section O.  Quality Payment Program",2.52847571990429e-05
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section II Health Related Supplemental Benefits",3.44788570211443e-05
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741339e-05
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928562e-05
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section III Improving Access to Part D Vaccines",2.62277505669558e-05
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868499e-05
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650513e-05
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section I Innovations in Health Plan Design",3.17543788246066e-05
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081107e-05
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section III Tier Composition",4.59243068332459e-05
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496443e-05
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649249e-05
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section III Expanding the Part D OTC Program",5.52438803782666e-05
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section D.  ESRD Rates",3.65706624378656e-05
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section I Plan Corrections",4.14166098663193e-05
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section A.  Update of the RxHCC Model",2.28230186141238e-05
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section II Tiered Cost Sharing of Medical Benefits",5.75024275519957e-05
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048513974e-05
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098689e-05
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section II Cost Plan Transition to MA under MACRA",7.7593472426291e-05
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section II Plans with Low Enrollment",5.12202792258072e-05
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273238e-05
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268921e-05
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598873e-05
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328334e-05
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669159e-05
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319155
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section B.  FFS Growth Percentage",4.04246404618554e-05
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section C.  IME Phase Out",7.35366337011384e-05
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114423e-05
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410088e-05
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000594e-05
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543178e-05
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078873
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897711e-05
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section II Cost Plan Competition Requirements",0.000117601526802602
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655974
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966471e-05
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091848e-05
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section I Enforcement Actions for Provider Directories",0.000100753072474101
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270551e-05
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559709
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section III Coordination of Benefits (COB) User Fee",7.68865316734746e-05
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313589
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section K.  Medicare Advantage Coding Pattern Adjustment",0.00010449577977768
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section II Outpatient Observation Services",0.000109941138994696
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section II Part C Optional Supplemental Benefits",0.00011441274415612
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.00010449577977768
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section I Annual Calendar",5.38342337295192e-05
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section III Specialty Tiers",0.000124543815635092
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820195e-05
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section A.  MA Growth Percentage",0.000146106292559713
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.000202086368443963
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768407
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640229
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635091
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section III Benefit Review",0.000122732519844414
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474103
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356355
"CMS-2017-0163-1150-1-4",74,"0.00649878858736579","Section II Employer Group Waiver Plans",0.000207044385747009
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.9941857989525e-07
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313883862e-06
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section I Validation Audits",7.80120548019396e-06
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section B.  Calculation of Fee for Service Cost",5.50936891093918e-06
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section G.  MA Employer Group Waiver Plans",8.42420574184296e-06
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section L.  Normalization Factors",1.14232413853527e-05
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045106904e-06
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section IV   Medicare Medicaid Plans",5.4878725630935e-06
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.1532515932983e-05
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section III CY 2019 Formulary Submission Window",1.2164198234309e-05
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351517e-05
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section E.  Clinical Trials",2.21636701369666e-05
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775368e-05
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section II Part C Cost Sharing Standards",1.4837603682059e-05
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section II Total Beneficiary Cost (TBC)",1.32115891376954e-05
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032524044e-05
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section C.  Part D Risk Sharing",2.5514090804639e-05
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.4985316250564e-05
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703516e-05
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section O.  Quality Payment Program",2.5284757199063e-05
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section II Health Related Supplemental Benefits",3.44788570211482e-05
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741375e-05
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928561e-05
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section III Improving Access to Part D Vaccines",2.62277505669578e-05
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868521e-05
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650501e-05
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section I Innovations in Health Plan Design",3.17543788246112e-05
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081198e-05
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section III Tier Composition",4.59243068332459e-05
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496558e-05
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649331e-05
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section III Expanding the Part D OTC Program",5.52438803782658e-05
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section D.  ESRD Rates",3.65706624378821e-05
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section I Plan Corrections",4.14166098663329e-05
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section A.  Update of the RxHCC Model",2.28230186141372e-05
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275519989e-05
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048513968e-05
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.5947545409864e-05
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724262967e-05
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section II Plans with Low Enrollment",5.12202792258194e-05
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273358e-05
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268846e-05
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598912e-05
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328373e-05
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669173e-05
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319155
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section B.  FFS Growth Percentage",4.04246404618549e-05
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section C.  IME Phase Out",7.35366337011484e-05
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114464e-05
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410123e-05
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000676e-05
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543197e-05
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078873
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897769e-05
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section II Cost Plan Competition Requirements",0.000117601526802611
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655973
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966476e-05
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",0.994847173264782
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474102
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270632e-05
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559708
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734711e-05
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313589
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777687
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section II Outpatient Observation Services",0.000109941138994696
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156119
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777679
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section I Annual Calendar",5.38342337295196e-05
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section III Specialty Tiers",0.000124543815635097
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820199e-05
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section A.  MA Growth Percentage",0.000146106292559711
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.000202086368443958
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768407
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640234
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635091
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section III Benefit Review",0.000122732519844416
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474105
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356358
"CMS-2017-0163-1150-1-4",75,"3.75469235631397e-05","Section II Employer Group Waiver Plans",0.000207044385747009
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418580144734e-07
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",0.0801267120584319
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section I Validation Audits",7.80120548018595e-06
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section B.  Calculation of Fee for Service Cost",5.50936891097771e-06
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section G.  MA Employer Group Waiver Plans",8.42420574183048e-06
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section L.  Normalization Factors",1.14232413853398e-05
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045106055e-06
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section IV   Medicare Medicaid Plans",5.48787256302678e-06
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329717e-05
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section III CY 2019 Formulary Submission Window",1.21641982342956e-05
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section I Incomplete and Inaccurate Bid Submissions",2.2639337035142e-05
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section E.  Clinical Trials",2.21636701369585e-05
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775226e-05
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section II Part C Cost Sharing Standards",1.48376036820464e-05
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section II Total Beneficiary Cost (TBC)",1.32115891376986e-05
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032524004e-05
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section C.  Part D Risk Sharing",2.55140908046384e-05
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505605e-05
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703413e-05
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section O.  Quality Payment Program",2.52847571990377e-05
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section II Health Related Supplemental Benefits",3.44788570211403e-05
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741302e-05
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928445e-05
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section III Improving Access to Part D Vaccines",2.62277505669508e-05
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868488e-05
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.7781938965047e-05
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section I Innovations in Health Plan Design",3.17543788245917e-05
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081043e-05
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section III Tier Composition",4.59243068332398e-05
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496399e-05
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649264e-05
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section III Expanding the Part D OTC Program",5.52438803782607e-05
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section D.  ESRD Rates",3.65706624378726e-05
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section I Plan Corrections",4.14166098663202e-05
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section A.  Update of the RxHCC Model",2.28230186141142e-05
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275519937e-05
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048513965e-05
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098652e-05
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section II Cost Plan Transition to MA under MACRA",7.7593472426293e-05
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section II Plans with Low Enrollment",5.12202792258047e-05
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273195e-05
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268656e-05
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598864e-05
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328362e-05
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669131e-05
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319156
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section B.  FFS Growth Percentage",4.04246404618552e-05
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section C.  IME Phase Out",7.35366337011341e-05
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114421e-05
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410059e-05
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000585e-05
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543234e-05
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078869
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897714e-05
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section II Cost Plan Competition Requirements",0.0001176015268026
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655975
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966428e-05
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091764e-05
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474101
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270534e-05
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.00014610629255971
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734709e-05
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313583
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777682
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section II Outpatient Observation Services",0.000109941138994698
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section II Part C Optional Supplemental Benefits",0.00011441274415612
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777678
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section I Annual Calendar",5.38342337295106e-05
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section III Specialty Tiers",0.00012454381563509
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820182e-05
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section A.  MA Growth Percentage",0.000146106292559709
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.000202086368443961
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768406
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640227
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.00012454381563509
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section III Benefit Review",0.000122732519844411
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474102
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356358
"CMS-2017-0163-1150-1-4",76,"3.75469235631291e-05","Section II Employer Group Waiver Plans",0.000207044385747009
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579897705e-07
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313889013e-06
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section I Validation Audits",7.80120548019232e-06
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section B.  Calculation of Fee for Service Cost",5.50936891099041e-06
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section G.  MA Employer Group Waiver Plans",8.42420574183645e-06
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section L.  Normalization Factors",1.14232413853483e-05
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045106258e-06
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section IV   Medicare Medicaid Plans",5.48787256308503e-06
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329701e-05
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section III CY 2019 Formulary Submission Window",1.21641982343123e-05
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351529e-05
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section E.  Clinical Trials",2.21636701369722e-05
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775283e-05
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section II Part C Cost Sharing Standards",1.48376036820615e-05
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section II Total Beneficiary Cost (TBC)",1.32115891376953e-05
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032524079e-05
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section C.  Part D Risk Sharing",2.55140908046406e-05
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505737e-05
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703461e-05
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section O.  Quality Payment Program",2.52847571990448e-05
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section II Health Related Supplemental Benefits",3.44788570211452e-05
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741369e-05
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928542e-05
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section III Improving Access to Part D Vaccines",2.62277505669938e-05
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347866845e-05
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",0.99752740743211
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section I Innovations in Health Plan Design",3.17543788246049e-05
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081072e-05
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section III Tier Composition",4.59243068332467e-05
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496408e-05
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",0.0489448255123231
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section III Expanding the Part D OTC Program",5.52438803782687e-05
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section D.  ESRD Rates",3.65706624378719e-05
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section I Plan Corrections",4.14166098663174e-05
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section A.  Update of the RxHCC Model",2.28230186141313e-05
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275520026e-05
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048513997e-05
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098699e-05
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section II Cost Plan Transition to MA under MACRA",7.7593472426298e-05
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section II Plans with Low Enrollment",5.12202792258096e-05
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273238e-05
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268976e-05
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598858e-05
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328349e-05
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669156e-05
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319155
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section B.  FFS Growth Percentage",4.04246404618622e-05
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section C.  IME Phase Out",7.35366337011414e-05
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114453e-05
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410123e-05
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000596e-05
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543256e-05
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section D.  Retiree Drug Subsidy Amounts",0.00015411072607888
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897711e-05
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section II Cost Plan Competition Requirements",0.000117601526802608
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655976
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966477e-05
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.7896929609192e-05
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474102
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270592e-05
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559706
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734873e-05
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313599
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777681
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section II Outpatient Observation Services",0.000109941138994701
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156117
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777664
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section I Annual Calendar",5.38342337295228e-05
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section III Specialty Tiers",0.000124543815635097
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820209e-05
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section A.  MA Growth Percentage",0.000146106292559713
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.00020208636844396
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768408
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640238
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635093
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section III Benefit Review",0.000122732519844425
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474115
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356354
"CMS-2017-0163-1150-1-4",77,"3.75469235631311e-05","Section II Employer Group Waiver Plans",0.00020704438574701
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418580182548e-07
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313884267e-06
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section I Validation Audits",7.8012054801923e-06
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section B.  Calculation of Fee for Service Cost",5.50936891099246e-06
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section G.  MA Employer Group Waiver Plans",8.42420574184134e-06
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section L.  Normalization Factors",1.14232413853457e-05
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045106843e-06
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section IV   Medicare Medicaid Plans",5.48787256309295e-06
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329717e-05
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section III CY 2019 Formulary Submission Window",1.2164198234313e-05
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351542e-05
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section E.  Clinical Trials",2.21636701369673e-05
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775371e-05
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section II Part C Cost Sharing Standards",1.48376036820565e-05
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section II Total Beneficiary Cost (TBC)",1.32115891376908e-05
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032523973e-05
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section C.  Part D Risk Sharing",2.55140908046382e-05
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505642e-05
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703467e-05
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section O.  Quality Payment Program",2.52847571990443e-05
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section II Health Related Supplemental Benefits",3.44788570211582e-05
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741395e-05
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928519e-05
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section III Improving Access to Part D Vaccines",2.62277505669569e-05
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868574e-05
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650493e-05
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section I Innovations in Health Plan Design",3.17543788246064e-05
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081182e-05
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section III Tier Composition",4.59243068332406e-05
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496484e-05
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.5643882464925e-05
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section III Expanding the Part D OTC Program",5.52438803782663e-05
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section D.  ESRD Rates",3.65706624378725e-05
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section I Plan Corrections",4.14166098663232e-05
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section A.  Update of the RxHCC Model",2.28230186141242e-05
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section II Tiered Cost Sharing of Medical Benefits",5.75024275519987e-05
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.4018204851403e-05
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098651e-05
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section II Cost Plan Transition to MA under MACRA",7.75934724263091e-05
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section II Plans with Low Enrollment",5.12202792258173e-05
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273325e-05
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268887e-05
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598912e-05
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328433e-05
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669138e-05
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319155
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section B.  FFS Growth Percentage",4.04246404618572e-05
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section C.  IME Phase Out",7.35366337011444e-05
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114472e-05
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410152e-05
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000622e-05
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543228e-05
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section D.  Retiree Drug Subsidy Amounts",0.00015411072607887
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897733e-05
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section II Cost Plan Competition Requirements",0.000117601526802603
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655977
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966511e-05
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.7896929609186e-05
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section I Enforcement Actions for Provider Directories",0.000100753072474101
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",0.995146834589992
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559709
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section III Coordination of Benefits (COB) User Fee",7.68865316734752e-05
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313589
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777687
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section II Outpatient Observation Services",0.000109941138994702
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section II Part C Optional Supplemental Benefits",0.000114412744156121
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777679
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section I Annual Calendar",5.38342337295203e-05
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section III Specialty Tiers",0.000124543815635091
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section N.  Encounter Data as a Diagnosis Source for 2019",9.9564379082021e-05
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section A.  MA Growth Percentage",0.000146106292559713
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.000202086368443961
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768411
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640231
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635094
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section III Benefit Review",0.000122732519844416
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474099
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356357
"CMS-2017-0163-1150-1-4",78,"0.0334830772544578","Section II Employer Group Waiver Plans",0.00020704438574701
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579872217e-07
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313888384e-06
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section I Validation Audits",7.80120548019448e-06
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section B.  Calculation of Fee for Service Cost",5.50936891073567e-06
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section G.  MA Employer Group Waiver Plans",8.42420574184328e-06
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section L.  Normalization Factors",1.14232413853495e-05
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045106627e-06
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section IV   Medicare Medicaid Plans",5.48787256309092e-06
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329755e-05
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section III CY 2019 Formulary Submission Window",1.2164198234303e-05
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351446e-05
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section E.  Clinical Trials",2.21636701369614e-05
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775203e-05
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section II Part C Cost Sharing Standards",1.4837603682051e-05
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section II Total Beneficiary Cost (TBC)",0.417274644547747
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032523954e-05
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section C.  Part D Risk Sharing",2.55140908046351e-05
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505599e-05
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703434e-05
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section O.  Quality Payment Program",2.52847571990342e-05
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section II Health Related Supplemental Benefits",3.44788570211451e-05
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741299e-05
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928541e-05
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section III Improving Access to Part D Vaccines",2.62277505669584e-05
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868523e-05
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650445e-05
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section I Innovations in Health Plan Design",3.17543788245994e-05
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081123e-05
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section III Tier Composition",4.5924306833245e-05
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496505e-05
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649236e-05
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section III Expanding the Part D OTC Program",5.52438803782647e-05
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section D.  ESRD Rates",3.65706624378839e-05
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section I Plan Corrections",4.14166098663233e-05
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section A.  Update of the RxHCC Model",2.28230186141212e-05
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275520023e-05
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048513959e-05
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098579e-05
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724262955e-05
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section II Plans with Low Enrollment",5.12202792258124e-05
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273261e-05
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268821e-05
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598859e-05
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328357e-05
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669188e-05
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319153
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section B.  FFS Growth Percentage",4.04246404618606e-05
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section C.  IME Phase Out",7.35366337011426e-05
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114376e-05
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410063e-05
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.6575108000066e-05
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543129e-05
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078868
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897736e-05
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section II Cost Plan Competition Requirements",0.000117601526802604
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655974
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966485e-05
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091885e-05
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474103
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270565e-05
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559709
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734753e-05
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313586
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777689
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section II Outpatient Observation Services",0.000109941138994696
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156118
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777679
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section I Annual Calendar",5.38342337295177e-05
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section III Specialty Tiers",0.000124543815635089
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.956437908202e-05
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section A.  MA Growth Percentage",0.000146106292559715
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.00020208636844396
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.0001209731537684
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.00011288233364023
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635087
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section III Benefit Review",0.000122732519844418
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474099
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356356
"CMS-2017-0163-1150-1-4",79,"3.75469235631379e-05","Section II Employer Group Waiver Plans",0.000207044385747011
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579905609e-07
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313888189e-06
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section I Validation Audits",7.80120548019511e-06
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section B.  Calculation of Fee for Service Cost",5.50936891099088e-06
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section G.  MA Employer Group Waiver Plans",8.42420574184424e-06
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section L.  Normalization Factors",1.14232413853521e-05
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045106678e-06
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section IV   Medicare Medicaid Plans",5.48787256308541e-06
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329746e-05
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section III CY 2019 Formulary Submission Window",1.21641982343028e-05
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351535e-05
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section E.  Clinical Trials",2.21636701369665e-05
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775365e-05
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section II Part C Cost Sharing Standards",1.48376036820511e-05
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section II Total Beneficiary Cost (TBC)",1.32115891376972e-05
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032523966e-05
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section C.  Part D Risk Sharing",2.55140908046397e-05
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505604e-05
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703508e-05
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section O.  Quality Payment Program",0.997749656609285
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section II Health Related Supplemental Benefits",3.4478857021148e-05
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741343e-05
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928506e-05
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section III Improving Access to Part D Vaccines",2.62277505669527e-05
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.2928234786859e-05
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650532e-05
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section I Innovations in Health Plan Design",3.17543788246093e-05
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081119e-05
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section III Tier Composition",4.59243068332412e-05
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496523e-05
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.5643882464932e-05
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section III Expanding the Part D OTC Program",5.5243880378264e-05
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section D.  ESRD Rates",3.65706624378718e-05
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section I Plan Corrections",4.14166098663217e-05
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section A.  Update of the RxHCC Model",2.2823018614121e-05
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section II Tiered Cost Sharing of Medical Benefits",5.75024275520015e-05
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048514005e-05
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098692e-05
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section II Cost Plan Transition to MA under MACRA",7.75934724262953e-05
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section II Plans with Low Enrollment",5.1220279225809e-05
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273233e-05
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268879e-05
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598891e-05
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section II Medicare Advantage (MA) Uniformity Flexibility",3.5197887032838e-05
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669181e-05
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319155
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section B.  FFS Growth Percentage",4.04246404618578e-05
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section C.  IME Phase Out",7.35366337011421e-05
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114365e-05
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410095e-05
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000671e-05
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543165e-05
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078869
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897722e-05
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section II Cost Plan Competition Requirements",0.000117601526802605
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655978
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966589e-05
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296092002e-05
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section I Enforcement Actions for Provider Directories",0.000100753072474098
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270619e-05
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559707
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section III Coordination of Benefits (COB) User Fee",7.68865316734648e-05
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313588
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section K.  Medicare Advantage Coding Pattern Adjustment",0.00010449577977769
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section II Outpatient Observation Services",0.000109941138994699
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section II Part C Optional Supplemental Benefits",0.000114412744156119
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777679
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section I Annual Calendar",5.38342337295224e-05
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section III Specialty Tiers",0.00012454381563509
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820229e-05
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section A.  MA Growth Percentage",0.000146106292559712
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.00020208636844396
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768415
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640233
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635092
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section III Benefit Review",0.000122732519844413
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.0001007530724741
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356356
"CMS-2017-0163-1150-1-4",80,"0.0067962328541794","Section II Employer Group Waiver Plans",0.000207044385747009
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579915275e-07
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313889327e-06
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section I Validation Audits",7.80120548019618e-06
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section B.  Calculation of Fee for Service Cost",5.50936891099142e-06
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section G.  MA Employer Group Waiver Plans",8.42420574183838e-06
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section L.  Normalization Factors",1.14232413853482e-05
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045106749e-06
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section IV   Medicare Medicaid Plans",5.4878725630842e-06
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329748e-05
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section III CY 2019 Formulary Submission Window",1.21641982343087e-05
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section I Incomplete and Inaccurate Bid Submissions",2.263933703515e-05
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section E.  Clinical Trials",2.21636701369635e-05
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775301e-05
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section II Part C Cost Sharing Standards",1.48376036820564e-05
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section II Total Beneficiary Cost (TBC)",1.32115891376896e-05
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032524021e-05
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section C.  Part D Risk Sharing",2.55140908046401e-05
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505651e-05
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703489e-05
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section O.  Quality Payment Program",2.52847571990448e-05
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section II Health Related Supplemental Benefits",3.44788570211546e-05
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741366e-05
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.8753890192864e-05
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section III Improving Access to Part D Vaccines",2.62277505669511e-05
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868598e-05
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650635e-05
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section I Innovations in Health Plan Design",3.17543788246023e-05
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081072e-05
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section III Tier Composition",4.5924306833243e-05
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496428e-05
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649341e-05
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section III Expanding the Part D OTC Program",5.5243880378274e-05
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section D.  ESRD Rates",3.6570662437867e-05
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section I Plan Corrections",4.14166098663212e-05
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section A.  Update of the RxHCC Model",2.28230186141213e-05
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275520049e-05
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048513982e-05
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098681e-05
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724262963e-05
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section II Plans with Low Enrollment",5.1220279225809e-05
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273234e-05
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268968e-05
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598927e-05
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328453e-05
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",0.993728485552444
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319153
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section B.  FFS Growth Percentage",4.0424640461859e-05
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section C.  IME Phase Out",7.35366337011429e-05
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114464e-05
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410118e-05
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000693e-05
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543218e-05
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section D.  Retiree Drug Subsidy Amounts",0.00015411072607887
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897733e-05
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section II Cost Plan Competition Requirements",0.000117601526802605
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.00012833167265598
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966515e-05
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091888e-05
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474105
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270609e-05
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559708
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section III Coordination of Benefits (COB) User Fee",7.6886531673479e-05
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313588
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777685
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section II Outpatient Observation Services",0.000109941138994706
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section II Part C Optional Supplemental Benefits",0.00011441274415612
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.990699875599786
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section I Annual Calendar",5.38342337295169e-05
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section III Specialty Tiers",0.000124543815635089
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820216e-05
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section A.  MA Growth Percentage",0.000146106292559711
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.000202086368443959
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768407
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640222
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635107
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section III Benefit Review",0.000122732519844415
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474102
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356358
"CMS-2017-0163-1150-1-4",81,"3.75469235631335e-05","Section II Employer Group Waiver Plans",0.000207044385747008
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579868599e-07
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313883242e-06
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section I Validation Audits",7.80120547987679e-06
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section B.  Calculation of Fee for Service Cost",5.50936891099303e-06
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section G.  MA Employer Group Waiver Plans",8.42420574183701e-06
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section L.  Normalization Factors",1.14232413853473e-05
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045106609e-06
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section IV   Medicare Medicaid Plans",5.48787256309526e-06
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329713e-05
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section III CY 2019 Formulary Submission Window",1.21641982343123e-05
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351578e-05
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section E.  Clinical Trials",2.21636701369678e-05
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775329e-05
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section II Part C Cost Sharing Standards",1.4837603682059e-05
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section II Total Beneficiary Cost (TBC)",1.32115891376924e-05
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032524148e-05
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section C.  Part D Risk Sharing",2.55140908046419e-05
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505688e-05
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703627e-05
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section O.  Quality Payment Program",2.52847571990477e-05
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section II Health Related Supplemental Benefits",3.44788570211478e-05
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741438e-05
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928515e-05
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section III Improving Access to Part D Vaccines",2.62277505669575e-05
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868593e-05
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650494e-05
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section I Innovations in Health Plan Design",3.17543788246076e-05
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081115e-05
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section III Tier Composition",4.59243068332568e-05
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496544e-05
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649263e-05
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section III Expanding the Part D OTC Program",5.52438803782693e-05
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section D.  ESRD Rates",3.65706624378768e-05
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section I Plan Corrections",4.14166098663359e-05
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section A.  Update of the RxHCC Model",2.28230186141204e-05
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275520032e-05
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048513987e-05
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098711e-05
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724263044e-05
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section II Plans with Low Enrollment",5.12202792258238e-05
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273341e-05
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268866e-05
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598902e-05
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328449e-05
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669159e-05
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319159
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section B.  FFS Growth Percentage",4.0424640461858e-05
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section C.  IME Phase Out",7.3536633701138e-05
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114414e-05
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410162e-05
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000706e-05
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543282e-05
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section D.  Retiree Drug Subsidy Amounts",0.00015411072607887
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",0.99421180383291
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section II Cost Plan Competition Requirements",0.000117601526802611
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.00012833167265598
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966462e-05
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091886e-05
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474102
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.4529948427063e-05
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559708
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734731e-05
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313589
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777684
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section II Outpatient Observation Services",0.000109941138994696
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156117
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777682
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section I Annual Calendar",5.38342337295215e-05
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section III Specialty Tiers",0.000124543815635095
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820223e-05
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section A.  MA Growth Percentage",0.000146106292559712
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.000202086368443961
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768421
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640233
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635094
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section III Benefit Review",0.000122732519844413
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474106
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356356
"CMS-2017-0163-1150-1-4",82,"3.75469235631331e-05","Section II Employer Group Waiver Plans",0.000207044385747002
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579945722e-07
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313889073e-06
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section I Validation Audits",7.80120548019515e-06
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section B.  Calculation of Fee for Service Cost",5.50936891099196e-06
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section G.  MA Employer Group Waiver Plans",8.42420574183401e-06
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section L.  Normalization Factors",1.1423241385347e-05
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045106669e-06
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section IV   Medicare Medicaid Plans",5.48787256308651e-06
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329713e-05
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section III CY 2019 Formulary Submission Window",1.21641982343079e-05
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351566e-05
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section E.  Clinical Trials",2.21636701369729e-05
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775356e-05
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section II Part C Cost Sharing Standards",1.48376036820548e-05
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section II Total Beneficiary Cost (TBC)",1.3211589137698e-05
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032523986e-05
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section C.  Part D Risk Sharing",2.55140908046408e-05
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505668e-05
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703483e-05
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section O.  Quality Payment Program",2.52847571990475e-05
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section II Health Related Supplemental Benefits",3.44788570211583e-05
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741399e-05
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928812e-05
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section III Improving Access to Part D Vaccines",2.62277505669661e-05
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868609e-05
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650537e-05
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section I Innovations in Health Plan Design",3.17543788246051e-05
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081087e-05
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section III Tier Composition",4.59243068332448e-05
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496462e-05
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649402e-05
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section III Expanding the Part D OTC Program",5.5243880378269e-05
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section D.  ESRD Rates",3.6570662437872e-05
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section I Plan Corrections",4.1416609866318e-05
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section A.  Update of the RxHCC Model",2.28230186141303e-05
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275520034e-05
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048514022e-05
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098677e-05
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section II Cost Plan Transition to MA under MACRA",7.7593472426303e-05
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section II Plans with Low Enrollment",5.12202792258154e-05
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273312e-05
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268947e-05
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598868e-05
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328602e-05
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669324e-05
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319154
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section B.  FFS Growth Percentage",4.04246404618619e-05
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section C.  IME Phase Out",7.35366337011415e-05
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114501e-05
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410198e-05
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000641e-05
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543151e-05
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078878
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897768e-05
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section II Cost Plan Competition Requirements",0.000117601526802612
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.988578481133618
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.9794507696653e-05
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091875e-05
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474104
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270625e-05
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559708
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734672e-05
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.00010197049231359
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.00010449577977768
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section II Outpatient Observation Services",0.000109941138994712
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156117
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777682
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section I Annual Calendar",5.38342337295229e-05
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section III Specialty Tiers",0.000124543815635088
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820208e-05
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section A.  MA Growth Percentage",0.000146106292559714
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.00020208636844396
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768408
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640233
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635103
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section III Benefit Review",0.000122732519844424
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474108
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356357
"CMS-2017-0163-1150-1-4",83,"3.75469235631367e-05","Section II Employer Group Waiver Plans",0.000207044385747002
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418580161083e-07
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313885647e-06
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section I Validation Audits",7.80120548019547e-06
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section B.  Calculation of Fee for Service Cost",5.50936891099344e-06
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section G.  MA Employer Group Waiver Plans",8.42420574184485e-06
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section L.  Normalization Factors",1.14232413853473e-05
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045106518e-06
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section IV   Medicare Medicaid Plans",5.4878725630815e-06
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329706e-05
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section III CY 2019 Formulary Submission Window",1.216419823431e-05
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351585e-05
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section E.  Clinical Trials",2.21636701369662e-05
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775352e-05
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section II Part C Cost Sharing Standards",1.48376036820601e-05
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section II Total Beneficiary Cost (TBC)",1.32115891376941e-05
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032523994e-05
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section C.  Part D Risk Sharing",2.55140908046428e-05
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505655e-05
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703495e-05
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section O.  Quality Payment Program",2.52847571990467e-05
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section II Health Related Supplemental Benefits",3.44788570211642e-05
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741339e-05
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928519e-05
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section III Improving Access to Part D Vaccines",2.62277505669581e-05
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868585e-05
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650567e-05
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section I Innovations in Health Plan Design",3.17543788246069e-05
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081133e-05
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section III Tier Composition",4.59243068332421e-05
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496463e-05
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649291e-05
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section III Expanding the Part D OTC Program",5.5243880378268e-05
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section D.  ESRD Rates",3.65706624378704e-05
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section I Plan Corrections",4.14166098663341e-05
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section A.  Update of the RxHCC Model",2.2823018614121e-05
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section II Tiered Cost Sharing of Medical Benefits",5.7502427551996e-05
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.4018204851404e-05
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098702e-05
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724263071e-05
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section II Plans with Low Enrollment",5.12202792258235e-05
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273384e-05
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268888e-05
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.7216522859894e-05
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328472e-05
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669202e-05
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319154
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section B.  FFS Growth Percentage",4.04246404618599e-05
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section C.  IME Phase Out",7.35366337011413e-05
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114459e-05
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410251e-05
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000624e-05
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543212e-05
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078871
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897771e-05
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section II Cost Plan Competition Requirements",0.000117601526802611
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655976
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966547e-05
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.789692960919e-05
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474104
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270609e-05
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.00014610629255973
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734779e-05
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.00010197049231359
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777682
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section II Outpatient Observation Services",0.000109941138994697
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section II Part C Optional Supplemental Benefits",0.735219317487352
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777681
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section I Annual Calendar",5.38342337295229e-05
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section III Specialty Tiers",0.000124543815635089
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820216e-05
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section A.  MA Growth Percentage",0.000146106292559711
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.000202086368443961
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768408
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640242
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635096
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section III Benefit Review",0.000122732519844421
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474106
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356358
"CMS-2017-0163-1150-1-4",84,"3.75469235631364e-05","Section II Employer Group Waiver Plans",0.000207044385747006
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418580168376e-07
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313885494e-06
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section I Validation Audits",7.80120548019408e-06
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section B.  Calculation of Fee for Service Cost",5.50936891065577e-06
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section G.  MA Employer Group Waiver Plans",8.42420574182088e-06
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section L.  Normalization Factors",1.14232413853573e-05
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.5297404506704e-06
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section IV   Medicare Medicaid Plans",5.48787256309383e-06
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329719e-05
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section III CY 2019 Formulary Submission Window",1.21641982343095e-05
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351519e-05
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section E.  Clinical Trials",2.2163670136964e-05
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775333e-05
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section II Part C Cost Sharing Standards",1.4837603682057e-05
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section II Total Beneficiary Cost (TBC)",1.32115891377061e-05
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032524003e-05
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section C.  Part D Risk Sharing",2.55140908046345e-05
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.4985316250563e-05
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703474e-05
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section O.  Quality Payment Program",2.5284757199046e-05
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section II Health Related Supplemental Benefits",3.44788570211515e-05
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741361e-05
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928601e-05
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section III Improving Access to Part D Vaccines",2.62277505669627e-05
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868606e-05
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650563e-05
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section I Innovations in Health Plan Design",3.17543788246075e-05
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081057e-05
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section III Tier Composition",4.59243068332437e-05
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.7474411449656e-05
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649385e-05
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section III Expanding the Part D OTC Program",5.52438803782686e-05
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section D.  ESRD Rates",3.65706624378987e-05
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section I Plan Corrections",4.14166098663177e-05
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section A.  Update of the RxHCC Model",2.28230186141254e-05
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275520011e-05
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048514001e-05
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098675e-05
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724262962e-05
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section II Plans with Low Enrollment",5.12202792258197e-05
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273278e-05
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268859e-05
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598901e-05
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328534e-05
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669194e-05
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319155
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section B.  FFS Growth Percentage",4.04246404618809e-05
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section C.  IME Phase Out",0.993455239600599
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114399e-05
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410175e-05
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000672e-05
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543224e-05
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078873
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897739e-05
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section II Cost Plan Competition Requirements",0.00011760152680261
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655974
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966666e-05
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296092147e-05
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474098
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270677e-05
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559712
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734778e-05
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313585
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777695
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section II Outpatient Observation Services",0.000109941138994696
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section II Part C Optional Supplemental Benefits",0.00011441274415612
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.00010449577977769
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section I Annual Calendar",5.3834233729521e-05
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section III Specialty Tiers",0.000124543815635091
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820265e-05
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section A.  MA Growth Percentage",0.000146106292559714
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.000202086368443959
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.00012097315376841
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640233
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635094
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section III Benefit Review",0.000122732519844418
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474099
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356352
"CMS-2017-0163-1150-1-4",85,"3.75469235631393e-05","Section II Employer Group Waiver Plans",0.000207044385747007
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579867286e-07
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.9644331388312e-06
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section I Validation Audits",7.80120548019857e-06
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section B.  Calculation of Fee for Service Cost",5.50936891098538e-06
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section G.  MA Employer Group Waiver Plans",8.42420574184196e-06
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section L.  Normalization Factors",1.14232413853596e-05
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045106403e-06
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section IV   Medicare Medicaid Plans",5.48787256309013e-06
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329741e-05
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section III CY 2019 Formulary Submission Window",1.21641982343053e-05
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351519e-05
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section E.  Clinical Trials",2.21636701369654e-05
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775261e-05
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section II Part C Cost Sharing Standards",1.48376036820549e-05
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section II Total Beneficiary Cost (TBC)",1.32115891376921e-05
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032524044e-05
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section C.  Part D Risk Sharing",0.997729245918387
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505598e-05
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.5493966770345e-05
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section O.  Quality Payment Program",2.52847571990443e-05
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section II Health Related Supplemental Benefits",3.44788570211465e-05
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.0492278874136e-05
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.8753890192856e-05
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section III Improving Access to Part D Vaccines",2.62277505669614e-05
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868509e-05
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650567e-05
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section I Innovations in Health Plan Design",3.17543788246017e-05
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081038e-05
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section III Tier Composition",4.5924306833244e-05
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496452e-05
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649302e-05
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section III Expanding the Part D OTC Program",5.52438803782618e-05
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section D.  ESRD Rates",3.65706624378812e-05
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section I Plan Corrections",4.14166098663223e-05
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section A.  Update of the RxHCC Model",2.28230186141382e-05
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275519946e-05
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048513965e-05
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.5947545409862e-05
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724262953e-05
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section II Plans with Low Enrollment",5.12202792258047e-05
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273253e-05
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268873e-05
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598892e-05
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328425e-05
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669117e-05
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.00010714932031916
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section B.  FFS Growth Percentage",4.04246404618561e-05
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section C.  IME Phase Out",7.35366337011422e-05
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114461e-05
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410054e-05
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000563e-05
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543163e-05
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078868
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897722e-05
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section II Cost Plan Competition Requirements",0.000117601526802603
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.00012833167265598
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966517e-05
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091837e-05
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474104
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270598e-05
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559707
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734656e-05
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313596
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777684
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section II Outpatient Observation Services",0.000109941138994695
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156116
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.00010449577977768
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section I Annual Calendar",5.38342337295184e-05
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section III Specialty Tiers",0.000124543815635099
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820338e-05
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section A.  MA Growth Percentage",0.000146106292559711
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.000202086368443959
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768408
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640232
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635089
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section III Benefit Review",0.000122732519844412
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474099
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356362
"CMS-2017-0163-1150-1-4",86,"3.75469235631358e-05","Section II Employer Group Waiver Plans",0.000207044385747008
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579880941e-07
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313886214e-06
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section I Validation Audits",7.80120548018916e-06
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section B.  Calculation of Fee for Service Cost",5.50936891099238e-06
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section G.  MA Employer Group Waiver Plans",8.42420574183694e-06
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section L.  Normalization Factors",1.14232413853464e-05
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045106002e-06
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section IV   Medicare Medicaid Plans",5.48787256309445e-06
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329717e-05
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section III CY 2019 Formulary Submission Window",1.21641982342999e-05
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section I Incomplete and Inaccurate Bid Submissions",2.2639337035149e-05
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section E.  Clinical Trials",2.21636701369736e-05
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775323e-05
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section II Part C Cost Sharing Standards",1.48376036820495e-05
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section II Total Beneficiary Cost (TBC)",1.32115891376862e-05
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032523946e-05
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section C.  Part D Risk Sharing",2.55140908046398e-05
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section II Maximum Out of Pocket (MOOP) Limits",2.4985316250562e-05
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703426e-05
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section O.  Quality Payment Program",2.5284757199043e-05
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section II Health Related Supplemental Benefits",3.44788570211416e-05
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741345e-05
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928642e-05
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section III Improving Access to Part D Vaccines",2.62277505669563e-05
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868522e-05
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650521e-05
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section I Innovations in Health Plan Design",3.17543788246059e-05
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081079e-05
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section III Tier Composition",4.59243068332449e-05
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496437e-05
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649314e-05
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section III Expanding the Part D OTC Program",5.52438803782676e-05
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section D.  ESRD Rates",3.65706624378695e-05
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section I Plan Corrections",4.14166098663203e-05
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section A.  Update of the RxHCC Model",2.28230186141277e-05
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section II Tiered Cost Sharing of Medical Benefits",5.75024275520044e-05
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.4018204851403e-05
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098689e-05
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section II Cost Plan Transition to MA under MACRA",7.75934724262976e-05
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section II Plans with Low Enrollment",5.12202792258193e-05
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273281e-05
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268907e-05
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598893e-05
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section II Medicare Advantage (MA) Uniformity Flexibility",0.996867388054077
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669197e-05
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319155
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section B.  FFS Growth Percentage",4.04246404618578e-05
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section C.  IME Phase Out",7.35366337011435e-05
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",0.992394924865382
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section II Overview of CY 2019 Benefits and Bid Review",4.5186604541015e-05
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000708e-05
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543171e-05
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078874
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897721e-05
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section II Cost Plan Competition Requirements",0.00011760152680261
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655978
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966461e-05
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.7896929609193e-05
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section I Enforcement Actions for Provider Directories",0.000100753072474099
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270613e-05
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559721
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section III Coordination of Benefits (COB) User Fee",7.68865316734677e-05
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313588
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777681
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section II Outpatient Observation Services",0.000109941138994701
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section II Part C Optional Supplemental Benefits",0.000114412744156117
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777677
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section I Annual Calendar",5.38342337295236e-05
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section III Specialty Tiers",0.000124543815635091
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820218e-05
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section A.  MA Growth Percentage",0.000146106292559714
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.000202086368443961
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768407
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640238
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635097
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section III Benefit Review",0.000122732519844417
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474099
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356357
"CMS-2017-0163-1150-1-4",87,"0.045876866375878","Section II Employer Group Waiver Plans",0.000207044385747008
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579916287e-07
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313888857e-06
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section I Validation Audits",7.80120548018988e-06
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section B.  Calculation of Fee for Service Cost",0.215978568972512
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section G.  MA Employer Group Waiver Plans",8.42420574184139e-06
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section L.  Normalization Factors",1.1423241385347e-05
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.5297404510536e-06
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section IV   Medicare Medicaid Plans",5.48787256308648e-06
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329659e-05
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section III CY 2019 Formulary Submission Window",1.21641982342943e-05
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351508e-05
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section E.  Clinical Trials",2.2163670136961e-05
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775199e-05
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section II Part C Cost Sharing Standards",1.48376036820593e-05
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section II Total Beneficiary Cost (TBC)",1.32115891377019e-05
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.0798103252399e-05
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section C.  Part D Risk Sharing",2.55140908046356e-05
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505597e-05
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703416e-05
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section O.  Quality Payment Program",2.52847571990385e-05
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section II Health Related Supplemental Benefits",3.44788570211552e-05
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741275e-05
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928497e-05
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section III Improving Access to Part D Vaccines",2.62277505669576e-05
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868554e-05
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650556e-05
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section I Innovations in Health Plan Design",3.17543788246014e-05
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081122e-05
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section III Tier Composition",4.59243068332441e-05
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496489e-05
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649267e-05
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section III Expanding the Part D OTC Program",5.5243880378263e-05
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section D.  ESRD Rates",3.65706624378486e-05
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section I Plan Corrections",4.14166098663162e-05
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section A.  Update of the RxHCC Model",2.28230186141155e-05
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section II Tiered Cost Sharing of Medical Benefits",5.7502427552e-05
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048513957e-05
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098582e-05
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724263029e-05
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section II Plans with Low Enrollment",5.1220279225815e-05
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273243e-05
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268827e-05
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598905e-05
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328424e-05
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669079e-05
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319153
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section B.  FFS Growth Percentage",4.0424640461868e-05
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section C.  IME Phase Out",7.35366337011479e-05
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114379e-05
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410107e-05
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.6575108000058e-05
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543182e-05
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078875
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897767e-05
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section II Cost Plan Competition Requirements",0.000117601526802604
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655976
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966446e-05
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091832e-05
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474104
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270549e-05
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559706
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734751e-05
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313588
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777686
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section II Outpatient Observation Services",0.000109941138994696
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156119
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777686
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section I Annual Calendar",5.38342337295149e-05
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section III Specialty Tiers",0.00012454381563509
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820174e-05
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section A.  MA Growth Percentage",0.000146106292559712
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.000202086368443961
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768403
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640233
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635094
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section III Benefit Review",0.000122732519844416
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474104
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356357
"CMS-2017-0163-1150-1-4",88,"3.75469235631212e-05","Section II Employer Group Waiver Plans",0.000207044385746999
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418579880817e-07
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313887953e-06
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section I Validation Audits",7.80120548019562e-06
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section B.  Calculation of Fee for Service Cost",5.50936891099221e-06
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section G.  MA Employer Group Waiver Plans",8.4242057418359e-06
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section L.  Normalization Factors",1.1423241385346e-05
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",7.52974045106051e-06
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section IV   Medicare Medicaid Plans",5.48787256308614e-06
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329729e-05
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section III CY 2019 Formulary Submission Window",1.21641982343022e-05
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351534e-05
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section E.  Clinical Trials",2.21636701369709e-05
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775365e-05
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section II Part C Cost Sharing Standards",1.48376036820546e-05
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section II Total Beneficiary Cost (TBC)",1.32115891376941e-05
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032523973e-05
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section C.  Part D Risk Sharing",2.55140908046383e-05
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505608e-05
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703453e-05
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section O.  Quality Payment Program",2.52847571990433e-05
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section II Health Related Supplemental Benefits",0.996931381725118
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741347e-05
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928562e-05
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section III Improving Access to Part D Vaccines",2.62277505669554e-05
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868559e-05
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650531e-05
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section I Innovations in Health Plan Design",3.17543788246033e-05
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081124e-05
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section III Tier Composition",4.59243068332441e-05
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496396e-05
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649305e-05
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section III Expanding the Part D OTC Program",5.52438803782717e-05
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section D.  ESRD Rates",3.65706624378677e-05
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section I Plan Corrections",4.14166098663223e-05
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section A.  Update of the RxHCC Model",2.28230186141237e-05
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275520029e-05
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048513978e-05
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098675e-05
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section II Cost Plan Transition to MA under MACRA",7.75934724262953e-05
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section II Plans with Low Enrollment",5.1220279225812e-05
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.60540109273316e-05
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268835e-05
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598941e-05
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328327e-05
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669213e-05
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319155
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section B.  FFS Growth Percentage",4.04246404618579e-05
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section C.  IME Phase Out",7.35366337011357e-05
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114477e-05
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410135e-05
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000665e-05
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.1533056654316e-05
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078874
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897757e-05
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section II Cost Plan Competition Requirements",0.000117601526802606
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655978
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966449e-05
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091817e-05
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474101
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270596e-05
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559708
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734641e-05
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313587
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.000104495779777683
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section II Outpatient Observation Services",0.000109941138994698
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156118
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777679
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section I Annual Calendar",5.38342337295186e-05
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section III Specialty Tiers",0.000124543815635088
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820224e-05
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section A.  MA Growth Percentage",0.000146106292559713
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.000202086368443961
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768411
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640226
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635092
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section III Benefit Review",0.000122732519844418
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.000100753072474101
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356356
"CMS-2017-0163-1150-1-4",89,"3.75469235631351e-05","Section II Employer Group Waiver Plans",0.000207044385747011
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section I Enhancements to the 2019 Star Ratings and Future Measurement Concepts",8.99418580149926e-07
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section III Improving Drug Utilization Review Controls in Medicare Part D",2.96443313889233e-06
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section I Validation Audits",7.80120548019905e-06
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section B.  Calculation of Fee for Service Cost",5.50936891089012e-06
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section G.  MA Employer Group Waiver Plans",8.42420574182993e-06
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section L.  Normalization Factors",1.14232413853413e-05
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section A.  MA Benchmark  Quality Bonus Payments and Rebate",0.3677748923792
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section IV   Medicare Medicaid Plans",5.48787256309442e-06
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section I.  ESRD Risk Adjustment Model for CY 2019",1.15325159329627e-05
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section III CY 2019 Formulary Submission Window",1.21641982343013e-05
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section I Incomplete and Inaccurate Bid Submissions",2.26393370351451e-05
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section E.  Clinical Trials",2.21636701369608e-05
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section II Improving Beneficiary Communications and Reducing Burden for Integrated D SNPs",1.51574028775205e-05
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section II Part C Cost Sharing Standards",1.48376036820572e-05
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section II Total Beneficiary Cost (TBC)",1.3211589137691e-05
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section III Using the Best Available Information when making B vs D Coverage Determinations for Immunosuppressants and Inhalation Durable Medical Equipment (DME) Supply Drugs",2.07981032523946e-05
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section C.  Part D Risk Sharing",2.5514090804634e-05
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section II Maximum Out of Pocket (MOOP) Limits",2.49853162505639e-05
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section I Audit of the Sponsoring Organization s Compliance Program Effectiveness",3.54939667703471e-05
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section O.  Quality Payment Program",2.52847571990363e-05
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section II Health Related Supplemental Benefits",3.44788570211389e-05
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section II Parts A and B Cost sharing for Individuals Enrolled in the Qualified Medicare Beneficiary (QMB) Program",3.04922788741349e-05
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section II Per Member Per Month (PMPM) Actuarial Equivalent (AE) Cost Sharing Limits",3.87538901928526e-05
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section III Improving Access to Part D Vaccines",2.62277505669574e-05
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section D.  Medicare Part D Benefit Parameters  Annual Adjustments for Defined Standard Benefit in 2019",1.29282347868478e-05
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section E.  Estimated Total Covered Part D Spending at Out of Pocket Threshold for Applicable Beneficiaries",2.77819389650543e-05
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section I Innovations in Health Plan Design",3.17543788246019e-05
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section II Encounter Data Listening Forums  Monitoring and Compliance Activities",3.24878506081104e-05
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section III Tier Composition",4.59243068332419e-05
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section J.  Frailty Adjustment for PACE organizations and FIDE SNPs",4.74744114496512e-05
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section E.  Reduced Coinsurance for Applicable Beneficiaries in the Coverage Gap",3.56438824649306e-05
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section III Expanding the Part D OTC Program",5.52438803782623e-05
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section D.  ESRD Rates",3.65706624378717e-05
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section I Plan Corrections",4.14166098663221e-05
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section A.  Update of the RxHCC Model",2.28230186141168e-05
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section II Tiered Cost Sharing of Medical Benefits",5.75024275520025e-05
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section II Special Needs Plan (SNP) Legislative Sunset Provision",9.40182048513957e-05
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section III Part D Mail Order Refill Consent Policy  Solicitation for Comments",3.59475454098614e-05
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section II Cost Plan Transition to MA under MACRA",7.7593472426297e-05
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section II Plans with Low Enrollment",5.12202792258193e-05
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section III Low Enrollment Plans (Stand alone PDPs only)",6.605401092733e-05
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section III Part D Benefit Parameters for Non Defined Standard Plans",3.72157628268851e-05
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section M.  Medical Loss Ratio Credibility Adjustment",8.72165228598917e-05
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section II Medicare Advantage (MA) Uniformity Flexibility",3.51978870328402e-05
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section II Medicare Diabetes Prevention Program (MDPP) Services Clarification",7.04664544669175e-05
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section B.  Encounter Data as a Diagnosis Source for 2019",0.000107149320319156
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section B.  FFS Growth Percentage",4.04246404618568e-05
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section C.  IME Phase Out",7.35366337011401e-05
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section II Enhanced Disease Management (EDM) for Dual Eligible Special Needs Plans (D SNPs) and Institutional Special Needs Plans (I SNPs)",8.54502824114437e-05
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section II Overview of CY 2019 Benefits and Bid Review",4.51866045410109e-05
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section II Transparency   Timeliness with Prior Authorization Processes",6.65751080000634e-05
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section III LIS Enrollee Cost sharing for Out of Network Part D Drugs",5.15330566543167e-05
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section D.  Retiree Drug Subsidy Amounts",0.000154110726078875
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section I Plan Finder Civil Money Penalty (CMP) Icon or Other Type of Notice",6.50359119897742e-05
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section II Cost Plan Competition Requirements",0.000117601526802604
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section II Medicare Advantage (MA) Segmented Service Area Options",0.000128331672655979
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section F.  Location of Network Areas for PFFS Plans in Plan Year 2020",7.97945076966496e-05
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section H.  Enhanced Medication Therapy Management (MTM) Model",5.78969296091867e-05
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section I Enforcement Actions for Provider Directories",0.000100753072474104
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section II Rewards and Incentives for Completion of a Health Risk Assessment (HRA)",5.45299484270589e-05
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section II Special Needs Plan (SNP) Specific Networks Research and Development",0.000146106292559708
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section III Coordination of Benefits (COB) User Fee",7.68865316734624e-05
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section III Medication Therapy Management (MTM) Annual Cost Threshold",0.000101970492313588
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section K.  Medicare Advantage Coding Pattern Adjustment",0.00010449577977768
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section II Outpatient Observation Services",0.000109941138994699
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section II Part C Optional Supplemental Benefits",0.000114412744156117
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section F.  Dispensing Fees and Vaccine Administration Fees for Applicable Drugs in the Coverage Gap",0.000104495779777683
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section I Annual Calendar",5.38342337295191e-05
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section III Specialty Tiers",0.000124543815635089
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section N.  Encounter Data as a Diagnosis Source for 2019",9.95643790820185e-05
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section A.  MA Growth Percentage",0.000146106292559714
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section G.  Part D Calendar Year Employer Group Waiver Plans Prospective Reinsurance Payment Amount",0.000202086368443959
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section I New Medicare Card Project (formerly the Social Security Number Removal Initiative  SSNRI)",0.000120973153768402
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section II Coverage of Supervised Exercise Therapy (SET) for Symptomatic Peripheral Artery Disease (PAD)",0.000112882333640234
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section II Meaningful Difference (Substantially Duplicative Plan Offerings)",0.000124543815635094
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section III Benefit Review",0.000122732519844413
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section III Timely Updates to LIS Status Based on Best Available Evidence",0.0001007530724741
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section H.  CMS HCC Risk Adjustment Model for CY 2019",0.000212251803356357
"CMS-2017-0163-1150-1-4",90,"3.75469235631365e-05","Section II Employer Group Waiver Plans",0.000207044385747011
